

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
14 April 2005 (14.04.2005)

PCT

(10) International Publication Number  
**WO 2005/033100 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 405/04**,  
C07H 15/00, C07D 205/08

(74) Agent: **CARRIERA, Andrea**; Isler & Pedrazzini AG,  
Gotthardstrasse 53, Postfach 6940, CH-8023 Zürich (CH).

(21) International Application Number:  
PCT/CH2004/000584

(22) International Filing Date:  
15 September 2004 (15.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
03405719.0 7 October 2003 (07.10.2003) EP

(71) Applicant (for all designated States except US): **LIPI-  
DEON BIOTECHNOLOGY AG** [CH/CH]; Her-  
mann-Hiltbrunner-Weg 25, CH-8713 Uerikon (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CARREIRA, Erick**  
[US/CH]; Chapfstrasse 73, CH-8126 Zumikon (CH). **HAUSER, Helmut** [AT/CH]; Hermann-Hiltbrunner-  
weg 25, CH-8713 Uerikon (CH). **KVAERNO, Lisbet**  
[DK/CH]; Kronenstrasse 37, App. 16, CH-8006 Zürich  
(CH). **RITTER, Tobias** [DE/CH]; Neugasse 52, CH-8005  
Zürich (CH). **WERDER, Moritz** [CH/CH]; Marktgasse  
16, CH-5620 Bremgarten (CH).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL HYPOCHOLESTEROLEMIC COMPOUNDS



(57) Abstract: The present invention relates to novel hypocholesterolemic compounds of formula (I) useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as to pharmaceutical compositions comprising said compounds alone or in combination with other active agents.

### **Novel hypocholesterolemic compounds**

The present invention relates to novel hypocholesterolemic compounds useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as to pharmaceutical compositions comprising said compounds alone or in combination with other active agents.

Atherosclerotic coronary heart disease represents the major cause for death and cardiovascular morbidity in the western world. Risk factors for atherosclerotic coronary heart disease include hypertension, diabetes mellitus, family history, male gender, cigarette smoke as well as serum cholesterol. Elevated concentrations of serum cholesterol have been demonstrated by a number of clinical studies to be a major contributing factor in the development and progression of atherosclerosis, which is characterized by the formation of cholesterol-containing plaques in the aorta and lesser arteries.

In mammals, 1/3 of the serum cholesterol is derived from exogenous dietary sources which enters the body through absorption in the intestine and 2/3 of the serum cholesterol are derived through endogenous de novo synthesis in the liver involving a complex set of enzyme-catalyzed reactions and regulatory mechanisms.

Recently it has been shown that intestinal cholesterol absorption is an energy-independent, protein-mediated process (Hauser, H. et al, *Biochemistry* **1998**, *37*, 17843-17850; Schulthess, G. et al, *Biochemistry* **2000**, *39*, 12623-12631; Werder, M. et al, *Biochemistry* **2001**, *40*, 11643-11650) rather than a passive diffusion process. The proteins facilitating intestinal cholesterol absorption were identified as two brush border membrane-resident scavenger receptors (Hauser, H. et al, *Biochemistry* **1998**, *37*,

17843-17850; Werder, M. et al, *Biochemistry* **2001**, *40*, 11643-11650). Both *in vitro* and *in vivo* animal experiments confirmed the presence of these two scavenger receptors in the intestinal BBM and proved that they are responsible for the protein-mediated cholesterol uptake.

Various 2-azetidinone compounds have been reported as being useful in lowering cholesterol and/or in inhibiting the formation of cholesterol-containing lesions in mammalian arterial walls: For example WO 93/02048, WO 94/17038, WO 95/08532, PCT/US95/03196, U.S. Pat. No. 5,633,246 describe 2-azetidinone compounds with different substituents at the 3-position, and U.S. Pat. No. 5,756,470 discloses 2-azetidinones having varying substituents at the 4 position. Other azetidinone derivatives include for example elastase inhibitory substituted azetidinones disclosed in European Patent 199,630B1 and European Patent Application 337,549A1. The most prominent representative of these 2-azetidinones, Ezetimibe (also known under trade names Zetia<sup>TM</sup> and Ezetrol<sup>®</sup>), has been in use as a cholesterol-lowering drug in monotherapy and in dual therapy combined with a statin. It is the first representative of the new class of cholesterol-lowering drugs that inhibit intestinal cholesterol absorption by targeting the two scavenger receptors in the intestinal brush border membrane described above.


However, it has been shown that the 2-azetidinones upon administration are readily absorbed and extensively metabolized into the pharmacologically active glucuronide of which over 95% remained in the intestinal wall upon direct administration as the glucuronide (van Heek, M. et al. *Br. J. Pharmacol.* **2000**, *129*, 1748-1754). In addition side effects such as allergic reactions including rash and angiodema have been reported.

Applicants have now discovered that the compounds of the present invention with the structural characteristics as depicted in

formula I and in particular formulas II and III are able to inhibit the protein-mediated process mentioned above by which cholesterol absorption is mediated, while overcoming the above described disadvantages of compounds known in the art. Thus the compounds of the present invention are particularly useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels.

In a first aspect, the present invention thus relates to novel hypocholesterolemic compounds of formula I, and in particular to compounds of formulas II and III having a four- or five-membered ring, respectively.

In one embodiment, the present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof,



wherein

P represents  $-N<$  or  $-C=$ ,

X represents independently of each other  $-CH_2-$ ,  $CR_1$  ( $sp_2$ -hybridised), O,  $-NH-$ ,  $=N-$ ,  $-CO-$  or  $-CS-$ , wherein  $R_1$  represents H or  $NR_2$ , wherein  $R_2$  represents H or lower alkyl, which optionally is linked to Z such that a bicyclic structure is formed;

n represents 1 or 2,





$R_a$  represents H, lower alkyl,  $-OR_3$ ,  $-O(CO)R_3$ ,  $-O(CO)OR_3$ ,  $-O(CO)NR_3R_4$ ,  $-NR_3R_4$ ,  $-NR_3(CO)R_4$ ,  $-COOR_3$ ,  $-CONR_3R_4$ , -



$\text{CH}=\text{CHCOOR}_3$ ,  $-\text{CF}_3$ ,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $\text{SO}_3\text{H}$ ,  $\text{PO}_3\text{H}$  or halogen, wherein  $\text{R}_3$  and  $\text{R}_4$  represent H or lower alkyl,

$\text{R}_b$  represents H, OH,  $-\text{OSO}_2\text{Me}$ ,  $-\text{OSO}_2\text{W}$  wherein W represents optionally substituted aryl or heteroaryl,  $-\text{OCO}(\text{CHOH})_2\text{COOR}_5$  wherein  $\text{R}_5$  represents H or lower alkyl; or represents the formula  $-\text{Sp}_3-\text{R}_6$ ,

wherein  $\text{Sp}_3$  represents a covalent bond,  $-\text{O}-$ ,  $-\text{OCH}_2-$ ,  $-\text{OSO}_2\text{CH}_2-$ ,  $-\text{OSO}_2-$ ,  $-\text{OSO}_2-(p)\text{C}_6\text{H}_4\text{O}-$  and  $\text{R}_6$  represents one of carbohydrate structures A-D:

**A****B****C****D**

wherein

$\text{R}_7$ ,  $\text{R}_8$ ,  $\text{R}_9$ ,  $\text{R}_{11}$ ,  $\text{R}_{12}$ ,  $\text{R}_{13}$  and  $\text{R}_{14}$  represent independently of each other H, lower alkyl, aryl(lower alkyl),  $-\text{CO}$ -lower alkyl,  $-\text{CO}$ -aryl,  $-\text{SO}_3^-$  or  $-\text{PO}_3^-$ ,

$\text{R}_{10}$  represents  $-\text{CH}_2\text{OR}_{16}$  or  $-\text{COOR}_{17}$ , and

$\text{R}_{15}$  represents  $-\text{CH}_2\text{OR}_{16}$ ,  $-\text{COOR}_{17}$ ,  $-\text{CH}_2\text{NH}_2$ ,  $-\text{CH}_2\text{OPO}_3^-$  or  $-\text{CH}_2\text{OSO}_3^-$ , wherein  $\text{R}_{16}$  and  $\text{R}_{17}$  independently of each other represent H, lower alkyl, aryl(lower alkyl),  $-\text{CO}$ -lower alkyl,  $-\text{CO}$ -aryl,  $-\text{SO}_3^-$  or  $-\text{PO}_3^-$ ,

- Z represents optionally substituted aryl or heteroaryl,
- Sp<sub>1</sub> represents a spacer unit, such as a straight-chain or branched lower alkyl group  $-(CH_2)_p-$ , wherein p is from 2-6, which is unsubstituted, mono or poly-substituted by -OH, -OR<sub>18</sub>, halogen or cyano group, wherein one or more -CH<sub>2</sub>- groups may independently be replaced by -O-, -CO-, -CO-O-, -O-CO-, -NR<sub>19</sub>-, -NR<sub>19</sub>-CO-, -CO-NR<sub>19</sub>-, -CH=CH-, -C≡C- and wherein R<sub>18</sub> and R<sub>19</sub> represent a hydrogen atom or lower alkyl;
- Sp<sub>2</sub> represents an optional spacer unit, such as a covalent bond or a straight-chain or branched lower alkyl group  $(CH_2)_q-$ , wherein q is from 1-6, which is unsubstituted, mono or poly-substituted by -OH, -OR<sub>20</sub>, halogen or cyano group, wherein one or more -CH<sub>2</sub>- groups may independently be replaced by -O-, -CO-, -CO-O-, -O-CO-, -NR<sub>21</sub>-, -NR<sub>21</sub>-CO-, -CO-NR<sub>21</sub>-, -CH=CH-, -C≡C- and wherein R<sub>20</sub> and R<sub>21</sub> represents a hydrogen atom or lower alkyl;


Y represents optionally substituted aryl or heteroaryl,

with the proviso, that if P = -N<, n=1, X = -CO- and Sp<sub>2</sub> represents a covalent bond, R<sub>6</sub> may not represent carbohydrate structures A or D for Sp<sub>3</sub> = -O- and R<sub>6</sub> may not represent carbohydrate B for Sp<sub>3</sub> = -OCH<sub>2</sub>-.


Preferably, if P = -N<, n=1, X = -CO- and Sp<sub>2</sub> represents a covalent bond, R<sub>b</sub> may not represent H or OH and Sp<sub>3</sub> may not represent a covalent bond, -O- or -OCH<sub>2</sub>-.

In a preferred embodiment, the present invention is directed towards compounds of formula I wherein P = -N<, n = 1 and X = -CO-, -CS-, -CH<sub>2</sub>- or -NH-.


Thus, the present invention is preferably directed towards compounds of formula IIa-d




IIa



IIb



IIc









IIId

or a pharmaceutically acceptable salt or solvate thereof,  
wherein the groups  $R_a$ ,  $R_b$ ,  $Sp_1$ ,  $Sp_2$ ,  $Y$  and  $Z$  are as defined above.

In another preferred embodiment, the present invention is directed towards compounds of formula I wherein for  $P = -N<$ ,  $-(X)_n-$  represents  $-OOC-$ ,  $-COO-$ ,  $-CONH-$ ,  $-CH=N-$ , and for  $P = -C=$ ,  $-(X)_n-$  represents  $-NH-N=$  or  $-O-N=$ .



Thus, the present invention is directed towards compounds of formula IIIa-f:



or a pharmaceutically acceptable salt or solvate thereof,  
wherein the groups  $R_a$ ,  $R_b$ ,  $SP_1$ ,  $SP_2$ ,  $Y$  and  $Z$  are as defined above.

In a further preferred embodiment, the present invention is directed towards compounds of formula I with  $P = -N<$  where  $-(X)_n-$  represents  $-CH-C=NR-$  or  $-CH-NH-CR-$  or wherein ring  $Z$  is coupled to  $-(X)_n-$  to form bicyclic compounds.

Thus, the present invention is further directed towards compounds of formula IIIg-h:



R<sub>a</sub> preferably represents H, lower alkyl, -OR<sub>3</sub>, -NR<sub>3</sub>R<sub>4</sub>, -COOR<sub>3</sub>, -CONR<sub>3</sub>R<sub>4</sub>, -CH=CHCOOR<sub>3</sub>, -CF<sub>3</sub>, -CN, -NO<sub>2</sub>, SO<sub>3</sub>H, PO<sub>3</sub>H or halogen, more preferably H, lower alkyl, -OR<sub>3</sub>, -NR<sub>3</sub>R<sub>4</sub>, -COOR<sub>3</sub>, -CONR<sub>3</sub>R<sub>4</sub> or halogen, most preferably H, lower alkyl, -OR<sub>19</sub> or halogen, wherein R<sub>3</sub> and R<sub>4</sub> represent independently of each other H or lower alkyl.

R<sub>b</sub> preferably represents H, OH, -OSO<sub>2</sub>Me, -OSO<sub>2</sub>W wherein W represents Phenyl (Ph) or isomers of salicylic acid (all combinations of disubstituted phenyl with OH and COOH substituents); or the formula -Sp<sub>3</sub>-R<sub>6</sub>, wherein Sp<sub>3</sub> preferably represents a covalent bond, -O-, -OCH<sub>2</sub>- or -OSO<sub>2</sub>CH<sub>2</sub>- and R<sub>6</sub> represents one of carbohydrate structures A-D, preferably carbohydrate structures A, B or D. More preferably R<sub>b</sub> represents H, OH, -OSO<sub>2</sub>Me, -OSO<sub>2</sub>Ph; or the formula -Sp<sub>3</sub>-R<sub>6</sub>, wherein Sp<sub>3</sub> preferably represents a covalent bond, -O-, -OCH<sub>2</sub>- or -OSO<sub>2</sub>CH<sub>2</sub>- and R<sub>6</sub> represents one of carbohydrate structures A-D, preferably carbohydrate structures A, B or D.

Sp<sub>1</sub> preferably represents a straight-chain or branched -(CH<sub>2</sub>)<sub>m</sub>-group, which is unsubstituted, mono or poly-substituted by -OH, -OR<sub>18</sub>, halogen or cyano group, wherein R<sub>18</sub> represents hydrogen or lower alkyl and m is 1 to 3. More preferably Sp<sub>1</sub> represents a -(CH<sub>2</sub>)<sub>3</sub>-, which is unsubstituted or substituted by -OH or halogen.

Sp<sub>2</sub> preferably represents a straight-chain or branched -(CH<sub>2</sub>)<sub>p</sub>-group, which is unsubstituted, mono or poly-substituted by -OH, -OR<sub>20</sub>, halogen or cyano group, wherein R<sub>20</sub> represents hydrogen or lower alkyl and p is 1 to 3. More preferably Sp<sub>1</sub> represents an unsubstituted -(CH<sub>2</sub>)<sub>p</sub>-, wherein p is 1 to 3, most preferably a covalent bond.

R<sub>15</sub> preferably represents -CH<sub>2</sub>OR<sub>16</sub>, -COOR<sub>17</sub> or -CH<sub>2</sub>NH<sub>2</sub>, wherein R<sub>16</sub> and R<sub>17</sub> independently of each other represent H, lower alkyl, aryl(lower alkyl), -CO-lower alkyl, -CO-aryl, -SO<sub>3</sub><sup>-</sup> or -PO<sub>3</sub><sup>-</sup>, preferably H, acetyl or benzyl.

R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>13</sub>, and R<sub>14</sub> preferably represent independently of each other H, lower alkyl, aryl-lower alkyl, -CO-lower alkyl, -CO-aryl, more preferably, H, acetyl or benzyl.

The term "optionally substituted aryl group" should be understood to include an aromatic ring system having 4 to 10, preferably 5, 6 or 10 ring atoms. The aryl group can be substituted with one or more substituents, which may be the same or different, and are selected from a group as defined hereinafter. Non-limiting examples of suitable aryl groups include phenyl, naphthalene or tetraline groups, most preferably phenyl groups substituted by halogeno, preferably fluoro.

The term "optionally substituted heteroaryl" should be understood to include an aromatic ring system of 5 to 14, preferably 5 to 10, more preferably 5 to 6 or 10 ring atoms, in which one or more of the atoms in the ring system is/are atoms other than carbon, for example nitrogen, oxygen or sulfur. The heteroaryl can be optionally substituted by one or more substituents, which may be the same or different, and are selected from a group as defined hereinafter. Examples of suitable 6-membered heteroaryl groups include pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl and the like. Examples of useful 5-membered heteroaryl rings include furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxazolyl and isoxazolyl. Useful bicyclic groups are benzo-fused ring systems derived from the heteroaryl groups named above, e.g., quinolyl, phthalazinyl, quinazolinyl, benzofuranyl, benzothienyl and indolyl.

The term "lower alkyl" should be understood to include straight chain and branched hydrocarbon groups having from 1 to 8, preferably 1 to 6, more preferably from 1 to 3 carbon atoms, which may be optionally substituted. Non-limiting examples of suitable lower alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, fluoromethyl and trifluoromethyl.

The term "branched" should be understood to represent a linear straight chain hydrocarbon group having one or more lower alkyl groups such as methyl, ethyl or propyl, attached to it.

The term "lower alkoxy" should be understood to include "lower alkyl-O-" groups, wherein the lower alkyl groups are as described above and have from 1 to 8, preferably 1 to 6, more preferably from 1 to 3 carbon atoms. Methoxy, ethoxy and isopropoxy groups are especially preferred.

The term "aryl(lower alkyl)" should be understood to include an aryl(lower alkyl) group in which the aryl and lower alkyl are as previously described. Non-limiting examples of suitable aryl(lower alkyl) groups include benzyl, phenethyl and naphth-1-enylmethyl.

If not otherwise indicated, the term "optionally substituted" should be understood to represent substituents independently selected from the group consisting of aryl, heteroaryl, aryl(lower alkyl), (lower alkyl)aryl, aralkenyl, heteroaralkyl, alkylheteroaryl, heteroaralkenyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halogen, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, aminoalkyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, preferably lower alkyl, hydroxy, lower alkoxy, cyano, alkylthio, amino, -NH(lower alkyl), -N(lower alkyl)<sub>2</sub> (which alkyls can be the same or different), carboxy, -C(O)O-(lower alkyl) and halogen. Those skilled in the art will recognize that the size and nature of the substituent(s) will affect the number of substituents which can be present.


The term "halogen" should be understood to include fluoro, chloro, bromo, iodo, preferably, fluoro and chloro, most preferably, fluoro.

It is understood that all isomers, including enantiomers,

stereoisomers, rotamers, tautomers and racemates of the compounds of formula I and in particular the compounds of formulas II and III are contemplated as being part of this invention. The invention includes stereoisomers in optically pure form and in admixture, including racemic mixtures. Isomers can be prepared using conventional techniques, either by reacting optically pure or optically enriched starting materials or by separating isomers of a compound of formula I and in particular the compounds of formulas II and III. In a preferred embodiment the stereochemistry in the central ring is such that the substituents at the 3- and 4-position are in trans configuration to each other.

In yet a further embodiment, preferred combinations of groups  $R_a$  and  $R_b$  include combinations wherein  $R_b$  is as defined hereinabove and is in para-position (in relation to the linker  $Sp_2$ ) and  $R_a$  is as defined hereinabove, most preferably H, and is in meta-position.

Thus in a further preferred embodiment the present invention is directed towards a compound of formula IVa,



IVa

wherein  $R_a$ ,  $R_b$ ,  $Sp_1$ ,  $Sp_2$ , P, X, Y, Z and n are as defined hereinabove.


Such preferred combinations are thus compounds of formulas IIa-f and IIIa-h wherein  $R_b$  is as defined hereinabove and is in para-position (in relation to the linker  $Sp_2$ ) and  $R_a$  is as defined



hereinabove, most preferably H, and is in meta-position.

Further preferred embodiments include combinations, wherein  $Sp_2$  is a covalent bond and Y and Z represent optionally substituted phenyl rings.

Thus in a further preferred embodiment the present invention is directed towards a compound of formula IVb,



IVb

wherein  $R_a$ ,  $R_b$ ,  $Sp_1$ , P and X are as defined hereinabove and wherein  $R_{21}$  and  $R_{22}$  preferably represent H, lower alkyl, lower alkoxy or halogen, most preferably in para-position.

Such combinations are thus compounds of formulas IIa-f and IIIa-h wherein  $Sp_2$  is a covalent bond and Y and Z represent optionally substituted phenyl rings.

Compounds of formula I and in particular compounds of formulas II and III may be prepared using methods of preparation known in the art and are described in the following paragraphs:

The 2-azetidinone portions of the compounds of formula II can be prepared by known methods, such as are disclosed in U.S. Pat. Nos. 5,631,365, 5,756,470, 5,767,115, 5,846,966, 6,207,822, U.S. Provisional Patent Application No. 60/279,288 filed Mar. 28, 2001, and PCT Patent Application WO 93/02048, each of which is incorporated herein by reference. Compounds of formula IIa according to the invention may then be obtained by further linkage


to appropriate carbohydrate structures using literature procedures as illustrated by the Examples.

Compounds of formula IIb may be obtained through conversion of  $\beta$ -lactams to thiolactams, most commonly performed with Lawesson's reagent (Verkoyen, C. and Rademacher, P. *Chem. Ber.* **1985**, *118*, 653-660; Yde, B. et al. *Tetrahedron* **1984**, *40*, 2047-2052; Steliou, K.; Mrani, M. *J. Am. Chem. Soc.* **1982**, *104*, 3104-3106; Clader, J. W. et al. *J. Med. Chem.* **1996**, *39*, 3684-3693).

Compounds of formula IIc may be obtained through conversion of  $\beta$ -lactams to azetidines, which may be achieved by a number of wellknown methods in the art, such as (1) direct one-step reduction with reducing agents of the composition  $AlH_xCl_{3-x}$ , such as chlorodihydroalane or alane (Jackson, M. B. et al. *Aust. J. Chem.* **1983**, *36*, 779), or diborane (Jackson, M. B. et al.; *Aust. J. Chem.* **1983**, *36*, 779-788),  $AlHCl_2$  and DIBAL-H (Yamashita, M. and Ojima, I. *J. Am. Chem. Soc.* **1983**, *105*, 6339-6342; Ojima, I. et al. *J. Org. Chem.* **1991**, *56*, 5263-5277); and (2) cyclodehydration of 1,3-amino alcohols using various methods (Sohar, P. et al. *Chem. Soc. Perkin Trans. 2* **2000**, 287-293; Suga, H. et al. *S. J. Am. Chem. Soc.* **1994**, *116*, 11197-11198; Barluenga, J. et al. *Tetrahedron* **1996**, *52*, 3095-3106; Obika, S. et al. *Tetrahedron Lett.* **2003**, *44*, 5267-5270) as also outlined in the Examples.


The preparation of compounds of formula IIIa is effected as outlined in Scheme I through initial Sharpless asymmetric amino hydroxylation reaction of the desired trans-1,2-disubstituted alkenes (Demko, Z. P. et al. *Org. Lett.* **2000**, *2*, 2221-2223; O'Brien, P. *Angew. Chem. Int. Edit. Engl.* **1999**, *38*, 326-329; Bodkin, J. A.; McLeod, M. D. *J. Chem. Soc. Perkin Trans. 1* **2002**, 2733-2746), followed by chromatographic separation to obtain the desired regioisomeric product. Subsequent cleavage of the *para*-toluene sulfonamide group furnishes a primary amine which upon Buchwald-Hartwig arylation reaction (Hartwig, J. F. *Acc. Chem. Res.* **1998**, *31*, 852-860; Wolfe, J. P.; Wagaw, S.; Marcoux, J. F.;

Buchwald, S. L. *Acc. Chem. Res.* **1998**, *31*, 805-818) and subsequent exposure to triphosgene eventually leads to the formation of the desired oxazolidinones of formula IIIa. Alternatively, they can be accessed as outlined in the Examples.




Scheme 1

Compounds of formula IIIe may be obtained e.g. as illustrated in Scheme II using known methods in the art (Mish, M. R. et al. *J. Am. Chem. Soc.* **1997**, *119*, 8379-8380; Guerra, F. M. et al. *Org. Lett.* **2000**, *2*, 4265-4267). Alternatively, compounds in which sp<sub>2</sub> is not a covalent bond can be synthesized as demonstrated in the Examples.



Scheme II

The preparation of pyrazolidinones of formula IIIc proceeds in an analogous strategy to that reported in the literature as illustrated in Scheme III (Lou, B. S. et al. *J. Org. Chem.* **1995**, *60*, 5509-5514; Tomkinson, N. C. O. *Rodd's Chemistry of Carbon Compounds (2nd Edition), Asymmetric Catalysis*, Ed. M. Sainsbury **2001**, *5*, 199-258).



Scheme III

It has been found that the use of sulfonate linkages in e.g. the Rb or Sp<sub>3</sub> group, i.e. linking carbohydrates to the phenylene ring is particularly beneficial in that the S=O double bonds in the linkages may function as hydrogen bond acceptors compared to the more non-polar nature of a C-glycoside linkage. Such linkages have not yet been reported to link carbohydrates to other kinds of molecules. Furthermore the linkages are non-hydrolyzable, i.e. the carbohydrates are not hydrolyzed off.

It has further been shown that the compounds of the invention display superior pharmacological activities and are able to overcome the drawbacks of known cholesterol-lowering agents using well-established methods in the art, e.g. evaluation of their IC<sub>50</sub> value for cholesterol uptake in rabbit brush border membrane vesicles (BBMV) as well as in Caco-2 cells (Hauser, H. et al, *Biochemistry* **1998**, *37*, 17843-17850; Schulthess, G. et al, *Biochemistry* **2000**, *39*, 12623-12631; Werder, M. et al, *Biochemistry* **2001**, *40*, 11643-11650; Boffelli, D. et al. *FEBS Lett.* **1997**,

411, 7-11) (see also Table I).

Thus, the compounds of the invention, e.g. compounds of formula I and their pharmaceutically acceptable acid addition salts, exhibit pharmacological activity and are, therefore, useful as pharmaceuticals. The compounds of the invention have been shown to effectively inhibit cholesterol absorption and are therefore useful in the treatment and/or prevention of atherosclerosis and of the reduction of cholesterol levels.

Thus in yet a further aspect, the present invention is directed to a method of treatment and/or prevention of atherosclerosis, of the reduction of cholesterol levels and of treating or preventing a vascular condition, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I and in particular a compound of formulas II and III.

The novel compounds of formula I can be used, for example, in the form of pharmaceutical compositions containing a therapeutically effective amount of the active ingredient, if appropriate together with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers suitable for enteral, e.g. oral, or parenteral administration. Accordingly, tablets or gelatin capsules are used that contain the active ingredient together with diluents, typically lactose, dextrose, saccharose, mannitol, sorbitol, cellulose and/or lubricants, e.g. diatomaceous earth, talcum, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Tablets may also contain binders, typically magnesium aluminium silicate, starches, typically corn starch, wheat starch, rice starch or arrow root starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, typically starches, agar, alginic acid or a salt thereof, e.g. sodium alginate, and/or effervescent mixtures, or absorbents, colourants, flavourings and

sweeteners.

Thus in another aspect, the invention relates to a pharmaceutical composition comprising a compound of formula I, and in particular a compound of formulas II and III (and optionally other therapeutically effective agents), and a pharmaceutically acceptable carrier for the treatment or prevention of arteriosclerosis or for the reduction of cholesterol levels.

The terms "effective amount" and "therapeutically effective amount" mean that amount of a compound of formula I and in particular compounds of formulas II and III (and optionally other therapeutically effective agents), that will elicit a biological or medical response of a tissue, system, animal or mammal, which includes alleviation of the symptoms of the condition or disease being treated and the prevention, slowing or halting of progression of one or more conditions, for example atherosclerosis, hypercholesterolemia.

The pharmaceutical compositions so obtained which, if desired, contain further pharmacologically active substances, are prepared in a manner known per se by conventional mixing, granulating, sugar-coating, solution or lyophilising methods and contain from about 0.1% to 100%, preferably from about 1% to about 50%, lyophilisate to about 100%, of active ingredient.

The compounds, compositions and treatments of the present invention can be administered by any suitable means which produce contact of these compounds with the site of action in the body, for example in the plasma, liver or small intestine of a mammal or human. Thus the novel compounds of formula I may also be used in the form of compositions for parenteral, oral, transdermal administration or infusion solutions. Such solutions are preferably isotonic aqueous solutions or suspension which, e.g. in the case of lyophilised compositions that contain the active ingredient by itself or together with a carrier, such as manni-

tol, can be prepared before use. The pharmaceutical compositions can be sterilised and/or can contain excipients, typically preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.

In yet a further aspect, the invention relates to a kit comprising an effective amount of a compound of formula I and in particular a compound of formulas II and III in a pharmaceutically acceptable carrier (and optionally an effective amount of another therapeutically effective agent), optionally in separate compartments.


The following non-limiting Examples illustrate the above-described invention in more detail.

## EXAMPLES

*Materials and Methods:* Reactions in anhydrous solvents were all performed using oven dried glassware under an atmosphere of argon. Reagent grade solvents were all purchased from chemical companies and used without prior purification. For chromatographic purification, technical grade solvents were distilled prior to use. TLC was performed using Machery-Nagel Alugram Sil G/UV<sub>254</sub> TLC plates and visualized with ultraviolet light at 254 nm and 12 g phosphor molybdic acid in 250 mL EtOH or 10% H<sub>2</sub>SO<sub>4</sub> in MeOH (v/v). Chromatographic purification of products was accomplished using dry column vacuum chromatography on Merck Silica Gel 60 (15 - 40 µm) according to literature procedures (Pedersen, D. S. and Rosenbohm, C. *Synthesis* **2001**, 2431-2434); fractions containing product were pooled, the solvents were evaporated under reduced pressure and the residue was dried under high vacuum to give the product. NMR spectra were recorded on a Varian Mercury 300MHz apparatus operating at 300 MHz and 75 MHz for <sup>1</sup>H and <sup>13</sup>C,

respectively, and chemical shifts ( $\delta$ ) were referenced to the internal solvent signals. IR-Spectra were recorded in  $\text{CHCl}_3$  on a Perkin Elmer Spectrum RX I FT-IR apparatus (thin films on NaCl plates) and are reported as absorption maxima in  $\text{cm}^{-1}$ . Elemental analysis was performed by the Mikroelementaranalytisches Laboratorium at the ETH, Zürich. High resolution matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) was recorded in positive ion mode.




**Example 1****V**

LiAlH<sub>4</sub> (114 mg, 3.0 mmol) and AlCl<sub>3</sub> (390 mg, 2.9 mmol) were suspended in anhydrous ether (15 mL) and refluxed for 30 min. Trans-1-(4-fluorophenyl)-3-[(3-phenyl)propyl]-4-phenyl-2-azetidinone (361 mg, 1.00 mmol; prepared according to Browne, M. et al. *Tetrahedron Lett.* **1995**, 36, 2555-2558) dissolved in anhydrous ether (15 mL) was added and after stirring at reflux for 30 min, the suspension was cooled and H<sub>2</sub>O (5 mL) was added dropwise followed by addition of 50% sat. aq. NaHCO<sub>3</sub> (30 mL). The layers were separated, the aqueous layer was extracted with EtOAc/hexane and ether and the combined organic layer was washed successively with sat. aq. NaHCO<sub>3</sub> (20 mL) and H<sub>2</sub>O (20 mL), evaporated on celite and purified by dry column vacuum chromatography (3.7 x 3.3 cm) on silica gel eluting with a gradient of 0-10% EtOAc in hexane (v/v) to give the desired compound **V** (281 mg, 81%) as a colourless oil.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.51-7.14 (10H, m), 6.87 (2H, t, *J* = 8.7 Hz), 6.38 (2H, dd, *J* = 4.7, 9.0 Hz), 4.46 (1H, d, *J* = 6.8 Hz), 4.17 (1H, t, *J* = 6.8 Hz), 3.35 (1H, dd, *J* = 6.8, 7.5 Hz), 2.69-2.58 (3H, m), 1.85-1.56 (4H, m). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) δ: 157.64, 154.52, 148.53, 142.69, 141.95 (C), 128.66, 128.25, 127.47, 125.99, 125.73, 115.41, 115.12, 113.04, 112.94 (CH), 74.37 (CH), 56.05 (CH<sub>2</sub>), 42.09 (CH), 35.85, 33.52, 28.92 (CH<sub>2</sub>). IR (cm<sup>-1</sup>): 3026, 2933, 2852, 1603, 1508, 1473, 1453, 1321, 1222, 1120, 823, 773, 747, 699. MALDI-MS (C<sub>24</sub>H<sub>24</sub>FN): [MH]<sup>+</sup> 346.1982 (calcd. 346.1971). Anal. Calcd for C<sub>24</sub>H<sub>24</sub>FN: C, 83.44; H, 7.00; N,


4.05. Found: C, 83.45; H, 7.06; N, 4.27.

### Example 2



VI

a)



VIa

Ezetimibe (commercially obtained or synthesized according to Wu, G. Z. et al., *J. Org. Chem.* **1999**, *64*, 3714-3718) (5.530 g, 13.5 mmol) was suspended in 2-propanol (70 mL), aq. NaOH (2M, 15 mL) followed by Ac<sub>2</sub>O (3.0 mL, 32 mmol) were added and the solution was stirred for 5 h followed by addition of sat. aq. NaHCO<sub>3</sub> (200 mL). After extraction with EtOAc (4 x 50 mL), the combined organic layer was washed successively with sat. aq. NaHCO<sub>3</sub> (50 mL) and H<sub>2</sub>O (50 mL), evaporated on celite and purified by dry column vacuum chromatography (5.2 x 5.5 cm) on silica gel eluting with a gradient of 0-100% EtOAc in hexane (v/v) to give the corresponding azetidinone acetate (5.930 g, 97%) as a white foam.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.31 (2H, d, *J* = 8.7 Hz), 7.29-7.18

(4H, m), 7.09 (2H, d,  $J = 8.7$  Hz), 6.99 (2H, t,  $J = 8.7$  Hz), 6.92 (2H, t,  $J = 8.7$  Hz), 4.67 (1H, bs), 4.61 (1H, d,  $J = 2.5$  Hz), 3.08-3.04 (1H, m), 2.75 (1H, bs), 2.29 (3H, s), 1.97-1.85 (4H, m).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 169.16, 167.23, 163.56, 160.46, 160.32, 157.24, 150.58, 139.94, 139.90, 134.85, 133.53, 133.50 (C), 127.32, 127.21, 126.78, 122.38, 118.34, 118.23, 115.95, 115.65, 115.35, 115.07 (CH), 72.95, 60.81, 60.33 (CH), 36.61, 25.07 ( $\text{CH}_2$ ), 21.19 ( $\text{CH}_3$ ). IR ( $\text{cm}^{-1}$ ): 3443, 3019, 2936, 2862, 1747, 1605, 1509, 1427, 1388, 1370, 1221, 1198, 1157, 1016, 835, 757, 668. MALDI-MS ( $\text{C}_{26}\text{H}_{23}\text{F}_2\text{NO}_4$ ):  $[\text{MH}-\text{H}_2\text{O}]^+$  434.1556 (calcd. 434.1568);  $[\text{MNa}]^+$  474.1485 (calcd. 474.1493))

Subsequently the acetate (1.864 g, 4.13 mmol) was dissolved in anhydrous DMF (25 mL), imidazole (939 mg, 13.8 mmol) and TBDMSCl (1.853 g, 12.3 mmol) were added sequentially and the solution was stirred for 3 h followed by addition of 50% sat. aq.  $\text{NaHCO}_3$  (150 mL). After extraction with EtOAc (4 x 40 mL), the combined organic layer was washed successively with sat. aq.  $\text{NaHCO}_3$  (40 mL) and  $\text{H}_2\text{O}$  (40 mL), evaporated on celite and purified by dry column vacuum chromatography (4.2 x 5.5 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding silylated azetidinone acetate (2.137 g, 91%) as a colourless oil.


$^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.31 (2H, d,  $J = 8.7$  Hz), 7.26-7.20 (4H, m), 7.10 (2H, d,  $J = 8.7$  Hz), 6.98 (2H, t,  $J = 8.7$  Hz), 6.91 (2H, t,  $J = 8.7$  Hz), 4.67 (1H, t,  $J = 5.3$  Hz), 4.58 (1H, d,  $J = 1.9$  Hz), 3.06-3.02 (1H, m), 2.28 (3H, s), 1.96-1.80 (4H, m), 0.88 (9H, s), 0.02 (3H, s), -0.16 (3H, s).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 169.16, 167.06, 163.42, 160.47, 160.16, 157.23, 150.62, 140.50, 135.10, 133.74, 133.70 (C), 127.26, 127.14, 126.77, 122.37, 118.27, 118.16, 115.89, 115.58, 115.03, 114.76 (CH), 73.74, 60.67, 60.53 (CH), 37.94 ( $\text{CH}_2$ ), 25.73 ( $\text{CH}_3$ ), 24.55 ( $\text{CH}_2$ ), 20.99 ( $\text{CH}_3$ ), 18.07 (C), -4.74, -5.05 ( $\text{CH}_3$ ). IR ( $\text{cm}^{-1}$ ): 2953, 2930, 2857, 1752, 1606, 1510, 1472, 1426, 1385, 1370, 1252, 1219,

1197, 1166, 1140, 1102, 1086, 1015, 912, 835, 777, 736. MALDI-MS:  $[\text{MH-TBDMSOH}]^+$  434.1556 (calcd. 434.1568);  $[\text{MNa}]^+$  588.2347 (calcd. 588.2358). Anal. Calcd for  $\text{C}_{32}\text{H}_{37}\text{F}_2\text{NO}_4\text{Si}$ : C, 67.94; H, 6.59; N, 2.48. Found: C, 67.94; H, 6.64; N, 2.37)

The silylated azetidinone acetate (5.123 g, 9.06 mmol) was dissolved in  $\text{CH}_2\text{Cl}_2$  (200 mL), neutral alumina (50 g) was added and the suspension was evaporated to dryness. The coated alumina was dried shortly under vacuum and then heated to 70°C for 5.5 h. After cooling, the alumina was extracted with 10% MeOH in  $\text{CH}_2\text{Cl}_2$  (8 x 50 mL) and the combined organic extracts were evaporated on celite and purified by dry column vacuum chromatography (5.4 x 5.5 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the silylated azetidinone phenol **VIa** (3.919 g, 83%) as a white foam.

$^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.26-7.14 (6H, m), 6.99-6.83 (6H, m), 6.16 (1H, bs), 4.65 (1H, t,  $J = 5.3$  Hz), 4.52 (1H, d,  $J = 1.9$  Hz), 3.04-2.98 (1H, m), 1.92-1.76 (4H, m), 0.86 (9H, s), 0.00 (3H, s), -0.17 (3H, s).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 167.82, 163.28, 160.42, 156.12, 140.50, 140.45, 133.57 (C), 128.92, 127.19, 127.15, 127.08, 118.43, 118.32, 116.05, 115.85, 115.55, 115.01, 114.72 (CH), 73.82, 61.17, 60.35 (CH), 38.07 ( $\text{CH}_2$ ), 25.89 ( $\text{CH}_3$ ), 24.68 ( $\text{CH}_2$ ), 18.25 (C), -4.54, -4.84 ( $\text{CH}_3$ ). IR ( $\text{cm}^{-1}$ ): 3351, 2953, 2938, 2857, 1722, 1615, 1604, 1510, 1450, 1391, 1361, 1252, 1223, 1156, 1103, 1087, 863, 834, 776, 760. MALDI-MS:  $[\text{MH-TBDMSOH}]^+$  392.1451 (calcd. 392.1462);  $[\text{MH}]^+$  524.2409 (calcd. 524.2433);  $[\text{MNa}]^+$  546.2242 (calcd. 546.2252). Anal. Calcd for  $\text{C}_{30}\text{H}_{35}\text{F}_2\text{NO}_3\text{Si}$ : C, 68.81; H, 6.74; N, 2.67. Found: C, 68.61; H, 6.82; N, 2.66.

b)

**VIb**


The silylated azetidinone phenol **VIa** (176 mg, 0.336 mmol) was dissolved in anhydrous  $\text{CH}_2\text{Cl}_2$  (10 mL), anhydrous pyridine (0.5 mL) followed by  $\text{MsCl}$  (0.1 mL, 1.29 mmol) were added and the solution was stirred for 22 h, diluted with  $\text{EtOAc}$  (50 mL) and washed sequentially with sat. aq.  $\text{NaHCO}_3$  (20 mL) and  $\text{H}_2\text{O}$  (20 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.2x3.3 cm) on silica gel eluting with a gradient of 0-50%  $\text{EtOAc}$  in hexane (v/v) to give the intermediate mesylate **VIb** (195.5 mg, 92%) as a colourless oil.

$^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.35 (2H, d,  $J = 8.7$  Hz), 7.28 (2H, d,  $J = 8.7$  Hz), 7.26-7.18 (4H, m), 6.98 (2H, t,  $J = 8.7$  Hz), 6.93 (2H, t,  $J = 8.7$  Hz), 4.67 (1H, dd,  $J = 4.4, 6.2$  Hz), 4.59 (1H, d,  $J = 1.9$  Hz), 3.16 (3H, s), 3.04-3.00 (1H, m), 1.93-1.79 (4H, m), 0.87 (9H, s), 0.01 (3H, s), -0.16 (3H, s).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 166.83, 163.46, 160.57, 160.21, 157.34, 148.88, 140.53, 140.49, 137.07, 133.59, 133.56 (C), 127.36, 127.28, 127.18, 122.94, 118.26, 118.16, 116.04, 115.73, 115.10, 114.81 (CH), 73.79, 60.67, 60.41 (CH), 37.97 ( $\text{CH}_2$ ), 37.59, 25.76 ( $\text{CH}_3$ ), 24.60 ( $\text{CH}_2$ ), 18.11 (C), -4.71, -5.02 ( $\text{CH}_3$ ). IR ( $\text{cm}^{-1}$ ): 2952, 2931, 2857, 1752, 1605, 1509, 1371, 1252, 1220, 1176, 1153, 1102, 1086, 971, 871, 835, 777. MALDI-MS:  $[\text{MH-TBDMSOH}]^+$  470.1228 (calcd. 470.12376);  $[\text{MNa}]^+$  624.2029 (calcd. 624.2027). Anal. Calcd for  $\text{C}_{31}\text{H}_{37}\text{F}_2\text{NO}_5\text{SiS}$ : C, 61.87; H, 6.20; N, 2.33. Found: C, 61.69; H, 6.19; N, 2.15).

c)

The intermediate mesylate received in the previous step (67.7 mg, 0.112 mmol) was dissolved in THF (2 mL), TBAF (0.2 mL, 1M in THF) was added and the solution was stirred for 1.5 h, diluted with EtOAc (20 mL) and washed successively with sat. aq. NaHCO<sub>3</sub> (10 mL) and H<sub>2</sub>O (10 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 2.0 cm) on silica gel eluting with a gradient of 0-90% EtOAc in hexane (v/v) to give the desired mesylated azetidinone VI (37.0 mg, 68%) as a white solid after coevaporation with hexane (10 mL).

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.37-7.17 (8H, m), 7.03-6.91 (4H, m), 4.69 (1H, t, *J* = 5.9 Hz), 4.65 (1H, d, *J* = 1.9 Hz), 3.16 (3H, s), 3.07-3.01 (1H, m), 2.63 (1H, bs), 2.03-1.84 (4H, m). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) δ: 167.11, 163.76, 160.68, 160.50, 157.44, 148.89, 139.92, 136.86, 133.41 (C), 127.40, 127.27, 122.98, 118.35, 118.24, 116.10, 115.79, 115.45, 115.18, 115.11 (CH), 73.03, 60.48, 60.41 (CH), 37.63 (CH<sub>3</sub>), 36.48, 25.00 (CH<sub>2</sub>). IR (cm<sup>-1</sup>): 3428, 2937, 1744, 1604, 1510, 1426, 1369, 1221, 1176, 1152, 1103, 1016, 971, 912, 872, 835, 788, 734. MALDI-MS: [MH-H<sub>2</sub>O]<sup>+</sup> 470.1239 (calcd. 470.1238); [MNa]<sup>+</sup> 510.1164 (calcd. 510.1163). Anal. Calcd for C<sub>25</sub>H<sub>23</sub>F<sub>2</sub>NO<sub>5</sub>S: C, 61.59; H, 4.75; N, 2.87. Found: C, 61.79; H, 4.89; N, 2.76.

**Example 3****VII**

LiAlH<sub>4</sub> (58 mg, 1.5 mmol) and AlCl<sub>3</sub> (202 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 30 min and cooled to 0°C. The mesylate **VIb** obtained in step 2b) (195.5 mg, 0.325 mmol) dissolved in anhydrous ether (5 mL) was added and after stirring at 0°C for 15 min, sat. aq. NaHCO<sub>3</sub> (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.6 x 3.3 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the intermediate silylated azetidine (146.4 mg, 77%) as a colourless oil.


<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.49 (2H, d, *J* = 8.7 Hz), 7.30 (2H, d, *J* = 8.7 Hz), 7.18 (2H, dd, *J* = 5.0, 8.7 Hz), 6.98 (2H, t, *J* = 8.7 Hz), 6.85 (2H, t, *J* = 8.7 Hz), 6.31 (2H, dd, *J* = 4.4, 9.3 Hz), 4.58 (1H, t, *J* = 5.3 Hz), 4.40 (1H, d, *J* = 6.8 Hz), 4.11 (1H, t, *J* = 7.2 Hz), 3.28 (1H, t, *J* = 7.2 Hz), 3.17 (3H, s), 2.56-2.49 (1H, m), 1.77-1.50 (4H, m), 0.88 (9H, s), 0.01 (3H, s), -0.15 (3H, s). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) δ: 163.22, 159.99, 157.69, 154.57, 148.23, 148.07, 141.97, 140.62 (C), 127.41, 127.13, 127.03, 122.25, 115.43, 115.13, 114.96, 114.68, 113.00, 112.90 (CH), 73.86, 73.29 (CH), 55.88 (CH<sub>2</sub>), 41.88 (CH), 37.90 (CH<sub>2</sub>), 37.43 (CH<sub>3</sub>), 29.43 (CH<sub>2</sub>), 25.85 (CH<sub>3</sub>), 18.24 (C), -4.53, -4.88 (CH<sub>3</sub>). IR (cm<sup>-1</sup>): 2932, 2856, 1605, 1509, 1473, 1372, 1331, 1252, 1222, 1198, 1171, 1151, 1090, 970, 870, 836, 776. MALDI-MS: [MH-TBDMSOH]<sup>+</sup> 456.1442 (calcd. 456.14449); [MNa]<sup>+</sup> 610.2236 (calcd. 610.22348). Anal. Calcd for C<sub>31</sub>H<sub>39</sub>F<sub>2</sub>NO<sub>4</sub>SiS: C, 63.34; H, 6.69; N, 2.38. Found: C, 63.49; H, 6.87; N, 2.33.

This intermediate silylated azetidine (146.3 mg, 0.249 mmol) was dissolved in anhydrous THF (5.0 mL, teflon bottle) at 0°C, anhydrous pyridine (1.0 mL) followed by HF·pyridine complex (1.0 mL) were added and the solution was stirred at 0°C for 1 h and at room temperature for 7 h, diluted with ether (30 mL) and washed with sat. aq. NaHCO<sub>3</sub> (3 x 10 mL). The organic layer was evapo-

rated on celite and purified by dry column vacuum chromatography (4.2 x 2.0 cm) on silica gel eluting with a gradient of 0-90% EtOAc in hexane (v/v) to give the desired mesylated azetidine **VII** (100.0 mg, 85%) as a white foam.

$^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.50 (2H, d,  $J = 8.7$  Hz), 7.28 (2H, d,  $J = 8.7$  Hz), 7.22 (2H, dd,  $J = 5.6, 8.7$  Hz), 7.01 (2H, t,  $J = 8.7$  Hz), 6.84 (2H, t,  $J = 8.7$  Hz), 6.30 (2H, dd,  $J = 4.3, 9.3$  Hz), 4.57 (1H, t,  $J = 5.6$  Hz), 4.41 (1H, d,  $J = 6.8$  Hz), 4.12 (1H, t,  $J = 6.8$  Hz), 3.30 (1H, dd,  $J = 6.8, 7.5$  Hz), 3.16 (3H, s), 2.55 (1H, dt,  $J = 6.8, 7.5$  Hz), 1.93 (1H, bs), 1.88-1.53 (4H, m).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 163.62, 160.37, 157.74, 154.61, 148.22, 148.01, 141.89, 139.95, 139.91 (C), 127.46, 127.28, 127.17, 122.29, 115.46, 115.42, 115.13, 113.02, 112.92 (CH), 73.43, 73.28 (CH), 55.92 ( $\text{CH}_2$ ), 41.81 (CH), 37.49 ( $\text{CH}_3$ ), 36.28, 29.85 ( $\text{CH}_2$ ). IR ( $\text{cm}^{-1}$ ): 3416, 2938, 2853, 1508, 1367, 1221, 1196, 1171, 1149, 970, 871, 823. MALDI-MS ( $\text{C}_{25}\text{H}_{25}\text{F}_2\text{NO}_4\text{S}$ ):  $[\text{MH}-\text{H}_2\text{O}]^+$  456.1447 (calcd. 456.1445);  $[\text{M}]^+$  473.1481 (calcd. 473.1472);  $[\text{MNa}]^+$  496.1380 (calcd. 496.1370).

#### Example 4



**VIII**

The silylated azetidinone phenol **VIa** obtained in step 2a) (143 mg, 0.273 mmol) and C-(hydroxymethyl)-2,3,4,6-tetra-O-benzyl- $\beta$ -D-



glucopyranoside (prepared according to RajanBabu, T. V. and Reddy, G. S. *J. Org. Chem.* **1986**, *51*, 5458-5461; 180 mg, 0.325 mmol) were dissolved in anhydrous THF (10 mL) at 0°C, Bu<sub>3</sub>P (0.20 mL, 0.80 mmol) and 1,1'-(azodicarbonyl)dipiperidine (206 mg, 0.82 mmol) were added sequentially and the suspension was allowed to warm to ambient temperature over several hours and stirred for 24 h. EtOAc/hexane (1:4 (v/v), 20 mL) was added, the suspension was filtered through celite (2 x 10 mL EtOAc/hexane (1:4 (v/v)) washings) and the filtrate was evaporated on celite and purified by dry column vacuum chromatography (4.1 x 3.3 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the corresponding C-glycoside (60.1 mg, 21%) as a colourless oil.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.37-7.17 (26H, m), 7.04-6.89 (6H, m), 4.96 (2H, bs), 4.89 (1H, d, *J* = 9.3 Hz), 4.86 (1H, d, *J* = 8.7 Hz), 4.69 (1H, t, *J* = 5.3 Hz), 4.63-4.53 (5H, m), 4.21 (1H, d, *J* = 10.6 Hz), 4.10 (1H, dd, *J* = 5.0, 10.6 Hz), 3.85-3.52 (7H, m), 3.07-3.02 (1H, m), 2.01-1.78 (4H, m), 0.91 (9H, s), 0.05 (3H, s), -0.13 (3H, s). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) δ: 167.25, 158.74, 140.53, 140.49, 138.29, 137.85, 137.79, 137.65, 133.81 (C), 129.53, 128.32, 128.28, 128.18, 127.96, 127.81, 127.78, 127.74, 127.66, 127.54, 127.48, 127.18, 127.08, 126.90, 118.22, 118.12, 115.77, 115.47, 115.30, 114.98, 114.70 (CH), 87.12, 79.14, 78.25, 77.87, 77.71 (CH), 75.56, 75.11, 75.03 (CH<sub>2</sub>), 73.82 (CH), 73.44, 68.93, 67.23 (CH<sub>2</sub>), 61.02, 60.47 (CH), 38.10 (CH<sub>2</sub>), 25.89 (CH<sub>3</sub>), 24.71 (CH<sub>2</sub>), 18.24 (C), -4.54, -4.83 (CH<sub>3</sub>). IR (cm<sup>-1</sup>): 2951, 2929, 2858, 1749, 1608, 1510, 1454, 1386, 1361, 1250, 1223, 1156, 1141, 1101, 1028, 911, 835, 777, 735, 699. MALDI-MS (C<sub>65</sub>H<sub>71</sub>F<sub>2</sub>NO<sub>8</sub>Si): [MNa]<sup>+</sup> 1082.4831 (calcd. 1082.4815).


This C-Glycoside (72 mg, 0.068 mmol) was subsequently dissolved in EtOH (5 mL), Pd(OH)<sub>2</sub>/C (20% (w/w), 40 mg) was added and the suspension was evacuated 4 times with H<sub>2</sub> and stirred under an H<sub>2</sub>-atmosphere for 17 h. The suspension was evaporated on celite and

purified by dry column vacuum chromatography (3.8 x 2.0 cm) on silica gel eluting with a gradient of 0-100% EtOAc in hexane followed by 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v) to give the debenzylated C-glycoside (28 mg, 59%) as colourless oil.


<sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) δ: 167.22, 163.28, 160.05, 158.36, 157.03, 140.57, 133.75, 130.30, 129.52, 127.22, 127.11, 118.23, 115.83, 115.54, 116.35, 115.05, 114.91, 114.76, 79.16, 78.33, 77.70, 73.88, 70.18, 69.52, 67.75, 61.54, 60.79, 60.57, 38.14, 25.91, 24.81, 18.27, -4.51, -4.80. IR (cm<sup>-1</sup>): 3391, 2930, 2858, 1747, 1609, 1510, 1387, 1362, 1223, 1140, 1086, 1043, 1014, 835, 758. MALDI-MS (C<sub>37</sub>H<sub>47</sub>F<sub>2</sub>NO<sub>8</sub>Si): [MH-TBDMSOH]<sup>+</sup> 568.2132 (calcd. 568.2147); [MNa]<sup>+</sup> 722.2939 (calcd. 722.2937).

Subsequently, the debenzylated C-Glycoside (27.0 mg, 0.039 mmol) was dissolved in THF (1.0 mL), TBAF (0.2 mL, 1M in THF) was added and the solution was stirred for 15 h, diluted with CH<sub>2</sub>Cl<sub>2</sub>, evaporated on celite and purified by dry column vacuum chromatography (3.5 x 2.0 cm) on silica gel eluting with a gradient of 0-18% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v) to give the desired C-glycoside **VIII** (14.0 mg, 62%) as a white solid after coevaporation with hexane (10 mL).

<sup>1</sup>H-NMR (300 MHz, CD<sub>3</sub>OD) δ: 7.33-7.23 (6H, m), 7.05-6.94 (6H, m), 4.78 (1H, d, *J* = 1.9 Hz), 4.59 (1H, t, *J* = 5.3 Hz), 4.29 (1H, dd, *J* = 1.5, 10.3 Hz), 4.13 (1H, dd, *J* = 5.6, 10.6 Hz), 3.85 (1H, d, *J* = 11.2 Hz), 3.67-3.61 (1H, m), 3.57-3.51 (1H, m), 3.44-3.37 (2H, m), 3.31-3.28 (2H, m), 3.11-3.06 (1H, m), 1.97-1.81 (4H, m). <sup>13</sup>C-NMR (75 MHz, CD<sub>3</sub>OD) δ: 169.20, 160.12, 130.69, 128.36, 128.25, 128.14, 119.52, 119.41, 116.35, 116.04, 115.93, 115.63, 115.35, 81.55, 79.49, 79.39, 73.35, 71.30, 71.23, 68.77, 62.66, 61.74, 60.86, 37.22, 25.84. MALDI-MS (C<sub>31</sub>H<sub>33</sub>F<sub>2</sub>NO<sub>8</sub>): [MH-TBDMSOH]<sup>+</sup> 568.2143 (calcd. 568.2147); [MNa]<sup>+</sup> 608.2073 (calcd. 608.2072).

**Example 5****IX**

a)

**IXa**

Methyl 2,3,4-Tri-O-benzyl- $\alpha$ -D-glucopyranoside (prepared according to Jaramillo, C. et al; Chiara, J. L.; Martinlomas, M. J. *Org. Chem.* **1994**, 59, 3135-3141; 1.181 g, 2.54 mmol) was dissolved in anhydrous  $\text{CH}_2\text{Cl}_2$  (25 mL) at  $0^\circ\text{C}$ , anhydrous pyridine (3.0 mL) followed by  $\text{MsCl}$  (0.50 mL, 6.4 mmol) were added and the solution was stirred at  $0^\circ\text{C}$  for 1 h and at room temperature for 7 h followed by addition of sat. aq.  $\text{NaHCO}_3$  (50 mL). The layers were separated and the aqueous layer extracted with EtOAc (3 x 25 mL). The combined organic layer was washed successively with sat. aq.  $\text{NaHCO}_3$  (25 mL) and  $\text{H}_2\text{O}$  (25 mL), evaporated on celite and purified by dry column vacuum chromatography (4.1 x 3.3 cm) on silica gel eluting with a gradient of 0-100%  $\text{CH}_2\text{Cl}_2$  in hexane (v/v) followed by 0.25-1.0% MeOH in  $\text{CH}_2\text{Cl}_2$  (v/v) to give the corresponding mesylate (1.303 g, 94%) as a colourless oil after coevaporation with acetonitrile (3 x 10 mL).

$^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.39-7.26 (15H, m), 5.02 (1H, d,  $J$  = 10.6 Hz), 4.92 (1H, d,  $J$  = 10.6 Hz), 4.84 (1H, d,  $J$  = 10.6 Hz), 4.80 (1H, d,  $J$  = 12.5 Hz), 4.66 (1H, d,  $J$  = 11.8 Hz), 4.63 (1H, d,  $J$  = 10.6 Hz), 4.60 (1H, d,  $J$  = 3.7 Hz), 4.41-4.32 (2H, m), 4.02 (1H, t,  $J$  = 9.3 Hz), 3.85 (1H, dt,  $J$  = 3.7, 10.0 Hz), 3.52 (1H, dt,  $J$  = 3.7, 6.2 Hz), 3.50 (1H, bs), 3.39 (3H, s), 2.98 (3H, s).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 138.30, 137.75, 137.56 (C), 128.36, 128.30, 127.94, 127.84, 127.76, 127.57 (CH), 98.06, 81.73, 79.69, 76.86 (CH), 75.73, 75.09, 73.44 ( $\text{CH}_2$ ), 68.59 (CH), 68.36 ( $\text{CH}_2$ ), 55.46, 37.54 ( $\text{CH}_3$ ). IR ( $\text{cm}^{-1}$ ): 3031, 2913, 1497, 1454, 1359, 1177, 1089, 1074, 1046, 1003, 965, 931, 813, 739, 699. MALDI-MS:  $[\text{MNa}]^+$  565.1873 (calcd. 565.1872). Anal. Calcd for  $\text{C}_{29}\text{H}_{34}\text{O}_8\text{S}$ : C, 64.19; H, 6.32. Found: C, 63.99; H, 6.27.

Subsequently, this mesylate (1.290 g, 2.38 mmol) was dissolved in EtOH (25 mL), KOSMe (869 mg, 7.61 mmol) was added and the unclear solution was stirred at reflux for 4 h (orange precipitate). After cooling, 50% sat. aq.  $\text{NaHCO}_3$  (100 mL) was added and the suspension was extracted with EtOAc (3 x 50 mL). The combined organic layer was washed successively with sat. aq.  $\text{NaHCO}_3$  (50 mL) and  $\text{H}_2\text{O}$  (50 mL), evaporated on celite and purified by dry column vacuum chromatography (4.1 x 3.3 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding thioacetate (1.189 g, 96%) as a light orange solid.

$^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.41-7.32 (15H, m), 5.03 (1H, d,  $J$  = 10.6 Hz), 4.94 (1H, d,  $J$  = 10.6 Hz), 4.86 (1H, d,  $J$  = 10.6 Hz), 4.82 (1H, d,  $J$  = 11.8 Hz), 4.69 (1H, d,  $J$  = 11.8 Hz), 4.66 (1H, d,  $J$  = 10.6 Hz), 4.58 (1H, d,  $J$  = 3.1 Hz), 4.02 (1H, t,  $J$  = 9.0 Hz), 3.81 (1H, dt,  $J$  = 2.5, 7.5 Hz), 3.55 (1H, dd,  $J$  = 3.7, 9.3 Hz), 3.48 (1H, dd,  $J$  = 3.1, 13.7 Hz), 3.40 (3H, s), 3.35 (1H, t,  $J$  = 9.5 Hz), 3.08 (1H, dd,  $J$  = 7.5, 13.7 Hz), 2.36 (3H, s).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 194.67, 138.46, 137.90, 137.78 (C), 128.33, 128.29, 128.03, 127.94, 127.85, 127.81, 127.74, 127.53

(CH), 97.72, 81.69, 80.36, 79.78 (CH), 75.64, 75.04, 73.22 (CH<sub>2</sub>), 69.23 (CH), 55.02 (CH<sub>3</sub>), 30.73 (CH<sub>2</sub>), 30.39 (CH<sub>3</sub>). IR (cm<sup>-1</sup>): 3063, 3031, 2908, 1694, 1497, 1454, 1358, 1201, 1156, 1136, 1092, 1072, 1050, 1029, 999, 955, 737, 698, 630. MALDI-MS: [MNa]<sup>+</sup> 545.1974 (calcd. 545.1974). Anal. Calcd for C<sub>30</sub>H<sub>34</sub>O<sub>6</sub>S: C, 68.94; H, 6.56. Found: C, 68.77; H, 6.63.

The thioacetate received above (1.180 g, 2.26 mmol) was then dissolved in AcOH (25 mL), KOAc (4.082 g, 41.6 mmol) followed by Oxone (2KHSO<sub>5</sub>·KHSO<sub>4</sub>·K<sub>2</sub>SO<sub>4</sub>, 4.019 g, 8.69 mmol) were added and after stirring for 15 h, sat. aq. NaHCO<sub>3</sub> (100 mL), H<sub>2</sub>O (50 mL) and sat. aq. Na<sub>2</sub>CO<sub>3</sub> (50 mL) were carefully added. After extraction with EtOAc (4 x 40 mL), the combined organic layer was washed with sat. aq. Na<sub>2</sub>CO<sub>3</sub> (50 mL), evaporated on celite and purified by dry column vacuum chromatography (4.0 x 3.3 cm) on silica gel eluting with a gradient of 0-90% EtOAc in hexane (v/v) followed by 0-50% MeOH in EtOAc (v/v) to give the corresponding sulfonate salt (1.116 g, 90%) as a white solid.


<sup>1</sup>H-NMR (300 MHz, CD<sub>3</sub>OD) δ: 7.37-7.21 (15H, m), 4.90 (1H, d, *J* = 11.2 Hz), 4.86 (1H, d, *J* = 10.6 Hz), 4.84 (1H, d, *J* = 11.2 Hz), 4.73 (1H, d, *J* = 3.1 Hz), 4.72 (1H, d, *J* = 11.2 Hz), 4.64 (1H, d, *J* = 12.5 Hz), 4.60 (1H, d, *J* = 11.2 Hz), 4.16 (1H, t, *J* = 9.2 Hz), 3.90 (1H, t, *J* = 9.3 Hz), 3.55 (1H, dd, *J* = 3.4, 9.3 Hz), 3.48 (3H, s), 3.30-3.22 (2H, m), 2.92 (1H, dd, *J* = 10.0, 14.3 Hz). <sup>13</sup>C-NMR (75 MHz, CD<sub>3</sub>OD) δ: 140.03, 139.57, 139.55 (C), 129.42, 129.31, 129.15, 128.93, 128.89, 128.84, 128.67, 128.59 (CH), 98.53, 83.03, 81.65, 81.52 (CH), 76.44, 75.83, 73.85 (CH<sub>2</sub>), 68.52 (CH), 55.95 (CH<sub>3</sub>), 53.65 (CH<sub>2</sub>). IR (cm<sup>-1</sup>): 3484, 3030, 2922, 1497, 1454, 1360, 1230, 1198, 1177, 1156, 1093, 1058, 1028, 736, 696. MALDI-MS (C<sub>28</sub>H<sub>31</sub>NaO<sub>8</sub>S): [MNa]<sup>+</sup> 573.1536 (calcd. 573.1535).

Finally, the obtained sulfonate salt (696 mg, 1.26 mmol) was suspended in anhydrous acetonitrile/CH<sub>2</sub>Cl<sub>2</sub> (10 mL, 1:1 (v/v)) at 0°C, Ph<sub>3</sub>P (1.002 g, 3.8 mmol) and thionyl chloride (0.40 mL, 5.5

mmol) were added sequentially and the suspension was stirred at room temperature for 13 h. EtOAc/hexane (1:4 (v/v), 100 mL) was added, the suspension was filtered through celite (4 x 15 mL EtOAc/hexane (1:3 (v/v)) washings) and the filtrate was evaporated and dried shortly under vacuum to give the desired sulfonyl chloride **IXa** (657 mg, 95%) as a yellowish oil.

$^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.42-7.28 (15H, m), 5.05 (1H, d,  $J$  = 10.6 Hz), 4.96 (1H, d,  $J$  = 11.8 Hz), 4.85 (1H, d,  $J$  = 10.6 Hz), 4.83 (1H, d,  $J$  = 11.8 Hz), 4.67 (1H, d,  $J$  = 12.5 Hz), 4.60 (1H, d,  $J$  = 11.2 Hz), 4.60 (1H, d,  $J$  = 3.1 Hz), 4.33 (1H, t,  $J$  = 9.6 Hz), 4.07 (1H, t,  $J$  = 9.0 Hz), 3.85 (1H, dd,  $J$  = 1.2, 13.7 Hz), 3.55 (1H, d,  $J$  = 9.3 Hz), 3.52 (1H, t,  $J$  = 10.0 Hz), 3.46 (3H, s), 3.26 (1H, t,  $J$  = 9.5 Hz).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 138.02, 137.57, 137.06 (C), 128.58, 128.36, 128.30, 128.23, 128.12, 127.92, 127.66 (CH), 98.00, 81.56, 79.41, 78.49 (CH), 75.85, 74.76, 73.38, 66.75 ( $\text{CH}_2$ ), 65.93 (CH), 55.90 ( $\text{CH}_3$ ). MALDI-MS ( $\text{C}_{28}\text{H}_{31}\text{ClO}_7\text{S}$ ):  $[\text{MNa}]^+$  569.1378 (calcd. 569.1377).

**b)**



**IXb**

The sulfonyl chloride **IXa** obtained in step 5a) (197 mg, 0.36 mmol) was suspended in anhydrous  $\text{CH}_2\text{Cl}_2$  (5 mL), anhydrous pyri-

dine (0.5 mL) followed by the silylated azetidinone phenol **Via** obtained in step 2a) (70.0 mg, 0.13 mmol) were added and the solution was stirred for 22 h, diluted with EtOAc (25 mL) and washed sequentially with sat. aq. NaHCO<sub>3</sub> (10 mL) and H<sub>2</sub>O (10 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.3 x 2.0 cm) on silica gel eluting with a gradient of 0-35% EtOAc in hexane (v/v) to give the corresponding glycosylated azetidinone (125.5 mg, 91%) as a colourless oil/glass.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.37-7.14 (23H, m), 7.00 (2H, t, *J* = 8.7 Hz), 6.95 (2H, t, *J* = 8.7 Hz), 5.05 (1H, d, *J* = 11.2 Hz), 4.97 (1H, d, *J* = 11.2 Hz), 4.84 (1H, d, *J* = 11.8 Hz), 4.82 (1H, d, *J* = 10.6 Hz), 4.69 (1H, t, *J* = 6.8 Hz), 4.67 (1H, d, *J* = 12.5 Hz), 4.60 (1H, d, *J* = 3.7 Hz), 4.56 (1H, d, *J* = 12.5 Hz), 4.54 (1H, d, *J* = 10.6 Hz), 4.29 (1H, t, *J* = 9.5 Hz), 4.06 (1H, t, *J* = 9.0 Hz), 3.57 (1H, t, *J* = 3.1 Hz), 3.53 (1H, d, *J* = 3.1 Hz), 3.46 (3H, s), 3.26 (1H, t, *J* = 9.3 Hz), 3.14 (1H, dd, *J* = 10.0, 14.3 Hz), 2.96 (1H, dt, *J* = 1.9, 6.8 Hz), 1.97-1.78 (4H, m), 0.90 (9H, s), 0.04 (3H, s), -0.13 (3H, s). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) δ: 166.62, 163.27, 160.37, 160.03, 157.14, 148.91, 140.33, 138.05, 137.63, 137.29, 136.67, 133.45, 133.42 (C), 128.44, 128.31, 128.18, 128.04, 127.96, 127.86, 127.65, 127.15, 127.03, 126.97, 123.15, 118.13, 118.03, 115.93, 115.64, 115.02, 114.75 (CH), 97.92, 81.67, 79.60, 79.23 (CH), 75.78, 74.86 (CH<sub>2</sub>), 73.78 (CH), 73.37 (CH<sub>2</sub>), 65.64, 60.66, 60.48 (CH), 55.73 (CH<sub>3</sub>), 51.63, 38.06 (CH<sub>2</sub>), 25.85 (CH<sub>3</sub>), 24.69 (CH<sub>2</sub>), 18.22 (C), -4.54, -4.87 (CH<sub>3</sub>). IR (cm<sup>-1</sup>): 3032, 2930, 2858, 1750, 1605, 1510, 1455, 1386, 1252, 1220, 1153, 1086, 1073, 1048, 870, 836, 755, 699. MALDI-MS: [MNa]<sup>+</sup> 1056.3969 (calcd. 1056.3964). Anal. Calcd for C<sub>58</sub>H<sub>65</sub>F<sub>2</sub>NO<sub>10</sub>SiS: C, 67.35; H, 6.33; N, 1.35. Found: C, 67.43; H, 6.44; N, 1.33.

Subsequently the glycosylated azetidinone (105.1 mg, 0.102 mmol) was dissolved in EtOH (5 mL), Pd(OH)<sub>2</sub>/C (20% (w/w), 33 mg) was

added and the suspension was evacuated 4 times with H<sub>2</sub> and stirred under an H<sub>2</sub>-atmosphere for 6 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 2.0 cm) on silica gel eluting with a gradient of 0-10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v) to give the debenzylated azetidinone (63.2 mg, 81%) as a colourless oil.

<sup>1</sup>H-NMR (300 MHz, acetone-*d*<sub>6</sub>) δ: 7.55 (2H, d, *J* = 8.7 Hz), 7.42 (2H, d, *J* = 8.7 Hz), 7.37 (2H, dd, *J* = 5.9, 8.4 Hz), 7.28 (2H, dd, *J* = 5.0, 9.3 Hz), 7.11-7.01 (4H, m), 4.96 (1H, d, *J* = 1.9 Hz), 4.84 (1H, t, *J* = 5.3 Hz), 4.69 (1H, d, *J* = 3.7 Hz), 4.61 (1H, d, *J* = 5.0 Hz), 4.35 (1H, d, *J* = 3.1 Hz), 4.16 (1H, dt, *J* = 1.2, 10.0 Hz), 3.87 (1H, dd, *J* = 1.2, 14.9 Hz), 3.79 (1H, d, *J* = 7.5 Hz), 3.65 (1H, t, *J* = 9.0 Hz), 3.56 (1H, dd, *J* = 10.0, 14.9 Hz), 3.45-3.40 (1H, m), 3.38 (3H, s), 3.27-3.14 (2H, m), 2.00-1.88 (4H, m), 0.87 (9H, s), 0.05 (3H, s), -0.15 (3H, s). <sup>13</sup>C-NMR (75 MHz, acetone-*d*<sub>6</sub>) δ: 167.25, 163.96, 160.84, 160.75, 157.65, 150.14, 141.91, 141.87, 138.13, 134.95, 134.91 (C), 128.32, 128.23, 123.84, 118.98, 118.88, 116.43, 116.12, 115.49, 115.21 (CH), 100.74, 74.77, 74.42, 73.55, 73.04, 68.01, 61.25, 60.50 (CH), 55.56 (CH<sub>3</sub>), 52.83, 38.50 (CH<sub>2</sub>), 26.16 (CH<sub>3</sub>), 25.34 (CH<sub>2</sub>), 18.65 (C), -4.47, -4.71 (CH<sub>3</sub>). IR (cm<sup>-1</sup>): 3396, 2951, 2931, 2857, 1754, 1701, 1605, 1510, 1426, 1385, 1250, 1220, 1151, 1103, 1088, 1053, 1015, 988, 872, 836, 778. MALDI-MS (C<sub>37</sub>H<sub>47</sub>F<sub>2</sub>NO<sub>10</sub>SSi): [MNa]<sup>+</sup> 786.2559 (calcd. 786.2556).

This debenzylated azetidinone (58.9 mg, 0.077 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle), anhydrous pyridine (0.5 mL) followed by HF·pyridine complex (0.5 mL) were added and the solution was stirred for 14.5 h, diluted with ether (20 mL) and washed with sat. aq. NaHCO<sub>3</sub> (3 x 5 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 2.0 cm) on silica gel eluting with a gradient of 0-10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v) to give the desired azetidinone **Ixb** (44.9 mg, 90%) as a white solid.




$^1\text{H}$ -NMR (300 MHz, acetone- $d_6$ )  $\delta$ : 7.56 (2H, d,  $J$  = 8.7 Hz), 7.43 (2H, d,  $J$  = 8.7 Hz), 7.37 (2H, dd,  $J$  = 5.6, 8.7 Hz), 7.30 (2H, dd,  $J$  = 4.7, 9.0 Hz), 7.06 (2H, d,  $J$  = 9.3 Hz), 7.03 (2H, d,  $J$  = 8.7 Hz), 4.99 (1H, d,  $J$  = 2.5 Hz), 4.69 (1H, d,  $J$  = 3.7 Hz), 4.61 (1H, d,  $J$  = 5.0 Hz), 4.42 (1H, d,  $J$  = 3.7 Hz), 4.34 (1H, bs), 4.15 (1H, dt,  $J$  = 1.2, 8.7 Hz), 3.86 (1H, dd,  $J$  = 1.2, 14.9 Hz), 3.79 (1H, d,  $J$  = 8.1 Hz), 3.65 (1H, t,  $J$  = 8.7 Hz), 3.57 (1H, dd,  $J$  = 10.0, 14.9 Hz), 3.44-3.38 (1H, m), 3.38 (3H, s), 3.32-3.14 (2H, m), 2.08-1.86 (4H, m).  $^{13}\text{C}$ -NMR (75 MHz, acetone- $d_6$ )  $\delta$ : 167.42, 163.87, 160.85, 157.67, 150.13, 142.52, 138.18, 134.93 (C), 128.35, 128.22, 128.13, 123.83, 119.01, 118.89, 116.44, 116.13, 115.40, 115.11 (CH), 100.74, 74.77, 73.56, 73.04, 72.77, 68.01, 61.27, 60.56 (CH), 55.56 ( $\text{CH}_3$ ), 52.83, 37.54, 25.70 ( $\text{CH}_2$ ). IR ( $\text{cm}^{-1}$ ): 3395, 2925, 1732, 1604, 1509, 1365, 1219, 1148, 1103, 1051, 1014, 871, 834, 752. MALDI-MS:  $[\text{MNa}]^+$  672.1693 (calcd. 672.1691). Anal. Calcd for  $\text{C}_{31}\text{H}_{33}\text{F}_2\text{NO}_{10}\text{S}$ : C, 57.31; H, 5.12; N, 2.16. Found: C, 57.34; H, 5.26; N, 2.21.

**c)**


$\text{LiAlH}_4$  (57 mg, 1.5 mmol) and  $\text{AlCl}_3$  (200 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 30 min and cooled to  $0^\circ\text{C}$ . The azetidinone **Ixb** obtained under step 5b) (26.8 mg, 0.041 mmol) dissolved in anhydrous THF (1 mL, 2 x 0.5 mL rinse) was added and after stirring at  $0^\circ\text{C}$  for 10 min, sat. aq.  $\text{NaHCO}_3$  (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.7 x 2.0 cm) on silica gel eluting with a gradient of 0-12% MeOH in  $\text{CH}_2\text{Cl}_2$  (v/v) to give the desired azetidine **IX** (20.4 mg, 78%) as a colourless oil.

$^1\text{H}$ -NMR (300 MHz, acetone- $d_6$ )  $\delta$ : 7.63-7.59 (2H, m), 7.49-7.42 (2H, m), 7.36-7.29 (2H, m), 7.10-7.01 (2H, m), 6.92-6.77 (2H, m), 6.40-6.35 (2H, m), 4.72 (1H, d,  $J$  = 3.7 Hz), 4.62 (1H, d,  $J$  = 5.0 Hz), 4.61 (1H, bs), 4.52 (1H, d,  $J$  = 6.9 Hz), 4.31 (2H, t,  $J$

= 4.4 Hz), 4.21-4.15 (2H, m), 3.90 (1H, dd,  $J$  = 1.2, 14.9 Hz), 3.76 (1H, d,  $J$  = 8.1 Hz), 3.68 (1H, dd,  $J$  = 3.7, 9.3 Hz), 3.66-3.57 (2H, m), 3.41 (3H, s, OMe), 3.38-3.31 (1H, m), 3.25 (1H, dt,  $J$  = 5.0, 13.7 Hz), 2.62 (1H, dd,  $J$  = 6.8, 14.3 Hz), 1.92-1.84 (1H, m), 1.74-1.57 (3H, m).  $^{13}\text{C}$ -NMR (75 MHz, acetone- $d_6$ )  $\delta$ : 163.90, 160.69, 158.31, 155.22, 149.93, 149.72, 149.52, 142.90, 142.84 (C), 129.60, 129.44, 128.30, 128.24, 128.13, 123.51, 122.99, 115.95, 115.91, 115.66, 115.40, 115.11, 113.87, 113.77, 113.67, 113.57 (CH), 100.84, 74.86, 74.03, 73.68, 73.14, 72.87, 68.09 (CH), 56.67 (CH<sub>2</sub>), 55.63 (CH<sub>3</sub>), 52.83 (CH<sub>2</sub>), 42.78 (CH), 37.60, 29.83 (CH<sub>2</sub>). IR (cm<sup>-1</sup>): 3390, 2935, 2850, 1605, 1508, 1474, 1366, 1221, 1147, 1052, 1015, 874, 824, 755. MALDI-MS (C<sub>31</sub>H<sub>35</sub>F<sub>2</sub>NO<sub>9</sub>S): [MH-H<sub>2</sub>O]<sup>+</sup> 618.1968 (calcd. 618.1973); [MH]<sup>+</sup> 636.2045 (calcd. 636.2079); [MNa]<sup>+</sup> 658.1901 (calcd. 658.1898).

**Example 6**

a)



The above sulfonyl chloride **Xa** was prepared according to the methods described under step 5a) using C-(Hydroxymethyl)-2,3,4,6-tetra-O-benzyl- $\beta$ -D-glucopyranoside (prepared according to RajanBabu, T. V.; Reddy, G. S. *J. Org. Chem.* **1986**, *51*, 5458-5461) as the starting material.

**b)**

The sulfonyl chloride **Xa** obtained under step 6a) (871 mg, 1.26 mmol) was suspended in anhydrous  $\text{CH}_2\text{Cl}_2$  (10 mL), anhydrous pyridine (1.0 mL) followed by the silylated azetidinone phenol **Via** obtained in step 2a) (334 mg, 0.634 mmol) were added and the solution was stirred for 13 h, diluted with EtOAc (50 mL) and washed sequentially with sat. aq.  $\text{NaHCO}_3$  (20 mL) and  $\text{H}_2\text{O}$  (20 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.3 x 3.3 cm) on silica gel eluting with a gradient of 0-100%  $\text{CH}_2\text{Cl}_2$  in hexane (v/v) to give the corresponding glycosylated azetidinone (657 mg, 92%) as a white foam.

$^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.37-7.15 (28H, m), 7.01 (2H, t,  $J$  = 8.7 Hz), 6.96 (2H, t,  $J$  = 8.7 Hz), 5.03-4.81 (4H, m), 4.73-4.51 (6H, m), 3.95 (1H, t,  $J$  = 8.4 Hz), 3.78 (4H, bs), 3.57-3.53 (1H, m), 3.48 (1H, d,  $J$  = 1.2 Hz), 3.40 (1H, t,  $J$  = 9.0 Hz), 3.24 (1H, dd,  $J$  = 9.3, 14.9 Hz), 3.02-2.95 (1H, m), 1.97-1.80 (4H, m), 0.92 (9H, s), 0.06 (3H, s), -0.11 (3H, s).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 166.72, 163.24, 160.35, 160.01, 157.13, 149.25, 140.37, 140.33, 137.90, 137.65, 137.58, 137.12, 136.97, 136.52, 133.52, 133.48 (C), 128.46, 128.32, 128.28, 128.17, 128.02, 127.97, 127.81, 127.76, 127.67, 127.63, 127.52, 127.13, 127.02, 123.32, 118.13, 118.02, 115.90, 115.60, 115.01, 114.72 (CH), 86.83, 79.13, 78.83, 77.73 (CH), 75.56, 75.00, 74.85 ( $\text{CH}_2$ ), 74.19, 73.77 (CH), 73.31 ( $\text{CH}_2$ ), 68.36, 60.57, 60.53 (CH), 51.31, 38.03 ( $\text{CH}_2$ ), 25.85 ( $\text{CH}_3$ ), 24.67 ( $\text{CH}_2$ ), 18.20 (C), -4.57, -4.87 ( $\text{CH}_3$ ). IR ( $\text{cm}^{-1}$ ): 2951, 2929, 2858, 1751, 1605, 1510, 1454, 1386, 1362, 1251,

1220, 1151, 1102, 871, 835, 776, 754, 699. MALDI-MS:  $[\text{MNa}]^+$  1146.4440 (calcd. 1146.4434). Anal. Calcd for  $\text{C}_{65}\text{H}_{71}\text{F}_2\text{NO}_{10}\text{SiS}$ : C, 69.43; H, 6.36; N, 1.25. Found: C, 69.27; H, 6.47; N, 1.28.

The glycosylated azetidinone obtained above (236 mg, 0.210 mmol) was then dissolved in EtOH/EtOAc (10 mL, 1:1 (v/v)),  $\text{Pd}(\text{OH})_2/\text{C}$  (20% (w/w), 73 mg) was added and the suspension was evacuated 4 times with  $\text{H}_2$  and stirred under an  $\text{H}_2$ -atmosphere for 3.5 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of 0-20% MeOH in  $\text{CH}_2\text{Cl}_2$  (v/v) to give the debenzylated azetidinone (145 mg, 90%) as a white foam.


$^1\text{H}$ -NMR (300 MHz, acetone- $d_6$ )  $\delta$ : 7.55 (2H, dd,  $J = 6.5, 8.7$  Hz), 7.47 (2H, d,  $J = 8.4$  Hz), 7.40-7.20 (4H, m), 7.11-6.98 (4H, m), 4.97 (1H, dd,  $J = 2.3, 10.5$  Hz), 4.83 (1H, bs), 4.61 (1H, bs), 4.48 (1H, bs), 4.30 (1H, bs), 3.90-3.81 (3H, m), 3.71-3.64 (1H, m), 3.56-3.38 (5H, m), 3.25-3.14 (2H, m), 2.66 (1H, t,  $J = 7.2$  Hz), 1.98-1.81 (4H, m), 0.88 (9H, s), 0.05 (3H, s), -0.15 (3H, s).  $^{13}\text{C}$ -NMR (75 MHz, acetone- $d_6$ )  $\delta$ : 168.30, 161.88, 158.69, 151.25, 142.96, 139.63, 139.16, 139.13, 135.98 (C), 131.66, 131.56, 129.36, 129.28, 124.92, 120.00, 119.90, 117.46, 117.16, 116.62, 116.52 (CH), 82.13, 80.16, 76.75, 75.44, 74.46, 72.35 (CH), 63.64 ( $\text{CH}_2$ ), 61.60, 61.55 (CH), 54.03, 39.52 ( $\text{CH}_2$ ), 27.20 ( $\text{CH}_3$ ), 26.35 ( $\text{CH}_2$ ), 19.68 (C), -3.44, -3.69 ( $\text{CH}_3$ ). IR ( $\text{cm}^{-1}$ ): 3380, 2930, 2858, 1749, 1604, 1510, 1385, 1363, 1220, 1172, 1149, 1088, 1032, 1016, 872, 835, 757. MALDI-MS:  $[\text{MNa}]^+$  786.2563 (calcd. 786.2556). Anal. Calcd for  $\text{C}_{37}\text{H}_{47}\text{F}_2\text{NO}_{10}\text{SiS}$ : C, 58.17; H, 6.20; N, 1.83. Found: C, 58.02; H, 6.26; N, 1.85.

The debenzylated azetidinone (31.5 mg, 0.041 mmol) was then dissolved in anhydrous THF (2.5 mL, teflon bottle), anhydrous pyridine (0.5 mL) followed by HF·pyridine complex (0.5 mL) were added and the solution was stirred for 24 h, diluted with ether (20 mL) and washed with sat. aq.  $\text{NaHCO}_3$  (3 x 5 mL). The organic layer

was evaporated on celite and purified by dry column vacuum chromatography (4.3 x 2.0 cm) on silica gel eluting with a gradient of 0-20% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v) to give the desired azetidinone **X** (9.8 mg, 37%) as a white solid.

<sup>1</sup>H-NMR (300 MHz, acetone-*d*<sub>6</sub>) δ: 7.55 (2H, d, *J* = 8.7 Hz), 7.47 (2H, d, *J* = 8.7 Hz), 7.36 (2H, dd, *J* = 5.6, 8.7 Hz), 7.29 (2H, dd, *J* = 4.8, 9.2 Hz), 7.06 (2H, d, *J* = 8.7 Hz), 7.03 (2H, d, *J* = 9.0 Hz), 4.98 (1H, d, *J* = 2.5 Hz), 4.68 (1H, bs), 4.58 (1H, bs), 4.38 (1H, bs), 4.27 (1H, bs), 3.89-3.80 (3H, m), 3.66 (1H, d, *J* = 10.6 Hz), 3.54-3.36 (5H, m), 3.24-3.14 (2H, m), 2.00-1.86 (4H, m). <sup>13</sup>C-NMR (75 MHz, acetone-*d*<sub>6</sub>) δ: 168.48, 151.29, 143.63, 139.23, 136.09 (C), 129.37, 129.29, 129.19, 124.97, 120.05, 119.94, 117.49, 117.18, 116.46, 116.18 (CH), 82.17, 80.18, 76.78, 74.49, 73.79, 72.42 (CH), 63.67 (CH<sub>2</sub>), 62.35, 61.63 (CH), 54.06, 38.62, 26.75 (CH<sub>2</sub>). IR (cm<sup>-1</sup>): 3364, 2924, 1734, 1509, 1388, 1220, 1148, 1102, 872, 835, 769. MALDI-MS (C<sub>31</sub>H<sub>33</sub>F<sub>2</sub>NO<sub>10</sub>S): [MNa]<sup>+</sup> 672.1744 (calcd. 672.1691).

### Example 7



**XI**

LiAlH<sub>4</sub> (57 mg, 1.5 mmol) and AlCl<sub>3</sub> (200 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 30 min and cooled to 0°C. The azetidinone **X** obtained in Example 6 (41.3 mg, 0.054 mmol) dissolved in anhydrous ether (5 mL) was added and


after stirring at 0°C for 10 min, sat. aq. NaHCO<sub>3</sub> (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 2.0 cm) on silica gel eluting with a gradient of 0-20% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v) to give the corresponding azetidine (38.2 mg, 94%) as a white foam.

<sup>1</sup>H-NMR (300 MHz, acetone-*d*<sub>6</sub>) δ: 7.58 (2H, d, *J* = 8.7 Hz), 7.47 (2H, d, *J* = 8.7 Hz), 7.29 (2H, dd, *J* = 5.6, 8.7 Hz), 7.05 (2H, t, *J* = 8.7 Hz), 6.88 (2H, t, *J* = 9.0 Hz), 6.37 (2H, dd, *J* 4.7, 9.0 Hz), 4.71 (1H, t, *J* = 5.5 Hz), 4.61 (1H, d, *J* = 5.0 Hz), 4.49 (2H, d, *J* = 6.8 Hz), 4.30 (1H, bs), 4.17 (1H, t, *J* = 7.2 Hz), 3.92-3.83 (3H, m), 3.74-3.66 (1H, m), 3.57-3.40 (5H, m), 3.32-3.15 (2H, m), 2.63-2.56 (1H, m), 1.82-1.56 (4H, m), 0.87 (9H, s), 0.04 (3H, s), -0.17 (3H, s). <sup>13</sup>C-NMR (75 MHz, acetone-*d*<sub>6</sub>) δ: 164.97, 161.76, 159.31, 156.21, 150.76, 150.47, 150.45, 143.77, 143.11, 143.07 (C), 129.35, 129.22, 124.60, 116.95, 116.65, 116.48, 116.19, 114.86, 114.75 (CH), 82.15, 80.21, 76.81, 75.43, 74.99, 74.52, 72.41 (CH), 63.70, 57.54, 53.95 (CH<sub>2</sub>), 43.62 (CH), 39.47, 31.22 (CH<sub>2</sub>), 27.20 (CH<sub>3</sub>), 19.70 (C), -3.40, -3.68 (CH<sub>3</sub>). IR (cm<sup>-1</sup>): 3377, 2930, 2856, 1605, 1508, 1472, 1361, 1252, 1222, 1147, 1090, 1015, 871, 836, 776, 760. MALDI-MS (C<sub>37</sub>H<sub>49</sub>F<sub>2</sub>NO<sub>9</sub>SSi): [MNa]<sup>+</sup> 772.2767 (calcd. 772.2763).


The azetidine obtained above (34.3 mg, 0.046 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle), anhydrous pyridine (0.5 mL) followed by HF·pyridine complex (0.5 mL) were added and the solution was stirred for 14 h, diluted with ether (20 mL) and washed with sat. aq. NaHCO<sub>3</sub> (3 x 5 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.9 x 2.0 cm) on silica gel eluting with a gradient of 0-18% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v) to give the desired azetidine **XI** (20.2 mg, 69%) as a colourless oil.

<sup>1</sup>H-NMR (300 MHz, acetone-*d*<sub>6</sub>) δ: 7.61 (2H, d, *J* = 8.1 Hz), 7.48

(2H, d,  $J = 8.7$  Hz), 7.30 (2H, dd,  $J = 5.6, 8.7$  Hz), 7.04 (2H, t,  $J = 8.7$  Hz), 6.89 (2H, m), 6.38 (2H, dd,  $J = 4.4, 8.7$  Hz), 4.60 (2H, d,  $J = 4.4$  Hz), 4.52 (1H, d,  $J = 6.8$  Hz), 4.45 (1H, d,  $J = 2.5$  Hz), 4.29 (2H, d,  $J = 4.4$  Hz), 4.19 (1H, t,  $J = 6.8$  Hz), 4.03-3.83 (3H, m), 3.80-3.67 (1H, m), 3.60-3.31 (6H, m), 3.25 (1H, p,  $J = 4.4$  Hz), 2.62 (1H, dd,  $J = 7.5, 14.3$  Hz), 1.92-1.82 (1H, m), 1.78-1.61 (3H, m).  $^{13}\text{C}$ -NMR (75 MHz, acetone- $d_6$ )  $\delta$ : 164.04, 155.14, 149.92, 149.71, 149.47, 142.77, 129.48 (C), 128.19, 128.16, 128.05, 123.52, 123.03, 115.87, 115.58, 115.39, 115.32, 115.05, 113.78, 113.69, 113.61, 113.51 (CH), 81.09, 79.15, 75.76, 73.98, 73.46, 72.75, 71.36 (CH), 62.63, 56.60, 52.88 ( $\text{CH}_2$ ), 42.68 (CH), 37.52, 29.61 ( $\text{CH}_2$ ). IR ( $\text{cm}^{-1}$ ): 3370, 2933, 1605, 1508, 1474, 1360, 1220, 1146, 1087, 1015, 873, 823, 771. MALDI-MS ( $\text{C}_{31}\text{H}_{35}\text{F}_2\text{NO}_9\text{S}$ ):  $[\text{MH}-\text{H}_2\text{O}]^+$  618.1973 (calcd. 618.1973);  $[\text{M}]^+$  635.1996 (calcd. 635.2001);  $[\text{MNa}]^+$  658.1900 (calcd. 658.1898).

**Example 8****XII**

a)

**XIIa**


Ezetimibe (commercially obtained or synthesized according to Wu, G. Z. et al., *J. Org. Chem.* **1999**; 279 mg, 0.681 mmol) was dissolved in anhydrous DMF (5 mL), imidazole (262 mg, 3.84 mmol) and TBDMSCl (500 mg, 3.32 mmol) were added sequentially and the solution was stirred for 5 h followed by addition of 50% sat. aq. NaHCO<sub>3</sub> (50 mL). After extraction with EtOAc (4 x 20 mL), the combined organic layer was washed successively with sat. aq. NaHCO<sub>3</sub> (20 mL) and H<sub>2</sub>O (20 mL), evaporated on celite and purified by dry column vacuum chromatography (3.8 x 3.3 cm) on silica gel eluting with a gradient of 0-10% EtOAc in hexane (v/v) to give the fully silylated azetidinone **XIIa** (424 mg, 97%) as a colourless oil.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.25-7.21 (4H, m), 7.17 (2H, d, *J* = 8.1 Hz), 6.98 (2H, t, *J* = 8.7 Hz), 6.91 (2H, t, *J* = 8.7 Hz), 6.83 (2H, d, *J* = 8.1 Hz), 4.66 (1H, t, *J* = 5.6 Hz), 4.51 (1H, d, *J* = 2.5 Hz), 3.08-3.02 (1H, m), 1.96-1.78 (4H, m), 0.98 (9H, s), 0.88 (9H, s), 0.20 (6H, s), 0.02 (3H, s), -0.16 (3H, s). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) δ: 167.27, 163.28, 160.27, 160.04, 157.06, 155.71, 140.58, 140.54, 133.89, 133.86 (C), 129.99, 127.22, 127.11, 126.94, 120.56, 118.24, 118.15, 115.74, 115.44, 114.99, 114.72 (CH), 73.84, 61.08, 60.44 (CH), 38.08 (CH<sub>2</sub>), 25.90, 25.68 (CH<sub>3</sub>), 24.75 (CH<sub>2</sub>), 18.26, 18.24 (C), -4.28, -4.52, -4.83 (CH<sub>3</sub>).



IR ( $\text{cm}^{-1}$ ): 2954, 2930, 2858, 1752, 1607, 1510, 1385, 1259, 1223, 1101, 1085, 914, 834, 778. MALDI-MS:  $[\text{MH}-\text{TBDMSOH}]^+$  506.2329 (calcd. 506.2327);  $[\text{MH}]^+$  638.3289 (calcd. 638.3297);  $[\text{MNa}]^+$  660.3117 (calcd. 660.3117). Anal. Calcd for  $\text{C}_{36}\text{H}_{49}\text{F}_2\text{NO}_3\text{Si}_2$ : C, 67.78; H, 7.74; N, 2.20. Found: C, 67.70; H, 7.60; N, 2.02.

b)



**XIIb**

$\text{LiAlH}_4$  (57 mg, 1.5 mmol) and  $\text{AlCl}_3$  (200 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 40 min and cooled to  $0^\circ\text{C}$ . The fully silylated azetidinone **XIIa** obtained under step 8a) (180.8 mg, 0.283 mmol) dissolved in anhydrous ether (5 mL) was added and after stirring at  $0^\circ\text{C}$  for 30 min,  $\text{H}_2\text{O}$  (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (3.5 x 3.3 cm) on silica gel eluting with a gradient of 0-50%  $\text{CH}_2\text{Cl}_2$  in hexane (v/v) to give the desired bicyclic amine **XIIb** (110.8 mg, 63%) as a colourless oil.

$^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.18-7.14 (2H, m), 6.95 (2H, t,  $J$  = 8.7 Hz), 6.88 (2H, d,  $J$  = 8.7 Hz), 6.74 (2H, d,  $J$  = 8.1 Hz), 6.68 (1H, dd,  $J$  = 2.8, 8.4 Hz), 6.44 (1H, dd,  $J$  = 6.5, 8.7 Hz), 6.38 (1H, dd,  $J$  = 2.8, 9.6 Hz), 4.48 (1H, dd,  $J$  = 5.0, 6.8 Hz), 3.78 (1H, bs), 3.61 (1H, d,  $J$  = 7.5 Hz), 3.26 (1H, dd,  $J$  = 3.1,

11.2 Hz), 2.91 (1H, dd,  $J = 7.8, 11.5$  Hz), 1.91-1.85 (1H, m), 1.68-1.44 (3H, m), 1.16-1.04 (1H, m), 0.99 (9H, s), 0.80 (9H, s), 0.20 (6H, s), 0.06 (3H, s), -0.21 (3H, s).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 163.60, 160.36, 157.37, 154.27, 141.53, 141.01, 138.13 (C), 130.07, 127.56, 127.46, 125.58, 125.50, 120.01, 117.27, 116.98, 115.17, 114.89, 114.78, 114.08, 113.79 (CH), 74.64, 48.97 (CH), 44.52 ( $\text{CH}_2$ ), 39.89 (CH), 38.67, 28.28 ( $\text{CH}_2$ ), 26.00, 25.90 ( $\text{CH}_3$ ), 18.38, 18.32 (C), -4.16, -4.43, -4.77 ( $\text{CH}_3$ ). IR ( $\text{cm}^{-1}$ ): 2955, 2930, 2858, 1607, 1506, 1472, 1408, 1361, 1258, 1222, 1170, 1144, 1085, 1006, 915, 837, 808, 779, 735, 667. MALDI-MS ( $\text{C}_{36}\text{H}_{51}\text{F}_2\text{NO}_2\text{Si}_2$ ):  $[\text{MH-TBDMSOH}]^+$  492.2517 (calcd. 492.2534);  $[\text{M}]^+$  623.3414 (calcd. 623.3426). Anal. Calcd for  $\text{C}_{36}\text{H}_{51}\text{F}_2\text{NO}_2\text{Si}_2$ : C, 69.30; H, 8.24; N, 2.24. Found: C, 69.47; H, 8.32; N, 2.15.


c)

The bicyclic amine **XIIb** obtained under step 8b) (39.8 mg, 0.064 mmol) was dissolved in THF (5 mL), TBAF (0.5 mL, 1M in THF) was added and the solution was stirred for 21 h, evaporated on celite and purified by dry column vacuum chromatography (3.7 x 2.0 cm) on silica gel eluting with a gradient of 0-100% EtOAc in hexane (v/v) to give the desired amine **XII** (27.7 mg, quant.) as a yellowish solid.

$^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.19-7.15 (2H, m), 6.97 (2H, t,  $J = 8.7$  Hz), 6.87 (2H, d,  $J = 8.4$  Hz), 6.74-6.66 (3H, m), 6.46 (1H, dd,  $J = 5.0, 8.7$  Hz), 6.38 (1H, dd,  $J = 2.2, 9.0$  Hz), 5.54 (1H, bs), 4.52 (1H, t,  $J = 6.5$  Hz), 3.61 (1H, d,  $J = 7.2$  Hz), 3.26 (1H, dd,  $J = 3.4, 11.5$  Hz), 2.90 (1H, dd,  $J = 7.5, 11.5$  Hz), 1.95-1.86 (1H, m), 1.78-1.68 (2H, m), 1.52-1.41 (1H, m), 1.19-1.06 (1H, m).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 163.55, 160.30, 157.10, 154.25, 154.00, 140.44, 139.95, 139.90, 137.07 (C), 129.90, 127.46, 127.36, 125.24, 116.99, 116.70, 115.28, 115.26, 115.21, 115.15, 115.00, 114.95, 114.84, 113.91, 113.61 (CH), 73.94, 48.53 (CH), 43.98 ( $\text{CH}_2$ ), 39.73 (CH), 36.43, 27.95 ( $\text{CH}_2$ ). IR ( $\text{cm}^{-1}$ ): 3335, 2925, 2853, 1607, 1511, 1223, 913, 836, 744. MALDI-MS

(C<sub>24</sub>H<sub>23</sub>F<sub>2</sub>NO<sub>2</sub>): [MH-H<sub>2</sub>O]<sup>+</sup> 378.1661 (calcd. 378.1670); [M]<sup>+</sup> 395.1689 (calcd. 395.1670)

### Example 9



**XIII**

The bicyclic amine **XIIb** obtained in step 8b) (503 mg, 0.806 mmol) was dissolved in THF (15 mL) at 0°C, TBAF (1.5 mL, 1M in THF) was added and the solution was stirred at 0°C for 1.5 h, diluted with EtOAc (50 mL) and washed successively with sat. aq. NaHCO<sub>3</sub> (20 mL) and H<sub>2</sub>O (20 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (3.4 x 3.3 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding phenol (344.2 mg, 84%) as a light yellow foam.

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.16 (2H, dd, *J* = 5.6, 8.1 Hz), 6.95 (2H, t, *J* = 8.7 Hz), 6.90 (2H, d, *J* = 8.7 Hz), 6.72 (2H, d, *J* = 8.7 Hz), 6.72-6.67 (1H, m), 6.48 (1H, dd, *J* = 4.4, 8.7 Hz), 6.39 (1H, dd, *J* = 2.7, 9.6 Hz), 4.49 (1H, dd, *J* = 5.6, 6.8 Hz), 4.40 (1H, bs), 3.61 (1H, d, *J* = 7.5 Hz), 3.28 (1H, dd, *J* = 2.7, 11.2 Hz), 2.92 (1H, dd, *J* = 8.1, 11.2 Hz), 1.93-1.87 (1H, m), 1.73-1.47 (3H, m), 1.20-1.15 (1H, m), 0.81 (9H, s), 0.06 (3H, s), -0.20 (3H, s). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) δ: 163.16, 159.93, 157.15, 154.03, 141.13, 141.09, 140.43, 140.40, 137.05 (C), 129.95,

127.21, 127.11, 125.69, 125.62, 116.92, 116.62, 115.23, 114.98, 114.87, 114.83, 114.55, 113.83, 113.53 (CH), 74.36, 48.77 (CH), 44.49 (CH<sub>2</sub>), 39.78 (CH), 38.46, 28.07 (CH<sub>2</sub>), 25.81 (CH<sub>3</sub>), 18.17 (C), -4.52, -4.90 (CH<sub>3</sub>). IR (cm<sup>-1</sup>): 3338, 2954, 2929, 2857, 1606, 1508, 1475, 1462, 1361, 1251, 1221, 1084, 836, 775, 760. MALDI-MS (C<sub>30</sub>H<sub>37</sub>F<sub>2</sub>NO<sub>2</sub>Si): [MH-TBDMSOH]<sup>+</sup> 378.1657 (calcd. 378.1670); [M]<sup>+</sup> 509.2553 (calcd. 509.2562).

The phenol obtained above (79 mg, 0.15 mmol) and 2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-β-D-glucopyranosyl)-α-D-glucopyranosyl 1-(2,2,2-trichloroacetimidate) (prepared according to Buijsman, R. C. et al., *Bioorg. Med. Chem.* **1999**, 7, 1881-1890; 267 mg, 0.34 mmol) were then dissolved in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (2 mL) at -25°C and BF<sub>3</sub>·OEt<sub>2</sub> in CH<sub>2</sub>Cl<sub>2</sub> (1:9 (v/v), 0.10 mL, 0.08 mmol) was added. After stirring for 2.5 h at -25 to -20°C, additional BF<sub>3</sub>·OEt<sub>2</sub> (0.05 mL, 0.39 mmol) was added and after additional 1 h at -25 to -20°C, sat. aq. NH<sub>4</sub>Cl (10 mL) and EtOAc (10 mL) were added. The layers were separated and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic layer was washed successively with sat. aq. NaHCO<sub>3</sub> (10 mL) and H<sub>2</sub>O (10 mL), evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-70% EtOAc in hexane (v/v) to give the glycosylated amine (169 mg, 97%) as a white foam.


<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.12 (2H, dd, *J* = 5.6, 8.7 Hz), 6.94-6.84 (6H, m), 6.66 (1H, dt, *J* = 2.5, 8.1 Hz), 6.42 (1H, dd, *J* = 4.4, 8.7 Hz), 6.29 (1H, dd, *J* = 2.7, 9.6 Hz), 5.29-4.90 (6H, m), 4.54-4.43 (3H, m), 4.37 (1H, dd, *J* = 4.4, 12.5 Hz), 4.16-4.02 (2H, m), 3.86 (1H, t, *J* = 9.0 Hz), 3.77-3.64 (2H, m), 3.60 (1H, d, *J* = 7.5 Hz), 3.23 (1H, dd, *J* = 2.7, 11.5 Hz), 2.88 (1H, dd, *J* = 8.1, 11.2 Hz), 2.07-1.96 (21H, m), 1.87-1.75 (1H, m), 1.70-1.38 (3H, m), 1.13-0.97 (1H, m), 0.76 (9H, s), -0.10 (3H, s), -0.25 (3H, s). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) δ: 170.38, 170.09, 169.67,

169.47, 169.20, 168.96, 163.25, 160.01, 156.95, 155.27, 153.85, 141.10, 140.73, 140.10 (C), 129.91, 127.21, 127.11, 124.80, 116.68, 114.83, 114.56, 113.62 (CH), 100.71, 98.80, 76.33, 74.20, 72.81, 72.69, 72.42, 71.89, 71.48, 71.27, 67.63 (CH), 61.84, 61.42 (CH<sub>2</sub>), 48.71 (CH), 44.19 (CH<sub>2</sub>), 39.61 (CH), 38.27, 27.85 (CH<sub>2</sub>), 25.64, 20.67, 20.58, 20.43 (CH<sub>3</sub>), 17.96 (C), -4.76, -5.14 (CH<sub>3</sub>). IR (cm<sup>-1</sup>): 2955, 2858, 1756, 1506, 1368, 1223, 1049, 837, 770. MALDI-MS (C<sub>56</sub>H<sub>71</sub>F<sub>2</sub>NO<sub>19</sub>Si): [MNa]<sup>+</sup> 1150.4235 (calcd. 1150.4255).

The glycosylated amine obtained above (370 mg, 0.328 mmol) was then dissolved in THF (10 mL), TBAF (1.0 mL, 1M in THF) was added and the solution was stirred for 27 h, diluted with EtOAc (40 mL) and washed successively with sat. aq. NaHCO<sub>3</sub> (15 mL) and H<sub>2</sub>O (15 mL). The organic layer was evaporated and the crude intermediate [MALDI-MS (C<sub>50</sub>H<sub>57</sub>F<sub>2</sub>NO<sub>19</sub>): [MNa]<sup>+</sup> 1036.3394 (calcd. 1036.3391)] was dissolved in MeOH/Et<sub>3</sub>N/THF (12 mL, 1:1:2 (v/v/v)), H<sub>2</sub>O (10.5 mL) was added dropwise and the solution was stirred for 18 h. sat. aq. NaHCO<sub>3</sub> (1 mL) was added dropwise and the suspension was evaporated on celite and purified by dry column vacuum chromatography (4.0 x 3.3 cm) on silica gel eluting with a gradient of 0-25% MeOH in EtOAc (v/v) to give the desired bicyclic amine **XIII** (80.5 mg, 34%) as a white solid after coevaporation with hexane (20 mL).

<sup>1</sup>H-NMR (300 MHz, CD<sub>3</sub>OD) δ: 7.20 (2H, dd, J = 5.6, 8.7 Hz), 7.02-6.93 (6H, m), 6.65 (1H, dt, J = 2.5, 8.7 Hz), 6.54 (1H, dd, J = 5.0, 8.7 Hz), 6.23 (1H, dd, J = 2.5, 10.0 Hz), 4.94 (1H, d, J = 7.5 Hz), 4.47-4.43 (2H, m), 3.92 (2H, bs), 3.90 (1H, d, J = 10.6 Hz), 3.72-3.52 (6H, m), 3.43-3.22 (5H, m), 2.86 (1H, dd, J = 8.1, 11.8 Hz), 1.96-1.84 (1H, m), 1.80-1.68 (2H, m), 1.50-1.35 (1H, m), 1.17-1.03 (1H, m). <sup>13</sup>C-NMR (75 MHz, CD<sub>3</sub>OD) δ: 164.71, 161.49, 157.30, 155.12, 142.58, 141.98, 141.95, 140.78 (C), 130.89, 128.83, 128.72, 126.64, 126.56, 117.52, 117.36, 117.09, 115.86, 115.57 (CH), 104.44, 101.98, 80.21, 78.01, 77.76, 76.49,

76.22, 74.83, 74.58, 74.41, 71.29 (CH), 62.39, 61.63 (CH<sub>2</sub>), 50.00 (CH), 45.09 (CH<sub>2</sub>), 40.95 (CH), 37.38, 29.09 (CH<sub>2</sub>). MALDI-MS (C<sub>36</sub>H<sub>43</sub>F<sub>2</sub>NO<sub>12</sub>): [MNa]<sup>+</sup> 742.2654 (calcd. 742.2651).

**Example 10****XIV**


The silylated azetidinone phenol **VIa** obtained in step 2a) (104.0 mg, 0.199 mmol) was dissolved in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (10 mL), anhydrous pyridine (0.5 mL) followed by PhSO<sub>2</sub>Cl (0.10 mL, 0.78 mmol) were added and the solution was stirred for 19 h. Additional PhSO<sub>2</sub>Cl (0.10 mL, 0.78 mmol) was added and the solution was stirred for further 69 h, diluted with EtOAc (50 mL) and washed sequentially with sat. aq. NaHCO<sub>3</sub> (20 mL) and H<sub>2</sub>O (20 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 3.3 cm) on silica gel eluting with a gradient of 0-100% CH<sub>2</sub>Cl<sub>2</sub> in hexane (v/v) followed by 0.5-1.0% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v) to give the corresponding benzene sulfonate (92.0 mg, 70%) as a colourless oil.

R<sub>F</sub> (1% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v)) 0.72; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.83 (2H, d, *J* = 7.5 Hz), 7.66 (1H, t, *J* = 7.5 Hz), 7.51 (2H, t, *J* = 7.5 Hz), 7.25-7.14 (6H, m), 7.00 (2H, d, *J* = 8.7 Hz), 6.97 (2H, d, *J* = 8.7 Hz), 6.91 (2H, t, *J* = 8.7 Hz), 4.66 (1H, dd, *J* = 4.4, 6.2 Hz), 4.55 (1H, d, *J* = 1.9 Hz), 3.02-2.96 (1H, m), 1.94-1.75 (4H, m), 0.87 (9H, s), 0.00 (3H, s), -0.16 (3H, s). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) δ: 166.82, 163.44, 160.51, 157.29, 149.35, 140.54 (C), 136.77 (CH), 135.26, 134.32, 133.56, 129.13 (C), 128.31, 127.27, 127.17, 127.08, 123.15, 118.23, 118.12, 115.93, 115.63,

115.09, 114.82, 73.76, 60.53, 60.40 (CH), 37.92 (CH<sub>2</sub>), 25.75 (CH<sub>3</sub>), 24.59 (CH<sub>2</sub>), 18.10 (C), -4.71, -5.03 (CH<sub>3</sub>). IR (cm<sup>-1</sup>): 2953, 2930, 2857, 1752, 1605, 1510, 1450, 1382, 1252, 1221, 1202, 1181, 1155, 1093, 1016, 868, 835, 776, 753, 700, 687. MALDI-MS (C<sub>36</sub>H<sub>39</sub>F<sub>2</sub>NO<sub>5</sub>SSi): [MH-TBDMSOH]<sup>+</sup> 532.1395 (calcd. 532.1394); [MNa]<sup>+</sup> 686.2185 (calcd. 686.2184).

This benzene sulfonate (90.0 mg, 0.136 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle) at 0°C, anhydrous pyridine (0.5 mL) followed by HF-pyridine complex (0.5 mL) were added and the solution allowed slowly to warm to room temperature. After 14 h, the mixture was diluted with ether (20 mL) and washed with sat. aq. NaHCO<sub>3</sub> (3 x 5 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (5.0 x 2.0 cm) on silica gel eluting with a gradient of 0-100% CH<sub>2</sub>Cl<sub>2</sub> in hexane (v/v) followed by 1-7% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v) to give  $\beta$ -lactam **XIV** (69.2 mg, 93%) as a white foam.

R<sub>F</sub> (3% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v)) 0.33; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.82 (2H, dd, *J* = 1.2, 7.5 Hz), 7.67 (1H, tt, *J* = 1.2, 7.5 Hz), 7.51 (2H, t, *J* = 7.5 Hz), 7.29-7.22 (4H, m), 7.15 (2H, dd, *J* = 4.4, 8.7 Hz), 6.99 (2H, t, *J* = 8.7 Hz), 6.98 (2H, d, *J* = 8.7 Hz), 6.92 (2H, t, *J* = 8.7 Hz), 4.68 (1H, dd, *J* = 5.6, 6.2 Hz), 4.60 (1H, d, *J* = 1.9 Hz), 3.06-2.98 (1H, m), 2.55 (1H, bs), 2.04-1.84 (4H, m). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$ : 166.87, 163.56, 160.44, 160.31, 157.22, 149.23, 139.84, 139.79 (C), 136.46 (CH), 135.10, 134.26, 133.37 (C), 129.07, 128.22, 127.26, 127.16, 127.02, 123.07, 118.21, 118.11, 115.93, 115.62, 115.36, 115.07, 72.98, 60.50, 60.32 (CH), 36.54, 25.09 (CH<sub>2</sub>). IR (cm<sup>-1</sup>): 3440, 3069, 3017, 2927, 2862, 1747, 1604, 1510, 1450, 1426, 1378, 1221, 1201, 1180, 1154, 1094, 1016, 868, 835, 753, 700, 687, 668. MALDI-MS (C<sub>30</sub>H<sub>25</sub>F<sub>2</sub>NO<sub>5</sub>S): [MH-H<sub>2</sub>O]<sup>+</sup> 532.1388 (calcd. 532.1394); [MNa]<sup>+</sup> 572.1302 (calcd. 572.1319).

**Example 11****XV**


LiAlH<sub>4</sub> (57 mg, 1.5 mmol) and AlCl<sub>3</sub> (202 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 30 min and cooled to 0°C. β-Lactam **XIV** obtained in example 10 (62.8 mg, 0.114 mmol) dissolved in anhydrous ether (5 mL) was added and after stirring at 0°C for 20 min, sat. aq. NaHCO<sub>3</sub> (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.8 x 2.0 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give azetidine **XV** (24.5 mg, 40%) as a white foam.

R<sub>f</sub> (1:1 EtOAc/hexane (v/v)) 0.46; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.88-7.82 (2H, m), 7.70-7.63 (1H, m), 7.55-7.47 (2H, m), 7.38-7.30 (2H, m), 7.24-7.19 (2H, m), 7.05-6.98 (4H, m), 6.83 (2H, t, *J* = 8.7 Hz), 6.26 (2H, dd, *J* = 4.4, 9.3 Hz), 4.56 (1H, dd, *J* = 5.0, 7.5 Hz), 4.36 (1H, d, *J* = 6.8 Hz), 4.09 (1H, dd, *J* = 6.8, 7.5 Hz), 3.27 (1H, dd, *J* = 6.8, 7.5 Hz), 2.79 (1H, d, *J* = 5.6 Hz), 2.52 (1H, dd, *J* = 6.8, 7.5 Hz), 1.89-1.52 (4H, m). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) δ: 163.65, 160.40, 157.73, 154.61, 148.65, 148.07, 141.59, 139.94, 135.36 (C), 134.11, 129.24, 129.03, 128.30, 127.28, 127.17, 122.54, 115.45, 115.15, 112.99, 112.90, 73.47, 73.32 (CH), 55.89 (CH<sub>2</sub>), 41.74 (CH), 36.30, 29.93 (CH<sub>2</sub>). IR (cm<sup>-1</sup>): 3411, 2937, 2853, 1604, 1508, 1474, 1450, 1374, 1221, 1198, 1175, 1151, 1093, 1016, 867, 823, 752, 700, 686. MALDI-MS (C<sub>30</sub>H<sub>27</sub>F<sub>2</sub>NO<sub>4</sub>S): [MH-H<sub>2</sub>O]<sup>+</sup> 518.1596 (calcd. 518.1601); [M]<sup>+</sup> 535.1619 (calcd. 535.1629); [MNa]<sup>+</sup> 558.1512 (calcd. 558.1527).

**Example 12**



52




## XVI

The silylated azetidinone phenol **VIa** obtained in step 2a) (105 mg, 0.201 mmol) was dissolved in anhydrous  $\text{CH}_2\text{Cl}_2$  (5 mL), anhydrous pyridine (0.5 mL, 5.0 mmol) and 3-carboxy-4-hydroxybenzene sulfonyl chloride (prepared according to Stewart, J. *J. Chem. Soc.* **1922**, 121, 2555-2561; 223 mg, 0.94 mmol) were added sequentially and the suspension was stirred at room temperature for 63 h. The mixture was evaporated on celite and purified by dry column vacuum chromatography (4.7 x 2.0 cm) on silica gel eluting with a gradient of 0-15% MeOH in  $\text{CH}_2\text{Cl}_2$  (v/v) to give the corresponding silylated sulfonate (76.2 mg, 53%) as a colourless oil.  $R_f$  (20% MeOH in  $\text{CH}_2\text{Cl}_2$  (v/v)) 0.68;  $^1\text{H-NMR}$  (300 MHz,  $\text{CD}_3\text{CN}$ )  $\delta$ : 10.36 (1H, bs), 8.31 (1H, bs), 7.69 (1H, bs), 7.31-7.13 (8H, m), 7.00 (2H, t,  $J = 7.5$  Hz), 6.89 (2H, t,  $J = 8.1$  Hz), 6.57 (1H, bs), 4.72 (1H, bs), 4.65 (1H, bs), 3.12 (1H, bs), 2.98 (1H, bs), 1.88-1.72 (4H, m), 0.84 (9H, s), 0.01 (3H, s), -0.18 (3H, s).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CD}_3\text{CN}$ )  $\delta$ : 168.91, 167.92, 163.57, 160.97, 157.89, 150.74, 142.17, 142.14, 137.17, 134.89 (C), 128.57, 128.45, 128.16, 123.34, 119.23, 119.17, 118.18, 116.68, 116.38, 115.71, 115.43, 74.39, 61.14, 60.64 (CH), 38.40 ( $\text{CH}_2$ ), 26.12 ( $\text{CH}_3$ ), 25.10 ( $\text{CH}_2$ ), 18.65 (C), -4.53, -4.69 ( $\text{CH}_3$ ). IR ( $\text{cm}^{-1}$ ): 3450, 2954, 2930, 2858, 1751, 1696, 1606, 1585, 1510, 1478, 1386, 1339, 1293, 1220, 1194, 1126, 1103, 1087, 1063, 1042, 835, 777, 758. MALDI-MS ( $\text{C}_{37}\text{H}_{39}\text{F}_2\text{NO}_8\text{SSi}$ ):  $[\text{M-H}+2\text{Na}]^+$  768.1851 (calcd. 768.1851).

This silylated sulfonate (74.2 mg, 62.5 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle) at 0°C, anhydrous pyridine (0.5 mL) followed by HF-pyridine complex (0.5 mL) were added and the solution allowed slowly to warm to room temperature. After 15 h, sat. aq. NaHCO<sub>3</sub> (15 mL) was added and the suspension was evaporated on celite and purified by dry column vacuum chromatography (4.4 x 2.0 cm) on silica gel eluting with a gradient of 0-25% MeOH in EtOAc (v/v) to give sulfonate **XVI** (43.6 mg, 70%) as a white solid.


R<sub>f</sub> (1:3 MeOH/EtOAc (v/v)) 0.44; <sup>1</sup>H-NMR (300 MHz, CD<sub>3</sub>OD) δ: 8.53 (1H, d, *J* = 1.9 Hz), 7.99 (1H, dd, *J* = 2.5, 8.7 Hz), 7.48 (1H, d, *J* = 8.7 Hz), 7.35-7.28 (6H, m), 7.07-6.97 (5H, m), 4.93 (1H, d, *J* = 2.5 Hz), 4.62 (1H, dd, *J* = 5.0, 6.2 Hz), 3.17-3.08 (1H, m), 1.97-1.84 (4H, m). <sup>13</sup>C-NMR (75 MHz, CD<sub>3</sub>OD) δ: 169.19, 164.04, 151.43, 142.04, 142.01, 138.00 (C), 137.35 (CH), 134.92 (C), 129.46, 128.72, 128.62, 128.44, 123.54, 119.86, 119.76, 118.63, 116.82, 116.51, 115.98, 115.68 (CH), 112.37 (C), 73.73, 61.65, 61.39 (CH), 37.49, 26.18 (CH<sub>2</sub>). MALDI-MS (C<sub>31</sub>H<sub>25</sub>F<sub>2</sub>NO<sub>8</sub>S): [M-H+2Na]<sup>+</sup> 654.1000 (calcd. 654.0986).

### Example 13



**XVII**

a)



**XVIIa**

The silylated azetidinone phenol **VIa** obtained in step 2a) (80.3 mg, 0.153 mmol) and alcohol **XVIIa** (prepared according to Spak, S. J.; Martin, O. R. *Tetrahedron* **2000**, *56*, 217-224; 101.5 mg, 0.103 mmol) were dissolved in anhydrous THF (10 mL) at 0°C, Bu<sub>3</sub>P (50 mg, 0.20 mmol) and 1,1'-(azodicarbonyl)dipiperidine (39.5 mg, 0.17 mmol) were added sequentially and the suspension was allowed to warm to ambient temperature over several hours. After stirring at room temperature for 26 h, EtOAc/hexane (1:4 (v/v), 30 mL) was added and the suspension was filtered through celite (2 x 10 mL EtOAc/hexane (1:4 (v/v)) washings). The filtrate was evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-25% EtOAc in hexane (v/v) to give a 1:1 mixture of the corresponding C-glycoside and unreacted phenol **VIa** (49.7 mg) as a white foam.

R<sub>f</sub> (1:1 EtOAc/hexane (v/v)) 0.64; <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) δ: 167.39, 163.27, 160.31, 158.82, 157.09, 140.54, 140.49, 139.05, 138.37, 138.29, 138.19, 137.85, 133.78, 133.73, 129.40, 128.96, 128.23, 128.12, 128.04, 127.94, 127.86, 127.73, 127.63, 127.57, 127.49, 127.41, 127.20, 127.10, 126.87, 118.30, 118.19, 116.01, 115.78, 115.49, 115.30, 114.99, 114.71, 102.41, 85.35, 84.84, 82.70, 79.29, 78.01, 77.82, 77.19, 75.64, 75.25, 75.10, 75.02, 74.96, 74.81, 73.84, 73.26, 68.99, 68.15, 67.49, 61.07, 60.44, 38.09, 25.90, 24.72, 18.25, -4.53, -4.83. MALDI-MS (C<sub>92</sub>H<sub>99</sub>F<sub>2</sub>NO<sub>13</sub>Si): [MNa]<sup>+</sup> 1514.6763 (calcd. 1514.6751).

This mixture of the C-glycoside and phenol **VIa** (49.7 mg) was dissolved in EtOH/EtOAc (10 mL, 1:1 (v/v)), Pd(OH)<sub>2</sub>/C (20% (w/w), 31 mg) was added and the suspension was evacuated 4 times with H<sub>2</sub> and stirred under an H<sub>2</sub>-atmosphere for 3 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of

0-20% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v) to give the corresponding debenzylated C-glycoside (18.7 mg, 21% from **VIa**) as a colourless oil.



R<sub>f</sub> (20% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v)) 0.44; <sup>1</sup>H-NMR (300 MHz, CD<sub>3</sub>OD) δ: 7.31-7.23 (6H, m), 7.04-6.94 (6H, m), 4.71 (1H, d, *J* = 1.9 Hz), 4.41 (1H, d, *J* = 7.5 Hz), 4.12 (1H, dd, *J* = 5.3, 10.9 Hz), 3.91-3.81 (3H, m), 3.66 (1H, d, *J* = 5.6, 11.8 Hz), 3.57-3.47 (3H, m), 3.40-3.20 (7H, m), 3.07 (1H, t, *J* = 5.9 Hz), 1.92-1.78 (4H, m), 0.87 (9H, s), 0.02 (3H, s), -0.18 (3H, s). <sup>13</sup>C-NMR (75 MHz, CD<sub>3</sub>OD) δ: 169.71, 160.66, 145.96, 142.43, 131.16, 131.05, 128.89, 128.80, 128.62, 120.00, 119.89, 116.83, 116.54, 116.41, 116.02, 115.74, 115.58, 104.65, 80.78, 80.43, 79.64, 78.16, 77.90, 75.13, 74.99, 71.43, 62.50, 62.08, 61.29, 38.96, 26.38, 25.75, 19.06, -4.40. MALDI-MS (C<sub>43</sub>H<sub>57</sub>F<sub>2</sub>NO<sub>13</sub>Si): [MNa]<sup>+</sup> 884.3668 (calcd. 884.3465).

This debenzylated C-glycoside (18.3 mg, 0.021 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle) at 0°C, anhydrous pyridine (0.50 mL) followed by HF-pyridine complex (0.50 mL) were added and the solution was stirred for 17 h. NaHCO<sub>3</sub> (s) was added and the suspension was evaporated on celite and purified by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of 0-20% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v) to give the desired C-glycoside **XVII** (10.3 mg, 65%) as a white solid.

R<sub>f</sub> (20% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (v/v)) 0.31; <sup>1</sup>H-NMR (300 MHz, CD<sub>3</sub>OD) δ: 7.33-7.24 (6H, m), 7.05-6.94 (6H, m), 4.78 (1H, d, *J* = 1.9 Hz), 4.60 (1H, t, *J* = 4.4 Hz), 4.41 (1H, d, *J* = 7.5 Hz), 4.30 (1H, d, *J* = 10.0 Hz), 4.12 (1H, dd, *J* = 5.0, 10.6 Hz), 3.91-3.84 (3H, m), 3.66 (1H, d, *J* = 5.6, 11.8 Hz), 3.57-3.49 (3H, m), 3.40-3.20 (6H, m), 3.10-3.06 (1H, m), 1.97-1.82 (4H, m). <sup>13</sup>C-NMR (75 MHz, CD<sub>3</sub>OD) δ: 169.52, 164.87, 160.42, 142.07, 133.18 (C), 131.03, 130.87, 128.68, 128.59, 128.47, 123.36, 119.86, 119.74, 116.69, 116.38, 116.25, 116.22, 115.96, 115.88, 115.68, 104.54, 80.71, 80.36, 79.58, 78.11, 77.85, 74.94, 73.70, 71.38 (CH), 69.02,

56

62.47 (CH<sub>2</sub>), 62.09 (CH<sub>2</sub>+CH), 61.20 (CH), 37.54, 26.18 (CH<sub>2</sub>).  
 MALDI-MS (C<sub>37</sub>H<sub>43</sub>F<sub>2</sub>NO<sub>13</sub>): [MNa]<sup>+</sup> 770.2589 (calcd. 770.2600).

**Example 14****XVIII****a)****XVIIIa**

Alcohol **XVIIa** (prepared according to Spak, S. J.; Martin, O. R. *Tetrahedron* **2000**, *56*, 217-224; 895.3 mg, 0.907 mmol) was dissolved in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (10 mL), anhydrous pyridine (1.0 mL) followed by MsCl (0.20 mL, 2.6 mmol) were added and after stirring for 1 h, sat. aq. NaHCO<sub>3</sub> (40 mL) was added. The layers were separated and the aqueous layer extracted with EtOAc (3 x 20 mL). The combined organic layer was washed successively with sat. aq. NaHCO<sub>3</sub> (20 mL) and H<sub>2</sub>O (20 mL), evaporated on celite and purified by dry column vacuum chromatography (4.2 x 3.3 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the corresponding mesylate (830.7 mg, 86%) as a white solid.

R<sub>f</sub> (1:1 EtOAc/hexane (v/v)) 0.67; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.49-7.24 (35H, m), 5.31 (1H, d, *J* = 11.2 Hz), 5.00 (1H, d, *J* =

11.2 Hz), 4.98-4.79 (6H, m), 4.66-4.36 (9H, m), 4.09 (1H, t,  $J = 9.3$  Hz), 3.90 (1H, dd,  $J = 2.8, 10.9$  Hz), 3.83 (1H, d,  $J = 10.0$  Hz), 3.75-3.62 (5H, m), 3.55-3.39 (5H, m), 2.97 (3H, s).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 138.97, 138.37, 138.21, 138.04, 137.61 (C), 128.37, 128.29, 128.18, 128.08, 127.93, 127.84, 127.76, 127.38, 127.34, 127.24, 102.51, 84.86, 82.64, 78.70, 77.94, 76.84, 76.53, 76.38, 75.57 (CH), 75.22, 75.09 ( $\text{CH}_2$ ), 74.96, 74.78 ( $\text{CH}_2$ , CH), 73.21, 73.02, 69.22, 68.89, 67.76 ( $\text{CH}_2$ ), 37.74 ( $\text{CH}_3$ ). IR ( $\text{cm}^{-1}$ ): 3063, 3030, 2867, 1497, 1454, 1358, 1277, 1209, 1174, 1150, 1092, 1071, 1028, 984, 922, 812, 737, 698, 527. MALDI-MS ( $\text{C}_{63}\text{H}_{68}\text{O}_{13}\text{S}$ ):  $[\text{MNa}]^+$  1087.4284 (calcd. 1087.4278). Anal. Calcd for  $\text{C}_{63}\text{H}_{68}\text{O}_{13}\text{S}$ : C, 71.03; H, 6.43. Found: C, 70.94; H, 6.62.

Subsequently, this mesylate (825 mg, 0.774 mmol) was dissolved in EtOH (20 mL), KOSMe (278 mg, 2.43 mmol), *i*PrOH (10 mL) and THF (10 mL) were added and the orange solution was stirred at reflux for 3 h (orange precipitate). Additional KOSMe (512 mg, 4.48 mmol) was added and the suspension was stirred at reflux for 16 h. After cooling, 50% sat. aq.  $\text{NaHCO}_3$  (100 mL) was added and the suspension was extracted with ether (4 x 30 mL). The combined organic layer was washed successively with sat. aq.  $\text{NaHCO}_3$  (50 mL) and  $\text{H}_2\text{O}$  (50 mL), evaporated on celite and purified by dry column vacuum chromatography (4.2 x 3.3 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the corresponding thioacetate (637 mg, 79%) as a light orange solid.

$R_f$  (1:3 EtOAc/hexane (v/v)) 0.45;  $^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.43-7.19 (35H, m), 5.22 (1H, d,  $J = 11.2$  Hz), 4.92 (1H, d,  $J = 11.2$  Hz), 4.88 (1H, d,  $J = 11.2$  Hz), 4.87-4.71 (5H, m), 4.62 (1H, d,  $J = 12.5$  Hz), 4.60-4.43 (5H, m), 4.41 (1H, d,  $J = 11.8$  Hz), 4.06 (1H, t,  $J = 9.3$  Hz), 3.86 (1H, dd,  $J = 3.7, 11.2$  Hz), 3.75 (1H, dd,  $J = 1.6, 10.9$  Hz), 3.69-3.55 (5H, m), 3.51-3.31 (6H, m), 3.05 (1H, dd,  $J = 6.8, 13.7$  Hz), 2.34 (3H, s).  $^{13}\text{C}$ -NMR

(75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 195.04, 139.19, 138.53, 138.30, 138.24, 138.17, 137.96 (C), 128.33, 128.26, 128.20, 128.04, 127.79, 127.71, 127.63, 127.55, 127.47, 127.29, 127.19, 102.40, 85.12, 84.88, 82.71, 79.85, 79.30, 78.05, 77.87 (CH), 75.62, 75.18 ( $\text{CH}_2$ ), 75.09 (CH), 74.94, 74.81, 73.26, 73.21, 68.96, 67.86, 31.12 ( $\text{CH}_2$ ), 30.49 ( $\text{CH}_3$ ). IR ( $\text{cm}^{-1}$ ): 3030, 2868, 1692, 1496, 1454, 1358, 1210, 1067, 1028, 773, 735, 698, 626. MALDI-MS ( $\text{C}_{64}\text{H}_{68}\text{O}_{11}\text{S}$ ):  $[\text{MNa}]^+$  1067.4365 (calcd. 1067.4380). Anal. Calcd for  $\text{C}_{64}\text{H}_{68}\text{O}_{11}\text{S}$ : C, 73.54; H, 6.56. Found: C, 73.50; H, 6.60.

The thioacetate received above (631 mg, 0.604 mmol) was suspended in AcOH (10 mL), KOAc (933 mg, 9.5 mmol) followed by Oxone ( $2\text{KHSO}_5 \cdot \text{KHSO}_4 \cdot \text{K}_2\text{SO}_4$ , 1.179 g, 2.55 mmol) were added and after stirring for 18 h, sat. aq.  $\text{Na}_2\text{CO}_3$  (50 mL) and  $\text{H}_2\text{O}$  (50 mL) were carefully added. After extraction with  $\text{CHCl}_3$  (4 x 25 mL), the combined organic layer was washed with sat. aq.  $\text{Na}_2\text{CO}_3$  (25 mL), evaporated on celite and purified by dry column vacuum chromatography (4.1 x 3.3 cm) on silica gel eluting with a gradient of 0-20% MeOH in  $\text{CH}_2\text{Cl}_2$  (v/v) to give the corresponding sulfinate salt (622 mg, 96%) as a colourless oil.

$R_f$  (10% MeOH in  $\text{CH}_2\text{Cl}_2$  (v/v)) 0.29;  $^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.40-7.14 (35H, m), 5.19-4.34 (15H, m), 4.17-3.22 (15H, m).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 138.97, 138.32, 138.21, 138.06, 137.88, 137.84, 128.70, 128.36, 128.18, 128.05, 127.86, 127.76, 127.63, 127.57, 127.44, 127.29, 127.20, 126.94, 84.53, 84.45, 82.01, 79.48, 77.96, 77.75, 76.06, 76.01, 75.46, 74.94, 74.79, 74.67, 74.57, 73.28, 73.08, 73.02, 53.42. IR ( $\text{cm}^{-1}$ ): 3478, 3063, 3030, 2870, 1497, 1454, 1361, 1315, 1210, 1174, 1069, 1048, 1028, 736, 698, 621. MALDI-MS ( $\text{C}_{62}\text{H}_{65}\text{NaO}_{13}\text{S}$ ):  $[\text{MH}]^+$  1073.4098 (calcd. 1073.4122);  $[\text{MNa}]^+$  1095.3926 (calcd. 1095.3941).

Finally, the obtained sulfinate salt (334 mg, 0.311 mmol) was dissolved in anhydrous acetonitrile/ $\text{CH}_2\text{Cl}_2$  (4 mL, 1:1 (v/v)) at

0°C,  $\text{Ph}_3\text{P}$  (264 mg, 1.01 mmol) and thionyl chloride (0.10 mL, 1.37 mmol) were added sequentially at 0°C and the suspension was stirred at room temperature for 6 h. EtOAc/hexane (1:4 (v/v), 30 mL) was added, the suspension was filtered through a short pad of silica gel (4 x 5 mL EtOAc/hexane (1:3 (v/v)) washings) and the filtrate was evaporated and dried shortly under vacuum to give the desired sulfonyl chloride **XVIIIa** (220 mg, 66%) as a light yellow foam.

$R_f$  (1:3 EtOAc/hexane (v/v)) 0.38;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.50-7.26 (35H, m), 5.30 (1H, d,  $J = 11.2$  Hz), 4.98 (1H, d,  $J = 10.6$  Hz), 4.96-4.81 (5H, m), 4.79 (1H, d,  $J = 10.6$  Hz), 4.67-4.50 (6H, m), 4.48 (1H, d,  $J = 11.8$  Hz), 4.23-4.15 (1H, m), 3.98-3.91 (2H, m), 3.85-3.57 (8H, m), 3.51-3.38 (3H, m), 3.30 (1H, t  $J = 9.0$  Hz).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 138.77, 138.45, 138.17, 138.11, 137.78, 137.27 (C), 128.63, 128.38, 128.31, 128.18, 128.12, 127.94, 127.78, 127.70, 127.63, 127.55, 127.42, 127.29, 102.32, 84.98, 84.80, 82.66, 79.23, 77.95, 77.82, 75.78 (CH), 75.60, 75.38 ( $\text{CH}_2$ ), 75.12 (CH), 74.99, 74.78, 74.70 ( $\text{CH}_2$ ), 74.21 (CH), 73.24, 68.95, 67.35, 66.79 ( $\text{CH}_2$ ). IR ( $\text{cm}^{-1}$ ): 3089, 3063, 3030, 2868, 1496, 1454, 1362, 1313, 1280, 1209, 1167, 1091, 1067, 1028, 913, 771, 736, 698, 601. MALDI-MS ( $\text{C}_{62}\text{H}_{65}\text{ClO}_{12}\text{S}$ ):  $[\text{MNa}]^+$  1091.3767 (calcd. 1091.3783).

The sulfonyl chloride **XVIIIa** (271 mg, 0.253 mmol) was dissolved in anhydrous  $\text{CH}_2\text{Cl}_2$  (3 mL), anhydrous pyridine (0.5 mL) followed by the silylated azetidinone phenol **VIa** obtained in step 2a) (75.7 mg, 0.145 mmol) were added and the solution was stirred for 38 h, diluted with EtOAc (50 mL) and washed sequentially with sat. aq.  $\text{NaHCO}_3$  (15 mL) and  $\text{H}_2\text{O}$  (15 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.5 x 3.3 cm) on silica gel eluting with a gradient of 0-20% EtOAc in toluene (v/v) to give the corresponding sulfonate mixed with unreacted phenol **VIa** (166 mg, 4:1 mixture) as



a white foam.

$R_f$  (1:1 EtOAc/hexane (v/v)) 0.73;  $^1H$ -NMR (300 MHz,  $CDCl_3$ )  $\delta$ : 7.49-7.17 (41H, m), 7.06 (2H, d,  $J$  = 8.7 Hz), 7.02 (2H, t,  $J$  = 8.1 Hz), 6.96 (2H, d,  $J$  = 8.7 Hz), 5.31 (1H, d,  $J$  = 11.2 Hz), 5.01-4.74 (7H, m), 4.65-4.45 (8H, m), 4.21 (1H, t,  $J$  = 9.3 Hz), 4.02-3.96 (2H, m), 3.86-3.60 (6H, m), 3.53-3.47 (4H, m), 3.33 (1H, d,  $J$  = 9.3 Hz), 3.26 (1H, t,  $J$  = 9.0 Hz), 3.19 (1H, d,  $J$  = 9.3 Hz), 3.06-3.00 (1H, m), 2.06-1.84 (4H, m), 0.96 (9H, s), 0.10 (3H, s), -0.07 (3H, s).  $^{13}C$ -NMR (75 MHz,  $CDCl_3$ )  $\delta$ : 166.70, 160.35, 160.00, 156.27, 149.33, 140.35, 140.31, 138.63, 138.26, 138.00, 137.90, 137.59, 137.45, 137.29, 136.51, 133.47 (C), 128.82, 128.73, 128.34, 128.19, 128.08, 127.98, 127.85, 127.66, 127.56, 127.45, 127.30, 127.25, 127.12, 127.01, 125.10, 123.32, 118.11, 118.01, 115.91, 115.60, 115.00, 114.93, 114.72, 102.39, 84.93, 84.80, 82.56, 78.82, 78.55, 77.95, 75.99 (CH), 75.60, 75.31 ( $CH_2$ ), 75.15 (CH), 74.96, 74.76 ( $CH_2$ ), 74.23, 73.77 (CH), 73.21, 73.08, 68.97, 67.62 ( $CH_2$ ), 61.02, 60.57, 60.39 (CH), 51.26, 38.02 ( $CH_2$ ), 25.85 ( $CH_3$ ), 24.67 ( $CH_2$ ), 18.19 (C), -4.56, -4.87 ( $CH_3$ ).  $^{19}F$ -NMR (282 MHz,  $CDCl_3$ )  $\delta$ : -114.94 (1F, septet,  $J$  = 4.3 Hz), -117.10 (1F, septet,  $J$  = 4.3 Hz). MALDI-MS ( $C_{92}H_{99}F_2NO_{15}SiS$ ):  $[MNa]^+$  1578.6365 (calcd. 1578.6370).

Subsequently, this sulfonate (166 mg 4:1 mixture) was dissolved in EtOH (5 mL),  $Pd(OH)_2/C$  (20% (w/w), 94 mg) was added and the suspension was evacuated 4 times with  $H_2$  and stirred under an  $H_2$ -atmosphere for 11.5 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.3 x 2.0 cm) on silica gel eluting with a gradient of 0-10% MeOH in  $CH_2Cl_2$  (v/v) to give the corresponding debenzylated  $\beta$ -lactam (69.5 mg, 52% from phenol **VIa**) as a colourless oil.

$R_f$  (20% MeOH in  $CH_2Cl_2$  (v/v)) 0.46;  $^1H$ -NMR (300 MHz,  $CD_3OD$ )  $\delta$ : 7.46-7.38 (4H, m), 7.31-7.23 (4H, m), 7.04-6.95 (4H, m), 4.75-4.68 (1H, m), 4.44 (1H, d,  $J$  = 8.1 Hz), 3.92-3.80 (5H, m), 3.69-


3.18 (11H, m), 3.10-3.05 (1H, m), 1.95-1.75 (4H, m), 0.86 (9H, s), 0.01 (3H, s), -0.19 (3H, s).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$ : 169.31, 169.21, 161.76, 158.91, 150.96, 142.28, 138.45, 135.01, 134.98, 131.06, 130.95 (C), 128.83, 124.50, 119.92, 119.83, 116.99, 116.68, 116.10, 116.04, 115.81, 115.74, 104.54, 80.33, 80.10, 78.11, 77.81, 77.72, 76.30, 75.13, 74.89, 73.61, 71.38 (CH), 62.47, 61.63 ( $\text{CH}_2$ ), 61.56, 61.47 (CH), 53.26, 38.83 ( $\text{CH}_2$ ), 26.38 ( $\text{CH}_3$ ), 25.75 ( $\text{CH}_2$ ), 19.04 (C), -4.40, -4.70 ( $\text{CH}_3$ ).  $^{19}\text{F}$ -NMR (282 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$ : -117.94 (1F, septet,  $J = 4.3$  Hz), -120.10 (1F, septet,  $J = 4.3$  Hz). MALDI-MS ( $\text{C}_{43}\text{H}_{57}\text{F}_2\text{NO}_{15}\text{SiS}$ ):  $[\text{MNa}]^+$  948.3088 (calcd. 948.3084).

This debenzylated  $\beta$ -Lactam (59.5 mg, 0.073 mmol) was dissolved in anhydrous THF (2.0 mL, teflon bottle), anhydrous pyridine (0.40 mL) followed by HF-pyridine complex (0.40 mL) were added and the solution was stirred for 14 h. Sat. aq.  $\text{NaHCO}_3$  (5 mL) was added and the suspension was evaporated on celite and purified by dry column vacuum chromatography (4.4 x 2.0 cm) on silica gel eluting with a gradient of 10-20% MeOH in  $\text{CH}_2\text{Cl}_2$  (v/v) to give the desired  $\beta$ -lactam **XVIII** (38.1 mg, 64%) as a white solid.


$R_f$  (10% MeOH in  $\text{CH}_2\text{Cl}_2$  (v/v)) 0.17 (eluted thrice);  $^1\text{H}$ -NMR (300 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$ : 7.45 (2H, t,  $J = 9.3$  Hz), 7.40 (2H, d,  $J = 8.7$  Hz), 7.33-7.24 (4H, m), 7.02 (2H, t,  $J = 8.1$  Hz), 6.98 (2H, d,  $J = 8.7$  Hz), 4.90 (1H, d,  $J = 1.9$  Hz), 4.60 (1H, dd,  $J = 5.0, 6.2$  Hz), 4.43 (1H, d,  $J = 7.5$  Hz), 3.92-3.79 (5H, m), 3.69-3.49 (4H, m), 3.44-3.18 (6H, m), 3.12-3.06 (1H, m), 1.99-1.82 (4H, m).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$ : 169.31, 165.08, 162.17, 161.85, 158.96, 150.98, 142.15, 138.51, 135.01 (C), 128.88, 128.76, 124.46, 119.97, 119.86, 116.99, 116.68, 116.13, 115.84, 104.54, 80.35, 80.06, 78.11, 77.81, 77.71, 76.31, 74.91, 73.77, 73.63, 71.39 (CH), 62.45, 61.50 ( $\text{CH}_2$ ), 61.42 (CH), 53.26, 37.45, 26.12 ( $\text{CH}_2$ ).  $^{19}\text{F}$ -NMR (282 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$ : -118.08 (1F, septet,  $J = 4.3$  Hz), -120.21 (1F, septet,  $J = 4.3$  Hz). MALDI-MS ( $\text{C}_{37}\text{H}_{43}\text{F}_2\text{NO}_{15}\text{S}$ ):  $[\text{MNa}]^+$

834.2223 (calcd. 834.2219).

### Example 15



a)



A 50 mL Schlenk flask was charged with  $\text{Zn}(\text{OTf})_2$  (12.647 g, 34.79 mmol) and heated to 120°C under high-vacuum (0.2 Torr) for 3.5 h. After cooling, (+)-*N*-methylephedrine (6.595 g, 36.79 mmol) was added and the flask was purged with Ar for 15 min. Anhydrous toluene (14 mL) followed by  $\text{Et}_3\text{N}$  (3.874 g, 38.3 mmol) were added and after 3 h stirring, benzyl propargyl ether (prepared according to Ren, X. F.; Turos, E.; Lake, C. H.; Churchill, M. R. *J. Org. Chem.* **1995**, *60*, 6468-6483; 5.556 g, 38.00 mmol) was added in one portion. After 20 min stirring, the mixture was transferred to a precooled acetone bath (8°C), stirred for 5 min and *p*- $\text{FC}_6\text{H}_4\text{CHO}$  (3.632 g, 29.26 mmol) was added in one portion. After 15 h stirring at 9 to 12°C, the suspension was diluted with EtOAc

(125 mL) and washed with sat. aq.  $\text{NH}_4\text{Cl}$  (2 x 30 mL) and brine (30 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (5.4 x 5.5 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give propargyl alcohol **XIXa** (5.896 g, 75%) as a light yellow oil.

Enantiomeric excess as determined by HPLC analysis: 96% ee;  $R_t$  20 min (*R*-**XIXa**), 28 min (*S*-**XIXa**) (Chiracel OD-H 25 cm, 6% *i*PrOH in hexane, flow 1.0 mL/min, 254 nm).  $R_f$  (1:3 EtOAc/hexane (v/v)) 0.28; ;  $^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.50 (2H, dd,  $J$  = 5.6, 8.7 Hz), 7.38-7.32 (5H, m), 7.06 (2H, t,  $J$  = 8.7 Hz), 5.48 (1H, s), 4.60 (2H, s), 4.26 (2H, s), 2.84 (1H, s).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 164.01, 160.75, 136.95, 136.04 (C), 128.30, 128.21, 127.92, 127.81, 115.43, 115.13 (CH), 86.13, 82.62 (C), 71.74 ( $\text{CH}_2$ ), 63.74 (CH), 57.35 ( $\text{CH}_2$ ).  $^{19}\text{F}$ -NMR (282 MHz,  $\text{CDCl}_3$ )  $\delta$ : -113.28 (1F, septet,  $J$  = 4.3 Hz). IR ( $\text{cm}^{-1}$ ): 3390, 3066, 3032, 2859, 1604, 1508, 1455, 1413, 1386, 1355, 1224, 1158, 1121, 1096, 1072, 1028, 1014, 842, 772, 744, 699, 592, 561, 498. MALDI-MS ( $\text{C}_{17}\text{H}_{15}\text{FO}_2$ ):  $[\text{MNa}]^+$  293.0947 (calcd. 293.0954). Anal. Calcd for  $\text{C}_{17}\text{H}_{15}\text{FO}_2$ : C, 75.54; H, 5.59. Found: C, 75.39; H, 5.62.

Subsequently this propargyl alcohol (4.108 g, 15.20 mmol) was dissolved in anhydrous DMF (50 mL), imidazole (2.123 g, 31.1 mmol) and TBDMSCl (3.590 mg, 23.8 mmol) were added sequentially and the solution was stirred for 3.5 h followed by addition of 50% sat. aq.  $\text{NaHCO}_3$  (150 mL). After extraction with ether (4 x 50 mL), the combined organic layer was washed successively with sat. aq.  $\text{NaHCO}_3$  (50 mL) and  $\text{H}_2\text{O}$  (50 mL), evaporated and dried shortly under high vacuum. The residue was dissolved in EtOH (40 mL),  $\text{Na}_2\text{CO}_3$  (3.229 g, 30.5 mmol) and Pd/C (10% (w/w), 223 mg) were added and the suspension was evacuated 4 times with  $\text{H}_2$  and stirred under an  $\text{H}_2$ -atmosphere for 19 h. The suspension was diluted with 10% EtOAc/hexane (250 mL (v/v)) and filtered through a short plug of silica gel (2 x 25 mL 20% EtOAc/hexane washings

(v/v)), evaporated and dried shortly under high vacuum. The residue was dissolved in EtOH (40 mL), Pd/C (10% (w/w), 142 mg) was added and the suspension was evacuated 4 times with H<sub>2</sub> and stirred under an H<sub>2</sub>-atmosphere for 1 h. Additional Pd/C (10% (w/w), 190 mg) was added and the suspension was evacuated 4 times with H<sub>2</sub> and stirred under an H<sub>2</sub>-atmosphere for 1.25 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (5.2 x 5.5 cm) on silica gel eluting with a gradient of 0-25% EtOAc in hexane (v/v) to give the corresponding alcohol (3.643 g, 80%) as a light yellow oil.

R<sub>f</sub> (1:3 EtOAc/hexane (v/v)) 0.37; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.24 (2H, dd, *J* = 5.6, 8.7 Hz), 6.97 (2H, t, *J* = 8.7 Hz), 4.69 (1H, dt, *J* = 1.2, 5.0 Hz), 3.59 (2H, dt, *J* = 1.2, 6.2 Hz), 2.18 (1H, bs), 1.77-1.45 (4H, m), 0.87 (9H, s), 0.02 (3H, s), -0.15 (3H, s). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) δ: 163.37, 160.13, 140.96, 140.91 (C), 127.32, 127.23, 114.94, 114.64, 74.16 (CH), 62.76, 37.19, 28.47 (CH<sub>2</sub>), 25.76 (CH<sub>3</sub>), 18.15 (C), -4.71, -5.05 (CH<sub>3</sub>). IR (cm<sup>-1</sup>): 3339, 2954, 2930, 2885, 2858, 1606, 1510, 1472, 1463, 1362, 1252, 1223, 1156, 1092, 1060, 984, 890, 836, 776, 668, 560. MALDI-MS (C<sub>16</sub>H<sub>27</sub>FO<sub>2</sub>Si): [MNa]<sup>+</sup> 321.1643 (calcd. 321.1662). Anal. Calcd for C<sub>16</sub>H<sub>27</sub>FO<sub>2</sub>Si: C, 64.39; H, 9.12. Found: C, 64.36; H, 9.15.

The alcohol obtained above was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (50 mL), Dess-Martin periodinane (5.658 g, 13.3 mmol) was added and the milky solution was stirred at room temperature for 1.5 h. Sat. aq. Na<sub>2</sub>SO<sub>3</sub> (100 mL) was added and the layers were swirled until the solid had dissolved. The layers were separated and the aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 x 40 mL). The combined organic phase was evaporated on celite and purified by dry column vacuum chromatography (5.1 x 5.5 cm) on silica gel eluting with a gradient of 0-10% EtOAc in hexane (v/v) to give the corresponding aldehyde **XIXb** (2.093 g, 80%) as a light yellow oil.

$R_f$  (1:3 EtOAc/hexane (v/v)) 0.63;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 9.73 (1H, d,  $J = 1.5$  Hz), 7.25 (2H, dd,  $J = 5.6, 8.7$  Hz), 6.99 (2H, t,  $J = 9.0$  Hz), 4.74 (1H, dt,  $J = 5.0, 6.8$  Hz), 2.52-2.35 (2H, m), 2.06-1.88 (2H, m), 0.88 (9H, s), 0.02 (3H, s), -0.16 (3H, s).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 201.91 (CH), 163.35, 160.10, 140.13 (C), 127.20, 127.10, 115.04, 114.75, 73.03 (CH), 39.69, 33.11 ( $\text{CH}_2$ ), 25.85 ( $\text{CH}_3$ ), 18.21 (C), -4.61, -4.95 ( $\text{CH}_3$ ). IR ( $\text{cm}^{-1}$ ): 2955, 2938, 2888, 2858, 2720, 1727, 1606, 1509, 1472, 1464, 1412, 1390, 1362, 1254, 1223, 1156, 1090, 1014, 837, 776, 670, 540. Anal. Calcd for  $\text{C}_{16}\text{H}_{25}\text{FO}_2\text{Si}$ : C, 64.82; H, 8.50. Found: C, 64.95; H, 8.36.

LiCl (140.8 mg, 3.32 mmol) was heated shortly with a heat gun under high-vacuum and after cooling, anhydrous  $\text{CH}_3\text{CN}$  (5 mL), phosphonate **XIXc** (prepared according to Melekhov, A.; Fallis, A. G. *Tetrahedron Lett.* **1999**, 40, 7867-7870; 660 mg, 1.68 mmol) and DBU (221 mg, 1.45 mmol) were added sequentially. After 3 min stirring, the aldehyde **XIXb** (407.3 mg, 1.37 mmol) was added and the suspension was stirred at room temperature for 2.5 h followed by addition of 50% sat. aq.  $\text{NaHCO}_3$  (60 mL). After extraction with ether/hexane (1:1 (v/v), 4 x 25 mL), the combined organic layer was washed with brine (25 mL), evaporated on celite and purified by dry column vacuum chromatography (4.6 x 3.3 cm) on silica gel eluting with a gradient of 0-20% EtOAc in hexane (v/v) to give olefin **XIXd** (520.7 mg, 71%) as a colourless oil.

$R_f$  (1:3 EtOAc/hexane (v/v)) 0.43;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.25 (2H, dd,  $J = 5.6, 8.7$  Hz), 7.10-6.94 (3H, m), 6.53 (1H, d,  $J = 14.9$  Hz), 4.65 (1H, dd,  $J = 5.0, 7.5$  Hz), 3.91 (1H, dd,  $J = 5.6, 6.8$  Hz), 3.50 (1H, d,  $J = 13.7$  Hz), 3.42 (1H, d,  $J = 13.7$  Hz), 2.30-2.23 (2H, m), 2.09-2.02 (2H, m), 1.90-1.70 (5H, m), 1.43-1.30 (2H, m), 1.15 (3H, s), 0.95 (3H, s), 0.85 (9H, s), 0.01 (3H, s), -0.20 (3H, s).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 163.88, 163.39, 160.14, 150.06, 140.63 (C), 127.35, 127.26, 120.91,

114.98, 114.69, 73.24, 64.99 (CH), 53.04 (CH<sub>2</sub>), 48.33, 47.67 (C), 44.58 (CH), 38.61, 38.39, 32.71, 28.32, 26.40 (CH<sub>2</sub>), 25.72, 20.72, 19.78 (CH<sub>3</sub>), 18.04 (C), -4.74, -5.10 (CH<sub>3</sub>). IR (cm<sup>-1</sup>): 2956, 2885, 2859, 1684, 1640, 1605, 1509, 1472, 1414, 1374, 1332, 1295, 1250, 1220, 1165, 1134, 1083, 1049, 995, 970, 860, 836, 774, 544. MALDI-MS (C<sub>28</sub>H<sub>42</sub>FNO<sub>4</sub>SSi): [MNa]<sup>+</sup> 558.2479 (calcd. 558.2486). Anal. Calcd for C<sub>28</sub>H<sub>42</sub>FNO<sub>4</sub>SSi: C, 62.77; H, 7.90; N, 2.61. Found: C, 62.84; H, 7.78; N, 2.58.

Olefin **xixd** was dissolved in anhydrous toluene (2.0 mL), TMSCHN<sub>2</sub> (2 M in hexanes, 1.50 mL, 3.0 mmol) was added and the solution was stirred at room temperature for 64 h. After evaporation, the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 mL), TFA (202 mg, 1.77 mmol) was added and the solution was stirred for 20 min. Sat. aq. NaHCO<sub>3</sub> (1.5 mL) was added and the mixture was evaporated on celite and purified by dry column vacuum chromatography (4.5 x 3.3 cm) on silica gel eluting with a gradient of 0-40% EtOAc in hexane (v/v) to give the corresponding pyrazoline (468 mg, 84%) as a light yellow foam.

R<sub>f</sub> (1:3 EtOAc/hexane (v/v)) 0.25; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.21 (2H, dd, *J* = 5.6, 8.7 Hz), 6.95 (2H, t, *J* = 8.7 Hz), 6.60 (1H, s), 6.16 (1H, d, *J* = 5.6 Hz), 4.65 (1H, t, *J* = 5.0 Hz), 4.33 (1H, dd, *J* = 5.9, 9.7 Hz), 3.87 (1H, dd, *J* = 5.0, 7.5 Hz), 3.67-3.62 (1H, bs), 3.53 (1H, d, *J* = 13.7 Hz), 3.44 (1H, d, *J* = 13.7 Hz), 2.15-1.99 (2H, m), 1.91-1.86 (3H, m), 1.66-1.51 (3H, m), 1.47-1.21 (3H, m), 1.14 (3H, s), 0.95 (3H, s), 0.86 (9H, s), 0.01 (3H, s), -0.17 (3H, s). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>) δ: 167.96, 163.12, 159.89 (C), 146.91 (CH), 140.52, 140.49 (C), 127.15, 127.05, 114.83, 114.54, 73.37, 66.44, 65.09 (CH), 52.81 (CH<sub>2</sub>), 48.91 (C), 48.04 (CH), 47.79 (C), 44.33 (CH), 37.98, 37.79, 32.55, 26.76, 26.45 (CH<sub>2</sub>), 25.82, 20.68, 19.84 (CH<sub>3</sub>), 18.16 (C), -4.64, -4.90 (CH<sub>3</sub>). IR (cm<sup>-1</sup>): 3360, 2955, 2857, 1700, 1604, 1509, 1472, 1390, 1329, 1273, 1250, 1236, 1221, 1166, 1134,

1086, 1066, 994, 939, 836, 775, 694, 542. MALDI-MS ( $C_{29}H_{44}FN_3O_4SSi$ ):  $[MNa]^+$  600.2691 (calcd. 600.2704). Anal. Calcd for  $C_{29}H_{44}FN_3O_4SSi$ : C, 60.28; H, 7.67; N, 7.27. Found: C, 60.25; H, 7.83; N, 7.16.

This pyrazoline (409.8 mg, 0.709 mmol),  $Cu(OAc)_2$  (296 mg, 1.63 mmol) and  $(p-FC_6H_4)_3Bi$  (prepared according to Banfi, A.; Bartolletti, M.; Bellora, E.; Bignotti, M.; Turconi, M. *Synthesis* **1994**, 775-776; 950 mg, 1.92 mmol) were dissolved in anhydrous  $CH_2Cl_2$  (5 mL), anhydrous  $Et_3N$  (165 mg, 1.63 mmol) was added and the dark green suspension was stirred at room temperature for 12.5 h. After evaporation on celite the residue was purified by dry column vacuum chromatography (4.5 x 3.3 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give *N*-arylated pyrazoline **XIXe** (320.8 mg, 63%) as a light yellow foam.

$R_f$  (1:3 EtOAc/hexane (v/v)) 0.33;  $^1H$ -NMR (300 MHz,  $CDCl_3$ )  $\delta$ : 7.24 (2H, dd,  $J = 5.3, 8.4$  Hz), 7.01-6.94 (4H, m), 6.89 (2H, t,  $J = 8.7$  Hz), 6.68 (1H, d,  $J = 1.9$  Hz), 5.05 (1H, d,  $J = 3.7$  Hz), 4.62 (1H, t,  $J = 5.3$  Hz), 3.85 (1H, dd,  $J = 4.4, 7.5$  Hz), 3.59 (1H, d,  $J = 14.3$  Hz), 3.58 (1H, d,  $J = 14.3$  Hz), 3.41-3.35 (1H, m), 1.98-1.78 (5H, m), 1.72-1.60 (3H, m), 1.41-1.23 (3H, m), 1.21 (3H, s), 0.98 (3H, s), 0.88 (9H, s), 0.04 (3H, s), -0.17 (3H, s).  $^{13}C$ -NMR (75 MHz,  $CDCl_3$ )  $\delta$ : 169.54, 163.38, 160.14, 158.46, 155.30 (C), 142.10 (CH), 140.75 (C), 127.32, 127.22, 115.71, 115.40, 114.96, 114.67, 114.22, 114.12, 73.99, 65.48, 64.93 (CH), 53.02 (CH,  $CH_2$ ), 49.05, 47.77 (C), 44.31 (CH), 37.98, 36.95, 32.76, 27.79, 26.25 ( $CH_2$ ), 25.75, 20.37, 19.77 ( $CH_3$ ), 18.07 (C), -4.77, -5.01 ( $CH_3$ ).  $^{19}F$  (282 MHz,  $CDCl_3$ )  $\delta$ : -116.27 (1F, m), -125.73 (1F, septet,  $J = 4.3$  Hz). IR ( $cm^{-1}$ ): 2957, 2857, 1699, 1606, 1510, 1471, 1413, 1362, 1334, 1268, 1250, 1221, 1166, 1136, 1113, 1088, 1063, 987, 836, 776, 759, 538. MALDI-MS ( $C_{35}H_{47}F_2N_3O_4SSi$ ):  $[MH-TBDMSOH]^+$  540.2127 (calcd. 540.2132);  $[MNa]^+$



694.2909 (calcd. 694.2922). Anal. Calcd for  $C_{35}H_{47}F_2N_3O_4SSi$ : C, 62.56; H, 7.05; N, 6.25. Found: C, 62.37; H, 7.05; N, 6.03.

The *N*-arylated pyrazoline **XIXe** (101.5 mg, 0.151 mmol) was dissolved in anhydrous THF (5 mL)  $-78^{\circ}C$ ,  $LiAlH_4$  (33 mg, 0.87 mmol) was added and the suspension was stirred at  $-78^{\circ}C$  for 4.5 h. Sat. aq.  $NaHCO_3$  (1 mL) was added and the mixture was evaporated on celite and purified twice by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding alcohol (52.7 mg, 76%) as a light yellow oil.

$R_f$  (1:3 EtOAc/hexane (v/v)) 0.23;  $^1H$ -NMR (300 MHz,  $CDCl_3$ )  $\delta$ : 7.23 (2H, dd,  $J$  = 5.6, 8.7 Hz), 7.04-6.92 (6H, m), 6.67 (1H, d,  $J$  = 1.2 Hz), 4.64 (1H, t,  $J$  = 5.9 Hz), 3.81 (1H, dd,  $J$  = 4.0, 11.5 Hz), 3.68-3.58 (2H, m), 3.12 (1H, dd,  $J$  = 6.2, 6.8 Hz), 1.86 (1H, bs), 1.77-1.67 (2H, m), 1.58-1.48 (2H, m), 0.86 (9H, s), 0.00 (3H, s), -0.17 (3H, s).  $^{13}C$ -NMR (75 MHz,  $CDCl_3$ )  $\delta$ : 163.47, 160.22, 158.83, 155.68 (C), 144.84 (CH), 142.35, 140.67, 140.62 (C), 127.26, 127.16, 115.75, 115.46, 115.11, 115.06, 114.96, 114.83, 73.76, 66.81 (CH), 62.37 ( $CH_2$ ), 50.05 (CH), 37.72, 28.28 ( $CH_2$ ), 25.75 ( $CH_3$ ), 18.12 (C), -4.67, -5.01 ( $CH_3$ ).  $^{19}F$  (282 MHz,  $CDCl_3$ )  $\delta$ : -115.25 (1F, septet,  $J$  = 4.3 Hz), -124.25 (1F, septet,  $J$  = 4.3 Hz). IR ( $cm^{-1}$ ): 3401, 2953, 2930, 2885, 2858, 1672, 1605, 1509, 1472, 1463, 1416, 1362, 1296, 1252, 1223, 1156, 1086, 1006, 979, 938, 861, 835, 776, 666, 608, 554. MALDI-MS ( $C_{25}H_{34}F_2N_2O_2Si$ ): [MH- $CH_2O$ ] 429.2175 (calcd. 429.2174); [M-H] $^{+}$  459.2279 (calcd. 459.2279).

Subsequently this alcohol (70.8 mg, 0.154 mmol) was dissolved in anhydrous  $CH_2Cl_2$  (5 mL), anhydrous  $Et_3N$  (0.50 mL, 3.9 mmol), DMAP (6.8 mg, 0.056 mmol) and TsCl (69 mg, 0.36 mmol) were added and the solution was stirred at room temperature for 12.5 h, evaporated on celite and purified by dry column vacuum chromatography

(4.4 x 2.0 cm) on silica gel eluting with a gradient of 0-20% EtOAc in hexane (v/v) to give the corresponding tosylate (78.4 mg, 83%) as a colourless oil.

$R_f$  (1:3 EtOAc/hexane (v/v)) 0.44;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.68 (2H, d,  $J = 8.7$  Hz), 7.25 (4H, t,  $J = 8.1$  Hz), 6.99 (2H, t,  $J = 8.7$  Hz), 6.92-6.80 (4H, m), 6.64 (1H, d,  $J = 1.2$  Hz), 4.65 (1H, dd,  $J = 4.4, 6.8$  Hz), 4.12 (1H, dd,  $J = 2.5, 9.3$  Hz), 3.92-3.81 (2H, m), 3.08-3.01 (1H, m), 2.42 (3H, s), 1.80-1.43 (4H, m), 0.87 (9H, s), 0.01 (3H, s), -0.17 (3H, s).  $^{13}\text{C-NMR}$  (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 163.49, 160.24, 158.59, 155.43, 145.16 (C), 143.40 (CH), 140.54, 132.21 (C), 129.84, 127.82, 127.32, 127.21, 115.79, 115.48, 115.12, 114.83, 114.31, 114.22, 73.50 (CH), 67.45 ( $\text{CH}_2$ ), 62.42, 50.74 (CH), 37.35, 27.87 ( $\text{CH}_2$ ), 25.77, 21.59 ( $\text{CH}_3$ ), 18.10 (C), -4.67, -5.01 ( $\text{CH}_3$ ).  $^{19}\text{F}$  (282 MHz,  $\text{CDCl}_3$ )  $\delta$ : -116.01 (1F, m), -125.40 (1F, septet,  $J = 4.3$  Hz). IR ( $\text{cm}^{-1}$ ): 3055, 3034, 2953, 2930, 2886, 2857, 1603, 1509, 1472, 1463, 1365, 1307, 1294, 1252, 1223, 1190, 1177, 1156, 1096, 979, 862, 835, 775, 666, 608, 555. MALDI-MS ( $\text{C}_{32}\text{H}_{40}\text{F}_2\text{N}_2\text{O}_4\text{SSi}$ ):  $[\text{MH-TBDMSOH}]^+$  483.1559 (calcd. 483.1554);  $[\text{MNa}]^+$  637.2330 (calcd. 637.2344).

The tosylate received above was dissolved in anhydrous DMF (2.5 mL), hydroquinone (263 mg, 2.39 mmol) and  $\text{Cs}_2\text{CO}_3$  (102.1 mg, 0.313 mmol) were added and the suspension was stirred at 80°C for 12 h. EtOAc (30 mL) was added and the organic phase was washed with sat. aq.  $\text{NaHCO}_3$  (10 mL) and  $\text{H}_2\text{O}$  (10 mL), evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding phenol **XIXf** (70.9 mg, 86%) as a colourless oil.

$R_f$  (1:3 EtOAc/hexane (v/v)) 0.33;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.24 (2H, dd,  $J = 5.3, 8.4$  Hz), 7.06-6.93 (6H, m), 6.75-6.68 (5H, m), 4.67 (1H, dd,  $J = 4.4, 6.8$  Hz), 4.10-3.98 (2H, m), 3.74 (1H, dd,  $J = 1.2, 7.5$  Hz), 3.17-3.11 (1H, m), 1.86-1.54 (4H, m), 0.88


(9H, s), 0.02 (3H, s), -0.15 (3H, s).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 163.32, 160.08, 158.48, 155.35, 152.31, 149.86 (C), 143.85 (CH), 141.52, 141.49, 140.63 (C), 127.23, 127.12, 115.99, 115.73, 115.51, 115.44, 115.04, 114.75, 114.67, 114.57, 73.78 (CH), 67.79 ( $\text{CH}_2$ ), 63.88, 51.51 (CH), 37.77, 28.38 ( $\text{CH}_2$ ), 25.89 ( $\text{CH}_3$ ), 18.25 (C), -4.46, -4.80 ( $\text{CH}_3$ ).  $^{19}\text{F}$  (282 MHz,  $\text{CDCl}_3$ )  $\delta$ : -115.31 (1F, m), -124.71 (1F, septet,  $J = 4.3$  Hz). IR ( $\text{cm}^{-1}$ ): 3350, 3056, 2953, 2930, 2885, 2858, 1605, 1509, 1472, 1462, 1362, 1297, 1226, 1156, 1100, 1086, 1050, 1006, 939, 828, 776, 667, 609, 553, 518. MALDI-MS ( $\text{C}_{31}\text{H}_{38}\text{F}_2\text{N}_2\text{O}_3\text{Si}$ ):  $[\text{MH-TBDMSOH}]^+$  421.1720 (calcd. 421.1728);  $[\text{MH}]^+$  553.2677 (calcd. 553.2698);  $[\text{MNa}]^+$  575.2505 (calcd. 575.2517).

The phenol **XIXf** (18.4 mg, 0.0333 mmol) was dissolved in anhydrous THF (1.0 mL, teflon bottle) at 0°C, anhydrous pyridine (0.20 mL) followed by HF-pyridine complex (0.20 mL) were added and the solution was allowed to warm to room temperature over several h and stirred at room temperature for 22 h. Ether (20 mL) was added and the solution was washed with sat. aq.  $\text{NaHCO}_3$  (2 x 5 mL), evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-60% EtOAc in hexane (v/v) to give the desired diol **XIX** (14.4 mg, 99%) as a colourless oil.

$R_f$  (1:1 EtOAc/hexane (v/v)) 0.27;  $^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.29 (2H, dd,  $J = 5.3, 8.4$  Hz), 7.06-6.93 (6H, m), 6.75-6.67 (5H, m), 4.70 (1H, t,  $J = 6.5$  Hz), 4.09-4.03 (2H, m), 3.72 (1H, t,  $J = 10.0$  Hz), 3.18 (1H, dd,  $J = 4.4, 6.2$  Hz), 1.99-1.50 (4H, m).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 163.72, 160.47, 155.31, 152.26, 149.95 (C), 143.53 (CH), 141.41, 139.78 (C), 127.41, 127.29, 116.01, 115.77, 115.51, 115.23, 114.54, 114.42, 73.49 (CH), 67.60 ( $\text{CH}_2$ ), 63.67, 51.35 (CH), 35.89, 28.70 ( $\text{CH}_2$ ).  $^{19}\text{F}$  (282 MHz,  $\text{CDCl}_3$ )  $\delta$ : -114.89 (1F, septet,  $J = 4.3$  Hz), -124.64 (1F, septet,  $J = 4.3$  Hz). IR ( $\text{cm}^{-1}$ ): 3320, 2927, 1604, 1508, 1453, 1366, 1225, 1157,

1102, 1044, 910, 826, 733, 609. MALDI-MS ( $C_{25}H_{24}F_2N_2O_3$ ):  $[MH-H_2O]^+$  421.1717 (calcd. 421.1728);  $[M]^+$  438.1755 (calcd. 438.1755);  $[MH]^+$  439.1825 (calcd. 439.1833);  $[MNa]^+$  461.1650 (calcd. 461.1653).

### Example 16



The phenol **XIXf** obtained in step 15a) (28.4 mg, 0.0514 mmol) was dissolved in anhydrous  $CH_2Cl_2$  (2 mL), anhydrous pyridine (0.10 mL, 1.3 mmol) and  $MsCl$  (0.05 mL, 0.51 mmol) were added and the solution was stirred at room temperature for 22.5 h, evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the corresponding mesylate (29.2 mg, 90%) as a colourless oil.


$R_f$  (1:1 EtOAc/hexane (v/v)) 0.64;  $^1H$ -NMR (300 MHz,  $CDCl_3$ )  $\delta$ : 7.26-7.17 (6H, m), 7.06-6.94 (6H, m), 6.83 (2H, d,  $J$  = 9.3 Hz), 6.71 (1H, d,  $J$  = 1.2 Hz), 4.66 (1H, dd,  $J$  = 4.4, 6.8 Hz), 4.11 (1H, dd,  $J$  = 4.0, 9.0 Hz), 4.04 (1H, dt,  $J$  = 4.4, 7.5 Hz), 3.81 (1H, dd,  $J$  = 7.5, 8.7 Hz), 3.11 (3H, s), 3.19-3.08 (1H, m), 1.85-1.52 (4H, m), 0.87 (9H, s), 0.01 (3H, s), -0.16 (3H, s).  $^{13}C$ -NMR (75 MHz,  $CDCl_3$ )  $\delta$ : 160.25, 158.65, 157.92, 157.23, 155.50 (C), 143.67 (CH), 142.93, 141.52, 140.67 (C), 127.30, 127.19, 123.18, 115.85, 115.56, 115.45, 115.14, 114.85, 114.64, 114.53, 73.76 (CH), 67.53 ( $CH_2$ ), 63.54, 51.60 (CH), 37.75 ( $CH_2$ ), 37.09 ( $CH_3$ ), 28.29 ( $CH_2$ ), 25.78 ( $CH_3$ ), 18.13 (C), -4.63, -4.98 ( $CH_3$ ).  $^{19}F$  (282 MHz,  $CDCl_3$ )  $\delta$ : -116.00 (1F, m), -125.47 (1F, septet,  $J$  = 4.3 Hz). IR ( $cm^{-1}$ ): 2930, 2857, 1605, 1508, 1472, 1369, 1299, 1251, 1223, 1197, 1168, 1152, 1086, 1009, 970, 868, 836, 776,

609, 527. MALDI-MS ( $C_{32}H_{40}F_2N_2O_5SSi$ ):  $[MH-TBDMSOH]^+$  499.1504 (calcd. 499.1503);  $[MNa]^+$  653.2298 (calcd. 653.2293).

This mesylate (29.0 mg, 0.0460 mmol) was dissolved in anhydrous THF (1.0 mL, teflon bottle) at 0°C, anhydrous pyridine (0.20 mL) followed by HF-pyridine complex (0.20 mL) were added and the solution was allowed to warm to room temperature over several h and stirred at room temperature for 10 h. Ether (20 mL) was added and the solution was washed with sat. aq.  $NaHCO_3$  (2 x 5 mL), evaporated on celite and purified by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of 0-90% EtOAc in hexane (v/v) to give the desired mesylate **XX** (23.0 mg, 97%) as a colourless oil.

$R_f$  (1:1 EtOAc/hexane (v/v)) 0.18;  $^1H$ -NMR (300 MHz,  $CDCl_3$ )  $\delta$ : 7.30 (2H, dd,  $J$  = 5.6, 8.7 Hz), 7.18 (2H, d,  $J$  = 9.3 Hz), 7.06-6.94 (6H, m), 6.83 (2H, d,  $J$  = 9.3 Hz), 6.73 (1H, d,  $J$  = 1.2 Hz), 4.70 (1H, dd,  $J$  = 5.6, 6.8 Hz), 4.14-4.07 (2H, m), 3.84-3.77 (1H, m), 3.19-3.14 (1H, m), 3.10 (3H, s), 1.94 (1H, bs), 1.92-1.54 (4H, m).  $^{13}C$ -NMR (75 MHz,  $CDCl_3$ )  $\delta$ : 163.72, 160.47, 158.50, 157.04, 155.35 (C), 143.35 (CH), 142.82, 141.30, 141.26, 139.84 (C), 127.36, 127.26, 123.11, 115.81, 115.52, 115.41, 115.25, 114.52, 114.42, 73.44 (CH), 67.37 ( $CH_2$ ), 63.44, 51.43 (CH), 37.20 ( $CH_3$ ), 35.97, 28.73 ( $CH_2$ ).  $^{19}F$  (282 MHz,  $CDCl_3$ )  $\delta$ : -114.06 (1F, m), -124.49 (1F, septet,  $J$  = 4.3 Hz). IR ( $cm^{-1}$ ): 3550, 3404, 2936, 1604, 1508, 1366, 1299, 1249, 1223, 1196, 1168, 1151, 1039, 970, 913, 870, 835, 743, 528. MALDI-MS ( $C_{26}H_{26}F_2N_2O_5S$ ):  $[MH-H_2O]^+$  499.1500 (calcd. 499.1503);  $[M]^+$  516.1536 (calcd. 516.1504);  $[MH]^+$  517.1606 (calcd. 517.1609);  $[MNa]^+$  539.1428 (calcd. 539.1428).

#### Example 17



To a solution of acid **XXIa** (prepared according to B. A. Shinkre, V. G. Puranik, B. M. Bhawal, A. Deshmukh, *Tetrahedron: Asymmetry* **2003**, *14*, 453; 30.0 g, 102 mmol, 1.11 equiv) in  $\text{CH}_2\text{Cl}_2$  (600 ml) is added triethylamine (64.0 ml, 461 mmol, 5.00 equiv) followed by imine **XXIb** (prepared according to T. Kambara, K. Tomioka, *J. Org. Chem.* **1999**, *64*, 9282; 28.1 g, 92.1 mmol, 1.00 equiv). The solution is cooled to  $-20\text{ }^\circ\text{C}$  and triphosgene (16.4 g, 55.8 mmol, 0.600 equiv) is added in 50 ml  $\text{CH}_2\text{Cl}_2$  over a period of 20 min. The solution is warmed to  $23\text{ }^\circ\text{C}$  over a period of 8 h and stirred for additional 10 h at this temperature. The solution is poured onto 600 ml ice water and 200 ml  $\text{CH}_2\text{Cl}_2$ . The aqueous phase is extracted with  $\text{CH}_2\text{Cl}_2$  (3 \* 100 ml). The combined organic phases are washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (3/2 to 1/2 gradient) and then chromatography on silica gel eluting with EtOAc/  $\text{CH}_2\text{Cl}_2$  (7/1 to 3/1 gradient) to afford  $\beta$ -lactam **XXIc** as a colorless solid in 40 % yield along with 35 % yield of the undesired diastereomer.

mp: 132 °C.  $R_f$  = 0.38 (hexane/ ethyl acetate 1/1).  $\alpha_D$  = +77°, (CHCl<sub>3</sub>, c = 1.075, 30.5 °C). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.46-7.07 (m, 16 H), 6.92-6.84 (m, 2 H), 5.34 (d,  $J$  = 5.3 Hz, 1 H), 5.06 (s, 2 H), 4.95 (d,  $J$  = 5.3 Hz, 1 H), 4.60 (d,  $J$  = 2.5 Hz), 3.23 - 3.14 (m, 1 H), 2.90 (s, 3 H), 1.70 (s, 3 H), 0.83 (d,  $J$  = 6.2 Hz). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  165.4, 165.0, 159.3 ( $J$  = 244 Hz), 159.1, 137.1 ( $J$  = 5 Hz), 133.7, 129.9, 128.9, 128.6, 128.3, 128.0, 127.7, 125.7, 119.0 ( $J$  = 8 Hz), 116.0 ( $J$  = 23 Hz), 115.1, 100.1, 76.9, 71.2, 70.1, 62.2, 59.0, 33.8, 23.6, 12.4. IR (thin film): 2938, 1756, 1667, 1612, 1511, 1382, 1223, 1177, 1112, 1092, 834, 734. HRMS (EI): Calcd' for (C<sub>35</sub>H<sub>33</sub>FN<sub>2</sub>O<sub>5</sub><sup>+</sup>), 580.2374, found, 580.2369.

To a solution of  $\beta$ -lactam **XXIc** (17.0 g, 29.0 mmol, 1.00 equiv) in THF (242 ml) and water (48 ml) is added *p*-toluenesulfonic acid hydrate (55.7 g, 293 mmol, 10.0 equiv). The solution is heated to reflux for 5 h. The solution is concentrated to an approximate volume of 60 ml and then poured onto EtOAc (150 ml) and water (250 ml). The aqueous phase is extracted with EtOAc (4 \* 100 ml). The combined organic phases are washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (3/2 to 2/3 gradient) to afford the corresponding 3-hydroxy- $\beta$ -lactam as a colorless solid in 51 % yield.

mp: 168 °C.  $R_f$  = 0.26 (hexane/ ethyl acetate 3/2).  $\alpha_D$  = -129°, (acetone, c = 1.22, 29.5 °C). <sup>1</sup>H-NMR (300 MHz, acetone):  $\delta$  7.50-7.47 (m, 2 H), 7.42-7.29 (m, 5 H), 7.10-7.01 (m, 4 H), 5.33 (d,  $J$  = 5.3 Hz, 1 H), 5.27 (dd,  $J$  = 7.2 Hz, 5.3 Hz, 1 H), 5.11 (s, 2 H), 5.07 (d,  $J$  = 7.2 Hz, 1 H). <sup>13</sup>C-NMR (75 MHz, acetone):  $\delta$  166.5, 159.2, 159.0 ( $J$  = 241 Hz), 137.7, 134.7, 129.6, 128.6, 128.0, 127.8, 118.9 ( $J$  = 8 Hz), 115.8 ( $J$  = 23 Hz), 114.8, 78.0, 69.8, 62.3. IR (thin film): 3120, 1756, 1667, 1612, 1511, 1382,

1223, 1177, 1112, 1092, 834, 734. HRMS (EI): Calcd' for ( $C_{22}H_{18}FNO_3^+$ ), 363.1271, found, 363.1268. Anal. Calcd. for  $C_{22}H_{18}FNO_3$ : C, 72.72; H, 4.99; N, 3.85; found: C, 77.73; H, 5.20; N, 3.91.

To a suspension of this 3-hydroxy- $\beta$ -lactam (2.00 g, 5.50 mmol, 1.00 equiv) in methanol (55.0 ml) is added sodium methoxide (1.49 g, 27.5 mmol, 5.00 equiv). The suspension is stirred at 23 °C for 2 h. To the forming solution is added  $NH_4Cl_{(s)}$  and the suspension is concentrated in vacuo. To the solid is added EtOAc (50 ml) and water (50 ml). The aqueous phase is extracted with EtOAc (3 \* 20 ml). The combined organic phases are washed with brine, dried ( $Na_2SO_4$ ) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ethyl acetate (3/2 to 1/1 gradient) to afford the corresponding amino alcohol as a colorless solid in 89 % yield.

mp: 103 °C.  $R_f$  = 0.45 (hexane/ ethyl acetate 3/2).  $\alpha_D$  = +13.9°, ( $CH_2Cl_2$ , c = 1.10, 25.3 °C.  $^1H$ -NMR (300 MHz,  $CDCl_3$ ):  $\delta$  7.44-7.24 (m, 4 H), 6.97-6.91 (m, 2 H), 6.84-6.76 (m, 2 H), 6.53-6.46 (m, 2 H), 5.02 (s, 2 H), 4.81 (s, 1 H), 4.60 (s, 1 H), 4.46 (m, 1 H), 3.79 (s, 3 H), 3.07 (d,  $J$  = 3.7 Hz, 1 H).  $^{13}C$ -NMR (75 MHz,  $CDCl_3$ ), :  $\delta$  158.2, 155.8 ( $J$  = 233 Hz), 142.5, 136.8, 131.0, 128.5, 127.9, 127.9, 127.4, 155.5 ( $J$  = 22 Hz), 114.9, 114.8, 74.6, 70.0, 59.1, 53.1, 114.8, 78.0, 69.8, 62.3. IR (thin film): 3390, 1737, 1610, 1510, 1221, 1113, 823. MS (EI): 306.1748 (2.54 %), 186.2356 (18.8 %, 91.0908 (100 %). Anal. Calcd. for  $C_{23}H_{22}FNO_4$ : C, 69.86; H, 5.61; N, 3.54; found: C, 69.88; H, 5.78; N, 3.54.

To a solution of the amino alcohol received above (1.92 g, 4.86 mmol, 1.00 equiv) in  $CH_2Cl_2$  (24.0 ml) is added diisopropylethylamine (2.54 ml, 14.6 mmol, 3.00 equiv) and 4-*N,N*-dimethylaminopyridine (59.0 mg, 0.486 mmol, 0.10 equiv). The solution is cooled to -78 °C and triphosgene (1.44 g, 4.86 mmol,



1.00 equiv) in  $\text{CH}_2\text{Cl}_2$  (4.0 ml) is added over a period of 5 min. The solution is warmed to 23 °C over 8 h and stirred at this temperature for additional 5 h. To this solution is added water (50 ml) and concentrated aqueous ammonium hydroxide solution (3 ml). The aqueous phase is extracted with  $\text{CH}_2\text{Cl}_2$  (3 \* 20 ml). The combined organic phases are washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (2/1 to 1/1 gradient) to afford methyl ester **XXId** as a colourless solid in 82 % yield.

mp: 118 °C.  $R_f$  = 0.54 (hexane/ ethyl acetate 3/2).  $\alpha_D$  = +18°, ( $\text{CHCl}_3$ ,  $c$  = 1.10, 29.3 °C).  $^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.40–7.32 (m, 7 H), 7.29–7.22 (m, 2 H), 6.98–6.93 (m, 4 H), 5.33 (d,  $J$  = 4.4 Hz, 1 H), 5.03 (s, 2 H), 4.73 (d,  $J$  = 4.4 Hz, 1 H), 3.89 (s, 3 H).  $^{13}\text{C}$ -NMR (75 MHz,  $\text{CDCl}_3$ ):  $\delta$  168.9, 160.1 (d,  $J$  = 244 Hz), 159.7, 154.3, 136.7, 132.7, 129.5, 128.9, 128.4, 127.8, 127.7, 123.2 (d,  $J$  = 8 Hz), 116.1 (d,  $J$  = 22 Hz), 116.0, 77.9, 70.3, 36.6, 53.5. IR (thin film): 1769, 1552, 1388, 1227, 1099, 834. HRMS (MALDI): Calcd' for  $(\text{C}_{24}\text{H}_{20}\text{FNO}_5\text{Na}^+)$ , 444.1224, found, 444.1224. Anal. Calcd. for  $\text{C}_{24}\text{H}_{20}\text{FNO}_5$ : C, 68.40; H, 4.78; N, 3.32; found: C, 68.18; H, 4.91; N, 3.38.

To a suspension of methyl ester **XXId** (1.68 g, 3.99 mmol, 1.00 equiv) in ethanol (27.0 ml) is added at 23 °C sodium cyanoborohydride (226 mg, 5.98 mmol, 1.50 equiv). The suspension is stirred for 2 h at this temperature at which point all solids were dissolved. To this solution is added  $\text{NH}_4\text{Cl}_{(s)}$  and the volume is concentrated in vacuo to 5 ml. To this suspension is added water (50 ml) and EtOAc (50 ml). The aqueous phase is extracted with EtOAc. The combined organic phases are washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (1/1 to 2/3 gradient) to afford the corresponding alcohol

as a colorless solid in 92 % yield.

mp: 143 °C.  $R_f$  = 0.40 (hexane/ ethyl acetate 2/3).  $\alpha_D$  = -16°, (CHCl<sub>3</sub>,  $c$  = 1.54, 32.4 °C). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  7.42-7.19 (m, 9 H), 6.97-6.90 (m, 4 H), 5.26 (d,  $J$  = 6.5 Hz, 1 H), 5.02 (s, 2 H), 4.39 (m, 1 H), 3.99 (d,  $J$  = 12.5 Hz, 1 H), 3.74 (d,  $J$  = 12.5 Hz, 1 H), 2.77 (s, 1 H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),:  $\delta$  159.7 (d,  $J$  = 245 Hz), 159.0, 136.4, 132.7, 129.4, 128.5, 128.0, 127.9, 127.4, 123.6 (d,  $J$  = 8 Hz), 115.6 (d,  $J$  = 22 Hz), 115.6, 82.0, 70.1, 61.6, 61.2. IR (thin film): 3418, 2930, 2871, 1748, 1611, 1512, 1394, 1234. HRMS (EI): Calcd' for (C<sub>23</sub>H<sub>20</sub>FNO<sub>4</sub><sup>+</sup>), 393.1376, found, 393.1389. Anal. Calcd. for C<sub>23</sub>H<sub>20</sub>FNO<sub>4</sub>: C, 70.22; H, 5.12; N, 3.56; found: C, 70.26; H, 5.21; N, 3.61.

To a solution of oxalylchloride (508 mg, 4.00 mmol, 2.00 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (15.0 ml) is added at -78 °C dimethylsulfoxide (0.355 ml, 5.00 mmol, 2.50 equiv). After 10 min at -78 °C is added the alcohol received above (787 mg, 2.00 mmol, 1.00 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (15.0 ml) over a period of 5 min. After additional 5 min at this temperature triethylamine (1.14 ml, 8.00 mmol, 8.00 equiv) is added. After 5 min 1-(4-Fluoro-phenyl)-2-(triphenyl- $\lambda^5$ -phosphanylidene)-ethanone is added and the resulting suspension is warmed to 20 °C and stirred for additional 30 min. To the solution is added saturated aqueous Na<sub>2</sub>HCO<sub>3</sub> solution. The aqueous phase is extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic phases are washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (2/1 to 1/1 gradient) to afford the corresponding enone as a colorless solid in 89 % yield.

mp: 152 °C.  $R_f$  = 0.56 (hexane/ ethyl acetate 3/2).  $\alpha_D$  = +100°, (CHCl<sub>3</sub>,  $c$  = 0.60, 25.6 °C). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  8.06-7.99 (m, 2 H), 7.42-7.06 (m, 14 H), 7.00-6.92 (m, 4 H), 5.05-5.00 (m, 4 H). <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>),:  $\delta$  187.1, 165.9 (d,  $J$  = 254 Hz), 159.8 (d,  $J$  = 243 Hz), 159.4, 154.8, 140.0, 136.2, 133.2, 132.3,

131.4 (*d*, *J* = 9 Hz), 128.6, 128.1, 128.1, 127.9, 127.4, 125.8, 123.5 (*d*, *J* = 9 Hz), 115.9 (*d*, *J* = 24 Hz), 115.8 (*d*, *J* = 24 Hz), 115.8, 80.5, 70.2, 66.0. IR (thin film): 1760, 1675, 1597, 1511, 1385, 1227. HRMS (MALDI): Calcd' for (C<sub>31</sub>H<sub>23</sub>F<sub>2</sub>NO<sub>4</sub>Na<sup>+</sup>), 534.1493, found, 534.1482. Anal. Calcd. for C<sub>31</sub>H<sub>23</sub>F<sub>2</sub>NO<sub>4</sub>: C, 72.79; H, 4.53; N, 2.74; found: C, 72.51; H, 4.78; N, 2.73.

To this enone (910 mg, 1.78 mmol, 1.00 equiv) in ethanol (15.0 ml) is added at 23 °C palladium on carbon (10 %) (100 mg). The suspension is vigorously stirred under 1 atm of hydrogen gas for 3 h. The suspension is filtered through a pad of celite eluting with EtOAc concentrated and the residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (2/1 to 1/1 gradient). A portion of the resulting benzyl ether (310 mg, 0.604 mmol, 1.00 equiv) is dissolved in CH<sub>2</sub>Cl<sub>2</sub> and cooled to -20 °C. (R)-3,3-diphenyl-1-methyltetrahydro-3H-pyrrolo-oxazaborole-2-methyl-oxazaborolidin (solution in toluene (0.5 M) 0.600 ml, 0.302 mmol, 0.50 equiv) is added followed by borane dimethylsulfide complex (0.080 ml, 0.905 mmol, 1.50 equiv). The solution is stirred at -20 °C for 2 h, then warmed to 0 °C and quenched with methanol. To the solution is added saturated aqueous Na<sub>2</sub>HCO<sub>3</sub> solution and CH<sub>2</sub>Cl<sub>2</sub>. The aqueous phase is extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic phases are washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (3/2 to 1/1 gradient). A portion of the resulting alcohol (53 mg, 0.10 mmol, 1.0 equiv) is dissolved in ethanol and palladium on carbon (10 mg) is added. The suspension is vigorously stirred under an atmosphere of hydrogen for 2.5 h. The suspension is filtered through a plug of celite eluting with EtOAc. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (1/1 to 1/2 gradient) to afford the desired oxazolidinone **XXI** as a colorless solid in 57 % yield

from the starting enone.

mp: 98 °C.  $R_f$  = 0.41 (hexane/ ethyl acetate 2/3).  $\alpha_D$  = -1°, (CHCl<sub>3</sub>, c = 0.84, 27.6 °C). <sup>1</sup>H-NMR (300 MHz, acetone d<sub>6</sub>):  $\delta$  7.47-7.35 (m, 4 H), 7.29-7.24 (m, 2 H), 7.09-6.97 (m, 4 H), 6.85-6.79 (m, 2 H), 5.15 (d,  $J$  = 6.7 Hz, 1H), 4.76-4.68 (m, 1 H), 4.43-4.34 (m, 2 H), 2.02-1.76 (m, 4 H). <sup>13</sup>C-NMR (75 MHz, acetone d<sub>6</sub>):  $\delta$  162.0 (d,  $J$  = 243 Hz), 159.5 (d,  $J$  = 242 Hz), 157.9, 155.3, 142.2 (d,  $J$  = 3 Hz), 134.3 (d,  $J$  = 2 Hz), 129.1, 128.7, 127.8 (d,  $J$  = 8 Hz), 123.8 (d,  $J$  = 9 Hz), 116.1, 115.2 (d,  $J$  = 23 Hz), 114.9 (d,  $J$  = 21 Hz), 82.4, 72.3, 65.6, 35.0, 30.3. IR (thin film): 3316, 2925, 1726, 1603, 1511, 1224, 835. HRMS (MALDI): Calcd' for (C<sub>24</sub>H<sub>21</sub>F<sub>2</sub>NO<sub>4</sub>Na<sup>+</sup>), 448.1337, found, 448.1326.

### Example 18


The compounds of the invention and ezetimibe (commercially obtained or prepared according to Wu, G. Z. et al., *J. Org. Chem.* **1999**) together with the glucuronide (the metabolite of ezetimibe, prepared according to Vaccaro, W. D.; Davis, H. R. *Bioorg. Med. Chem. Lett.* **1998**, 8, 313-318) as appropriate reference compounds were evaluated by well-established methods to determine their inhibition of cholesterol uptake in rabbit brush border membrane vesicles (BBMV) (Table 1). Briefly, the scavenger receptor-mediated uptake of radiolabelled cholesterol ester from the loaded donor particles into the BBMV bilayer was measured in the presence of various compounds of the invention and appropriate reference compounds (Hauser, H. et al., *Biochemistry* **1998**, 37, 17843-17850; Werder, M. et al., *Biochemistry* **2001**, 40, 11643-11650; Boffelli, D. et al., *FEBS Lett.* **1997**, 411, 7-11.)

Table 1:

| Compound    | applied in donor SUV<br>(9 mol%)<br>Inhibition in (%) |
|-------------|-------------------------------------------------------|
| Ezetimibe   | 16 ± 4                                                |
| Glucuronide | 19 ± 4                                                |
| VI          | 30 ± 4                                                |
| VII         | 22 ± 2                                                |
| VIII        | 15 ± 3                                                |
| IXb         | 20 ± 5                                                |
| IX          | 27 ± 4                                                |
| X           | 15 ± 3                                                |
| XI          | 20 ± 5                                                |
| XIV         | 26 ± 3                                                |
| XV          | 19 ± 3                                                |
| XVI         | 21 ± 5                                                |
| XVII        | 28 ± 4                                                |
| XVIII       | 41 ± 4                                                |
| XXI         | 19 ± 2                                                |

Claims

1. A compound according to formula I



wherein

P represents  $-N<$  or  $-C=$ ,





X represents independently of each other  $-\text{CH}_2-$ ,  $\text{CR}_1$  ( $\text{sp}_2$ -hybridised), O,  $-\text{NH}-$ ,  $=\text{N}-$ ,  $-\text{CO}-$  or  $-\text{CS}-$ , wherein  $\text{R}_1$  represents H or  $\text{NR}_2$ , wherein  $\text{R}_2$  represents H or lower alkyl, which optionally is linked to Z such that a bicyclic structure is formed;

n represents 1 or 2,

$\text{R}_a$  represents H, lower alkyl,  $-\text{OR}_3$ ,  $-\text{O}(\text{CO})\text{R}_3$ ,  $-\text{O}(\text{CO})\text{OR}_3$ ,  $-\text{O}(\text{CO})\text{NR}_3\text{R}_4$ ,  $-\text{NR}_3\text{R}_4$ ,  $-\text{NR}_3(\text{CO})\text{R}_4$ ,  $-\text{COOR}_3$ ,  $-\text{CONR}_3\text{R}_4$ ,  $-\text{CH}=\text{CHCOOR}_3$ ,  $-\text{CF}_3$ ,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $\text{SO}_3\text{H}$ ,  $\text{PO}_3\text{H}$  or halogen, wherein  $\text{R}_3$  and  $\text{R}_4$  represent H or lower alkyl,

$\text{R}_b$  represents H, OH,  $-\text{OSO}_2\text{Me}$ ,  $-\text{OSO}_2\text{W}$  wherein W represents optionally substituted aryl or heteroaryl,  $-\text{OCO}(\text{CHOH})_2\text{COOR}_5$  wherein  $\text{R}_5$  represents H or lower alkyl; or represents the formula  $-\text{Sp}_3-\text{R}_6$ , wherein  $\text{Sp}_3$  represents a covalent bond,  $-\text{O}-$ ,  $-\text{OCH}_2-$ ,  $-\text{OSO}_2\text{CH}_2-$ ,  $-\text{OSO}_2-$ ,  $-\text{OSO}_2-(p)\text{C}_6\text{H}_4\text{O}-$  and  $\text{R}_6$  represents one of carbohydrate structures A-D:

82

**A****B****C****D**

wherein

$R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{11}$ ,  $R_{12}$ ,  $R_{13}$  and  $R_{14}$  represent independently of each other H, lower alkyl, aryl(lower alkyl), -CO-lower alkyl, -CO-aryl, -SO<sub>3</sub><sup>-</sup> or -PO<sub>3</sub><sup>-</sup>,

$R_{10}$  represents -CH<sub>2</sub>OR<sub>16</sub> or -COOR<sub>17</sub>, and

$R_{15}$  represents -CH<sub>2</sub>OR<sub>16</sub>, -COOR<sub>17</sub>, -CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>OPO<sub>3</sub><sup>-</sup> or -CH<sub>2</sub>OSO<sub>3</sub><sup>-</sup>, wherein  $R_{16}$  and  $R_{17}$  independently of each other represent H, lower alkyl, aryl(lower alkyl), -CO-lower alkyl, -CO-aryl, -SO<sub>3</sub><sup>-</sup> or -PO<sub>3</sub><sup>-</sup>,

$Z$  represents optionally substituted aryl or heteroaryl,  
 $Sp_1$  represents a spacer unit, such as a straight-chain or branched lower alkyl group -(CH<sub>2</sub>)<sub>p</sub>-, wherein  $p$  is from 2-6, which is unsubstituted, mono or poly-substituted by -OH, -OR<sub>18</sub>, halogen or cyano group, wherein one or more -CH<sub>2</sub>- groups may independently be replaced by -O-, -CO-, -CO-O-, -O-CO-, -NR<sub>19</sub>-, -NR<sub>19</sub>-CO-, -CO-NR<sub>19</sub>-, -CH=CH-, -C≡C- and wherein  $R_{18}$  and  $R_{19}$  represent a hydrogen atom or lower alkyl;

$Sp_2$  represents an optional spacer unit, such as a covalent bond or a straight-chain or branched lower alkyl group -

$(\text{CH}_2)_q-$ , wherein  $q$  is from 1-6, which is unsubstituted, mono or poly-substituted by  $-\text{OH}$ ,  $-\text{OR}_{20}$ , halogen or cyano group, wherein one or more  $-\text{CH}_2-$  groups may independently be replaced by  $-\text{O}-$ ,  $-\text{CO}-$ ,  $-\text{CO}-\text{O}-$ ,  $-\text{O}-\text{CO}-$ ,  $-\text{NR}_{21}-$ ,  $-\text{NR}_{21}-\text{CO}-$ ,  $-\text{CO}-\text{NR}_{21}-$ ,  $-\text{CH}=\text{CH}-$ ,  $-\text{C}\equiv\text{C}-$  and wherein  $\text{R}_{20}$  and  $\text{R}_{21}$  represents a hydrogen atom or lower alkyl;

Y represents optionally substituted aryl or heteroaryl,

with the proviso, that if  $\text{P} = -\text{N}<$ ,  $n=1$ ,  $\text{X} = -\text{CO}-$  and  $\text{Sp}_2$  represents a covalent bond,  $\text{R}_6$  may not represent carbohydrate structures A or D for  $\text{Sp}_3 = -\text{O}-$  and  $\text{R}_6$  may not represent carbohydrate B for  $\text{Sp}_3 = -\text{OCH}_2-$ .

2. A compound according to claim 1,

with the proviso, that if  $\text{P} = -\text{N}<$ ,  $n=1$ ,  $\text{X} = -\text{CO}-$  and  $\text{Sp}_2$  represents a covalent bond,  $\text{R}_b$  may not represent H or OH and  $\text{Sp}_3$  may not represent a covalent bond,  $-\text{O}-$  or  $-\text{OCH}_2-$ .

3. A compound according to claims 1 or 2 wherein  $\text{P} = -\text{N}<$ ,  $n = 1$  and  $\text{X} = -\text{CO}-$ ,  $-\text{CS}-$ ,  $-\text{CH}_2-$  or  $-\text{NH}-$ .

4. A compound according to claims 1 or 2 wherein  $\text{P} = -\text{N}<$ ,  $n = 1$  and  $\text{X} = -\text{CS}-$ ,  $-\text{CH}_2-$  or  $-\text{NH}-$ .


5. A compound according to claims 1 or 2 wherein  $\text{P} = -\text{N}<$  and  $-(\text{X})_n- = -\text{OOC}-$ ,  $-\text{COO}-$ ,  $-\text{CONH}-$ ,  $-\text{CH}=\text{N}-$ .

6. A compound according to claims 1 or 2 wherein  $\text{P} = -\text{C}=$  and  $-(\text{X})_n- = -\text{NH}-\text{N}=$  or  $-\text{O}-\text{N}=$ .

7. A compound according to claims 1 or 2 having the formula IVa




84



IVa

wherein  $R_a$ ,  $R_b$ ,  $SP_1$ ,  $SP_2$ ,  $P$ ,  $X$ ,  $Y$ ,  $Z$  and  $n$  are as defined in claims 1 or 2.

8. A compound according to claims 1 or 2 having the formula IVb,



IVb

wherein  $R_a$ ,  $R_b$ ,  $SP_1$ ,  $P$ ,  $X$  and  $n$  are as defined hereinabove and wherein  $R_{21}$  and  $R_{22}$  represent H, lower alkyl, lower alkoxy or halogen.

9. A compound according to claims 7 or 8 wherein  $P = -N<$ ,  $n = 1$  and  $X = -CO-$ ,  $-CS-$ ,  $-CH_2-$  or  $-NH-$ .
10. A compound according to claims 7 or 8 wherein  $P = -N<$ ,  $n = 1$  and  $X = -CS-$ ,  $-CH_2-$  or  $-NH-$ .
11. A compound according to claims 7 or 8 wherein  $P = -N<$  and  $-(X)_n = -OOC-$ ,  $-COO-$ ,  $-CONH-$ ,  $-CH=N-$ .
12. A compound according to claims 7 or 8 wherein  $P = -C=$  and  $-(X)_n = -NH-N=$  or  $-O-N=$ .
13. A pharmaceutical composition comprising a therapeutically

effective amount of a compound of any preceding claim with a pharmaceutically acceptable carrier.

14. A pharmaceutical composition according to claim 13 for the treatment or prevention of arteriosclerosis or for the reduction of cholesterol levels.
15. A kit comprising a pharmaceutical composition according to claim 13 for use in the treatment or prevention of arteriosclerosis or for the reduction of cholesterol levels.
16. A method for the treatment or prevention of arteriosclerosis or for the reduction of cholesterol levels comprising administering to a subject in need of such treatment an effective amount of a compound according to claims 1 to 12.
17. Use of a compound according to claims 1 to 12 for the manufacture of a medicament for the treatment or prevention of arteriosclerosis or for the reduction of cholesterol levels.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CH2004/000584

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D405/04 C07H15/00 C07D205/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                              | Relevant to claim No. |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X          | MUKERJEE A K ET AL: "RAPID SYNTHESIS OF DEHYDROPEPTIDES CARRYING A BETA-LACTAM MOIETY"<br>JOURNAL OF CHEMICAL RESEARCH. SYNOPSES, LONDON, GB, no. 7, 1993, pages 280-281, XP009027094<br>ISSN: 0308-2342<br>the whole document<br>-----<br>-/-- | 1-3,7-9               |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

28 October 2004

Date of mailing of the international search report

08/11/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Klein, D

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CH2004/000584

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                                                                                                                                                                                                          | Relevant to claim No. |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X          | <p>VAN HECK, MARGARET ET AL: "In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461"</p> <p>JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (1997), 283(1), 157-163, 1997, XP002275919</p> <p>figure 1</p> <p>-----</p>                                                                                                                                            | 1-3,7-9,<br>13-17     |
| X          | <p>WU, GEORGE GUANGZHONG: "A Concise Asymmetric Synthesis of A.beta.-Lactam-Based Cholesterol Absorption Inhibitor"</p> <p>ORGANIC PROCESS RESEARCH &amp; DEVELOPMENT (2000), 4(4), 298-300, 2000, XP002275920</p> <p>the whole document</p> <p>-----</p>                                                                                                                                                                                                                                                   | 1-3,7-9,<br>13-17     |
| X          | <p>UDUPI, R.H. ET AL: "Synthesis of 1-(2-carboxy-5-nitrophenyl)-3,4-substituted azetidin-2-ones as antiinflammatory and antimicrobial agents"</p> <p>INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY (1996), 6(2), 99-102, 1996, XP009027043</p> <p>the whole document</p> <p>-----</p>                                                                                                                                                                                                                            | 1-3                   |
| X          | <p>CLADER, JOHN W. ET AL: "2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus"</p> <p>JOURNAL OF MEDICINAL CHEMISTRY (1996), 39(19), 3684-3693, 1996, XP002275922</p> <p>the whole document</p> <p>-----</p>                                                                                                                                                                                                                                     | 1-3,7-9,<br>13-17     |
| X          | <p>OTTO H-H ET AL: "STEREOCHEMIE DER DEHYDRATISIERUNG UND HALOGENIERUNG DER ALPHAR- UND ALPHAS-ISOMERE VON 3-(ALPHA-HYDROXYBENZYL)-1,4-DIPHENYL-2-AZETIDINONEN STEREOCHEMISTRY OF DEHYDRATION AND HALOGENATION OF ALPHAR AND ALPHAS ISOMERIC 3-(ALPHA-HYDROXYBENZYL)-1,4-DIPHENYL"</p> <p>LIEBIGS ANNALEN DER CHEMIE, VERLAG CHEMIE GMBH. WEINHEIM, DE, no. 7, 1983, pages 1162-1168, XP001179959</p> <p>ISSN: 0170-2041</p> <p>the whole document</p> <p>-----</p> <p style="text-align: center;">-/--</p> | 1-3,7-9               |

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CH2004/000584

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                                                                                    | Relevant to claim No. |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X          | BROWNE, MARGARET ET AL: "Trans diastereoselective synthesis of 3-alkyl substituted.beta.-lactams via the acid chloride-imine reaction of nonactivated acid chlorides"<br>TETRAHEDRON LETTERS (1995), 36(15), 2555-8, 1995, XP004028248<br>the whole document<br>-----                                                                                                                 | 1-3,7-9,<br>13-17     |
| X          | BOSE, AJAY K. ET AL: "Studies on lactams. 101. Microwave-assisted rapid synthesis of.alpha.-amino-.beta.-lactams"<br>TETRAHEDRON LETTERS (1996), 37(39), 6989-6992, 1996, XP004030806<br>the whole document<br>-----                                                                                                                                                                  | 1-3,7-9               |
| X          | VAN LEUSEN, ALBERT M. ET AL: "Chemistry of sulfonylmethyl isocyanides. 12. Base-induced cycloaddition of sulfonylmethyl isocyanides to carbon,nitrogen double bonds. Synthesis of 1,5-disubstituted and 1,4,5-trisubstituted imidazoles from aldimines and imidoyl chlorides"<br>JOURNAL OF ORGANIC CHEMISTRY (1977), 42(7), 1153-9, 1977, XP002275923<br>the whole document<br>----- | 1-3,7,9               |
| X          | BURNETT, DUANE A. ET AL: "Synthesis of 3-(1-hydroxyethyl)-2-azetidinones via ester-imine condensations"<br>JOURNAL OF ORGANIC CHEMISTRY (1985), 50(25), 5120-3, 1985, XP002275924<br>the whole document<br>-----                                                                                                                                                                      | 1-3,7-9               |
| X          | BURNETT, DUANE A. ET AL: "2-Azetidinones as Inhibitors of Cholesterol Absorption"<br>JOURNAL OF MEDICINAL CHEMISTRY (1994), 37(12), 1733-6, 1994, XP002275925<br>the whole document<br>-----                                                                                                                                                                                          | 1,2,5-10              |
| X          | ROSENBLUM, STUART B. ET AL: "Synthesis of 3-arylpropenyl, 3-arylpropynyl and 3-arylpropyl 2-azetidinones as cholesterol absorption inhibitors: application of the palladium-catalyzed arylation of alkenes and alkynes"<br>TETRAHEDRON (2000), 56(31), 5735-5742, 2000, XP004213804<br>the whole document<br>-----                                                                    | 1-3,7-9,<br>13-17     |
|            | -----<br>-/--                                                                                                                                                                                                                                                                                                                                                                         |                       |

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CH2004/000584

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                              | Relevant to claim No. |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X          | KIRKUP M P ET AL: "(-)-SCH 57939: synthesis and pharmacological properties of a potent, metabolically stable cholesterol absorption inhibitor" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 6, no. 17, 3 September 1996 (1996-09-03), pages 2069-2072, XP004135657 ISSN: 0960-894X the whole document             | 1-3,7-9, 13-17        |
| X          | OTTO H-H ET AL: "DARSTELLUNG UND STEREOCHEMIE VON 3-(ALPHA-HYDROXYBENZYL)-1,4-DIPHENYL-2-AZETIDINONEN SYNTHESIS AND STEREOCHEMISTRY OF 3-(ALPHA-HYDROXYBENZYL)-1,4-DIPHENYL-2-AZETIDINONES" LIEBIGS ANNALEN DER CHEMIE, VERLAG CHEMIE GMBH. WEINHEIM, DE, 1983, pages 1152-1161, XP001012817 ISSN: 0170-2041 the whole document | 1-3,7-9               |
| X          | ROSENBLUM, STUART B. ET AL: "Discovery of 1-(4-Fluorophenyl)-(3R)-3-(4-fluorophenyl)-(3S)-hydroxypropyl-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption" JOURNAL OF MEDICINAL CHEMISTRY (1998), 41(6), 973-980, 1998, XP002275926 the whole document    | 1-3,7-9, 13-17        |
| X          | BURNETT, DUANE A. ET AL: "Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002), 12(3), 315-318, 2002, XP002275927 the whole document                                                                             | 1-3,7-9, 13-17        |
| X          | BURNETT, DUANE A. ET AL: "Synthesis of iodinated biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002), 12(3), 311-314, 2002, XP002275928 the whole document                                                                               | 1-3,7-9, 13-17        |
| X          | US 5 631 365 A (ROSENBLUM STUART B) 20 May 1997 (1997-05-20) the whole document                                                                                                                                                                                                                                                 | 1-3,7-9, 13-17        |
|            | -/--                                                                                                                                                                                                                                                                                                                            |                       |

International Application No  
PCT/CH2004/000584

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages                                            | Relevant to claim No. |
|------------|-------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X          | EP 0 524 595 A (SCHERING CORP)<br>27 January 1993 (1993-01-27)<br>the whole document<br>-----                                 | 1-3,7-9,<br>13-17     |
| X          | WO 00/63703 A (SCHERING CORP)<br>26 October 2000 (2000-10-26)<br>the whole document<br>-----                                  | 1-3,7-9,<br>13-17     |
| X          | US 5 633 246 A (DUGAR SUNDEEP ET AL)<br>27 May 1997 (1997-05-27)<br>the whole document<br>-----                               | 1-3,7-9,<br>13-17     |
| X          | WO 02/50090 A (SCHERING CORP)<br>27 June 2002 (2002-06-27)<br>the whole document<br>-----                                     | 1-3,7-9,<br>13-17     |
| X          | DE 36 20 467 A (CIBA GEIGY AG)<br>2 January 1987 (1987-01-02)<br>the whole document<br>-----                                  | 1-3,7-9,<br>13-17     |
| X          | WO 03/026643 A (SCHERING CORP)<br>3 April 2003 (2003-04-03)<br>* the whole document, in particular page<br>42 formula X, XI * | 1-3,7-9,<br>13-17     |
| X          | US 5 756 470 A (VAN HEEK MARGARET ET AL)<br>26 May 1998 (1998-05-26)<br>the whole document<br>-----                           | 1-17                  |
| X          | WO 97/16455 A (SCHERING CORP)<br>9 May 1997 (1997-05-09)<br>the whole document<br>-----                                       | 1-17                  |
| X          | US 2003/119428 A1 (DAVIS HARRY R ET AL)<br>26 June 2003 (2003-06-26)<br>the whole document<br>-----                           | 1-17                  |

## INTERNATIONAL SEARCH REPORT

national application No.  
PCT/CH2004/000584

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-7, 9-17  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



Continuation of Box II.2

Claims Nos.: 1-7, 9-17

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty or inventive step. So many documents were retrieved that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT).

Furthermore, present claims 1-7, 9-17 relate to an extremely large number of possible compounds. In fact, the claims contain so many options, variables or possible permutations that a lack of clarity (and conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and concise), namely claim 8.

Nevertheless, most of the references cited are also relevant to the subject-matter of claims 1-7, 9-17.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CH2004/000584

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|-------------------------------------------|---|---------------------|----------------------------|---------------------|
| US 5631365                                | A | 20-05-1997          | AT 180249 T                | 15-06-1999          |
|                                           |   |                     | AU 681445 B2               | 28-08-1997          |
|                                           |   |                     | AU 7795294 A               | 10-04-1995          |
|                                           |   |                     | CA 2172149 C               | 28-11-2000          |
|                                           |   |                     | CN 1131416 A ,B            | 18-09-1996          |
|                                           |   |                     | CZ 9600839 A3              | 14-08-1996          |
|                                           |   |                     | CZ 288891 B6               | 12-09-2001          |
|                                           |   |                     | DE 10399001 I1             | 12-06-2003          |
|                                           |   |                     | DE 69418613 D1             | 24-06-1999          |
|                                           |   |                     | DE 69418613 T2             | 30-09-1999          |
|                                           |   |                     | DK 720599 T3               | 08-11-1999          |
|                                           |   |                     | EP 0720599 A1              | 10-07-1996          |
|                                           |   |                     | ES 2132432 T3              | 16-08-1999          |
|                                           |   |                     | FI 961300 A                | 21-03-1996          |
|                                           |   |                     | GR 3030312 T3              | 30-09-1999          |
|                                           |   |                     | HU 73852 A2                | 30-09-1996          |
|                                           |   |                     | IL 110956 A                | 11-01-2001          |
|                                           |   |                     | JP 2803908 B2              | 24-09-1998          |
|                                           |   |                     | JP 8509989 T               | 22-10-1996          |
|                                           |   |                     | KR 186853 B1               | 01-05-1999          |
|                                           |   |                     | MA 23332 A1                | 01-04-1995          |
|                                           |   |                     | NL 300132 I1               | 01-10-2003          |
|                                           |   |                     | NO 961133 A                | 20-03-1996          |
|                                           |   |                     | NZ 274041 A                | 19-12-1997          |
|                                           |   |                     | PL 313589 A1               | 08-07-1996          |
|                                           |   |                     | RU 2138480 C1              | 27-09-1999          |
|                                           |   |                     | SG 46208 A1                | 20-02-1998          |
|                                           |   |                     | SK 35596 A3                | 05-02-1997          |
|                                           |   |                     | TW 427974 B                | 01-04-2001          |
|                                           |   |                     | WO 9508532 A1              | 30-03-1995          |
|                                           |   |                     | US RE37721 E1              | 28-05-2002          |
|                                           |   |                     | US 5767115 A               | 16-06-1998          |
|                                           |   |                     | US 5846966 A               | 08-12-1998          |
|                                           |   |                     | ZA 9407086 A               | 14-03-1995          |
| EP 0524595                                | A | 27-01-1993          | AT 158789 T                | 15-10-1997          |
|                                           |   |                     | AU 658441 B2               | 13-04-1995          |
|                                           |   |                     | AU 2398092 A               | 23-02-1993          |
|                                           |   |                     | BG 61118 B2                | 29-11-1996          |
|                                           |   |                     | CA 2114007 A1              | 04-02-1993          |
|                                           |   |                     | CN 1069024 A               | 17-02-1993          |
|                                           |   |                     | CZ 9400142 A3              | 13-07-1994          |
|                                           |   |                     | DE 69222532 D1             | 06-11-1997          |
|                                           |   |                     | DE 69222532 T2             | 26-02-1998          |
|                                           |   |                     | EE 9400342 A               | 15-04-1996          |
|                                           |   |                     | EP 0524595 A1              | 27-01-1993          |
|                                           |   |                     | EP 0596015 A1              | 11-05-1994          |
|                                           |   |                     | ES 2107548 T3              | 01-12-1997          |
|                                           |   |                     | FI 940296 A                | 21-01-1994          |
|                                           |   |                     | HU 67341 A2                | 28-03-1995          |
|                                           |   |                     | IE 922374 A1               | 27-01-1993          |
|                                           |   |                     | JP 2525125 B2              | 14-08-1996          |
|                                           |   |                     | JP 6508637 T               | 29-09-1994          |
|                                           |   |                     | MX 9204327 A1              | 29-07-1994          |
|                                           |   |                     | NO 940221 A                | 21-01-1994          |
|                                           |   |                     | NZ 243669 A                | 22-12-1994          |
|                                           |   |                     | OA 9878 A                  | 15-09-1994          |
|                                           |   |                     | SK 7994 A3                 | 06-07-1994          |

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CH2004/000584

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|-------------------------------------------|---|---------------------|----------------------------|---------------------|
| EP 0524595                                | A |                     | WO 9302048 A1              | 04-02-1993          |
|                                           |   |                     | US 6093812 A               | 25-07-2000          |
|                                           |   |                     | US 5561227 A               | 01-10-1996          |
|                                           |   |                     | US 5688785 A               | 18-11-1997          |
|                                           |   |                     | US 5688787 A               | 18-11-1997          |
|                                           |   |                     | US 5306817 A               | 26-04-1994          |
|                                           |   |                     | ZA 9205487 A               | 31-03-1993          |
| WO 0063703                                | A | 26-10-2000          | AU 4343500 A               | 02-11-2000          |
|                                           |   |                     | WO 0063703 A1              | 26-10-2000          |
|                                           |   |                     | US 2003215869 A1           | 20-11-2003          |
|                                           |   |                     | US 6593078 B1              | 15-07-2003          |
|                                           |   |                     | US 2002009714 A1           | 24-01-2002          |
| US 5633246                                | A | 27-05-1997          | US 5624920 A               | 29-04-1997          |
|                                           |   |                     | AT 213726 T                | 15-03-2002          |
|                                           |   |                     | AU 698750 B2               | 05-11-1998          |
|                                           |   |                     | AU 4140196 A               | 17-06-1996          |
|                                           |   |                     | BR 9509669 A               | 28-10-1997          |
|                                           |   |                     | CA 2205202 A1              | 30-05-1996          |
|                                           |   |                     | CN 1174548 A ,B            | 25-02-1998          |
|                                           |   |                     | CZ 9701486 A3              | 12-11-1997          |
|                                           |   |                     | DE 69525643 D1             | 04-04-2002          |
|                                           |   |                     | DE 69525643 T2             | 26-09-2002          |
|                                           |   |                     | DK 792264 T3               | 22-04-2002          |
|                                           |   |                     | EP 0792264 A1              | 03-09-1997          |
|                                           |   |                     | ES 2169162 T3              | 01-07-2002          |
|                                           |   |                     | FI 972099 A                | 16-05-1997          |
|                                           |   |                     | HK 1002558 A1              | 14-06-2002          |
|                                           |   |                     | HU 77088 A2                | 02-03-1998          |
|                                           |   |                     | JP 2908031 B2              | 21-06-1999          |
|                                           |   |                     | JP 9512833 T               | 22-12-1997          |
|                                           |   |                     | KR 235806 B1               | 01-02-2000          |
|                                           |   |                     | NO 972272 A                | 16-05-1997          |
|                                           |   |                     | NZ 296720 A                | 29-03-1999          |
|                                           |   |                     | PL 320092 A1               | 15-09-1997          |
|                                           |   |                     | PT 792264 T                | 31-07-2002          |
|                                           |   |                     | RU 2159243 C2              | 20-11-2000          |
|                                           |   |                     | SK 61697 A3                | 10-12-1997          |
|                                           |   |                     | WO 9616037 A1              | 30-05-1996          |
|                                           |   |                     | US 5744467 A               | 28-04-1998          |
| WO 0250090                                | A | 27-06-2002          | AT 279425 T                | 15-10-2004          |
|                                           |   |                     | AU 3104902 A               | 01-07-2002          |
|                                           |   |                     | BR 0116212 A               | 30-12-2003          |
|                                           |   |                     | CA 2432798 A1              | 27-06-2002          |
|                                           |   |                     | CN 1483039 T               | 17-03-2004          |
|                                           |   |                     | CZ 20031674 A3             | 15-10-2003          |
|                                           |   |                     | EP 1347987 A1              | 01-10-2003          |
|                                           |   |                     | HU 0302269 A2              | 28-10-2003          |
|                                           |   |                     | JP 2004516299 T            | 03-06-2004          |
|                                           |   |                     | NO 20032806 A              | 19-08-2003          |
|                                           |   |                     | SK 7702003 A3              | 07-10-2003          |
|                                           |   |                     | WO 0250090 A1              | 27-06-2002          |
|                                           |   |                     | US 2002137690 A1           | 26-09-2002          |
|                                           |   |                     | US 2003105028 A1           | 05-06-2003          |
| DE 3620467                                | A | 02-01-1987          | DE 3620467 A1              | 02-01-1987          |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CH2004/000584

| Patent document<br>cited in search report |    | Publication<br>date | Patent family<br>member(s)                                                                                                                                                                                                                                                                                                                                                                                                               | Publication<br>date                                                                                                                                                                                                                                                                                                                                                      |
|-------------------------------------------|----|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WO 03026643                               | A  | 03-04-2003          | CA 2460340 A1<br>EP 1429756 A2<br>WO 03026643 A2<br>US 2003119809 A1                                                                                                                                                                                                                                                                                                                                                                     | 03-04-2003<br>23-06-2004<br>03-04-2003<br>26-06-2003                                                                                                                                                                                                                                                                                                                     |
| US 5756470                                | A  | 26-05-1998          | NONE                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                          |
| WO 9716455                                | A  | 09-05-1997          | AT 219495 T<br>AU 712158 B2<br>AU 7517996 A<br>BR 9611401 A<br>CA 2235943 A1<br>CN 1205707 A , B<br>CZ 9801294 A3<br>DE 69621952 D1<br>DE 69621952 T2<br>DK 877750 T3<br>EP 0877750 A1<br>ES 2175141 T3<br>HK 1012507 A1<br>HU 9802539 A2<br>ID 16177 A<br>JP 10512592 T<br>JP 3385031 B2<br>JP 2001048895 A<br>NO 981950 A<br>NZ 321766 A<br>PL 327987 A1<br>PT 877750 T<br>SK 48398 A3<br>TW 448181 B<br>WO 9716455 A1<br>ZA 9609089 A | 15-07-2002<br>28-10-1999<br>22-05-1997<br>05-01-1999<br>09-05-1997<br>20-01-1999<br>14-10-1998<br>25-07-2002<br>16-01-2003<br>15-07-2002<br>18-11-1998<br>16-11-2002<br>18-10-2002<br>30-11-1998<br>11-09-1997<br>02-12-1998<br>10-03-2003<br>20-02-2001<br>26-06-1998<br>29-07-1999<br>04-01-1999<br>30-09-2002<br>04-11-1998<br>01-08-2001<br>09-05-1997<br>29-04-1997 |
| US 2003119428                             | A1 | 26-06-2003          | US 2003105028 A1<br>US 2003119757 A1<br>US 2003119796 A1                                                                                                                                                                                                                                                                                                                                                                                 | 05-06-2003<br>26-06-2003<br>26-06-2003                                                                                                                                                                                                                                                                                                                                   |